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ABSTRACT 
The main virulence factors of encapsulated bacteria such as Haemophilus influenzae 
type b (Hib) and pneumococcus are their capsular polysaccharides and antibodies 
against them have been shown to be protective against Hib and pneumococcal 
invasive diseases. However, polysaccharides are poorly immunogenic and do not 
induce protective antibody response in children under 2 years when administered on 
their own. In order to induce a memory B cell response and isotype switching, a 
protein carrier is usually conjugated to the polysaccharide to stimulate a T cell-
dependent response. However, this conjugation process is expensive and the final 
product is not thermostable.  
In this project, self-assembling thermostable microcrystals were used to co-immobilise 
a model capsular polysaccharide (Polyribosylribitol Phosphate; PRP) from Hib and 
tetanus toxoid (TT) to create a virtual polysaccharide-protein conjugate to mimic the 
commercially-available Hib conjugate vaccines.  
Self-assembling microcrystals loaded with both PRP and TT were prepared, and their 
physico-chemical and immunogenic properties were investigated. In vitro, the factors 
that influence crystal formation were determined, and antigen loading onto and 
release from the microcrystals was assessed.  The dynamics of the interactions 
between the crystals and some cells of the immune system were also investigated. In 
vivo, the crystals were tested in combination with varying buffers, administration 
routes and adjuvants in an attempt to optimise anti-PRP antibody production.  
13 
 
It was found that the crystal morphology and antigen entrapment could be 
manipulated by preparation conditions. The microcrystal formulation increases cellular 
uptake of antigens into bone marrow-derived dendritic cells and neutrophils. Despite 
the use of microcrystals with low level of free PRP, and combinations of different 
adjuvants, routes, buffers and doses, the microcrystals were not as immunogenic as a 
commercially-available Hib conjugate vaccine. 
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Chapter 1. Introduction 
Infectious diseases are a major cause of premature death and disability worldwide and 
responsible for approximately one-third of all deaths. Particularly affected are infants 
and young children in the world’s poorest regions. Since the introduction of routine 
vaccination schedules for infants, there have been significant decreases in the number 
of cases of childhood associated diseases such as diphtheria, tetanus, pertussis, polio 
and bacterial meningitis and pneumonia. However, infectious diseases still remain as 
one of the highest causes of worldwide morbidity and mortality, particularly in 
developing countries.  
 
There are 5 million deaths per year in children under the age of 5 years from infectious 
diseases, 2 million of them could be prevented by the use of existing vaccines (1-3). 
This represents approximately 20% of deaths of children under the age of five years, 
and 30% of deaths from those between 1-59 months of age (WHO 2011). In these 
developing countries, the implementation of vaccination programs can be problematic 
and therefore leaving children vulnerable. The diseases which inflict the highest toll 
upon young children include acute respiratory infections, diarrhoea and meningitis. 
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Figure 1.1. Childhood preventable deaths in 2012. 
Data from WHO 2011.  
 
 
1.1  Encapsulated bacteria 
The leading cause of respiratory infections and meningitis are a group of bacteria 
which have a polysaccharide (PS) capsule, known as encapsulated bacteria. The group 
includes organisms such as Neisseria meningititis, Streptococcus pneumoniae and 
Haemophilus influenzae, Group B streptococcus, Klebsiella pneumoniae and Salmonella 
typhi. The capsule is the most external structure and is made up of long polysaccharide 
chains which are usually negatively charged. The capsule is the first bacterial structure 
to be encountered by the immune system upon infection. The capsular 
polysaccharides can vary in structural features such as repeating unit composition, ring 
forms, glycosidic linkage position, anomeric-centre configurations and conformations 
(4). These differences contribute to the different immune responses to the 
polysaccharides. 
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The capsule is often the most important virulence determinant on the cell surface of 
many gram-negative and gram-positive bacteria. The capsule acts to prevent 
desiccation, aids adherence and resistance to non-specific host immunity. Most 
capsules are composed of neutral or acidic polysaccharides which are linked to the 
bacterial surface via covalent attachment to either phospholipids or lipid A molecules. 
Capsule polysaccharides are composed of monosaccharides joined by a means of a 
glycosidic linkage.  
The capsular polysaccharide can acts to evade the immune response by masking the 
underlying pathogen-associated molecular patterns (PAMPs) that are otherwise potent 
activators of the complement system as well as recognised by Toll-like receptors 
(TLRs). Encapsulated bacteria only weakly activate the complement system and 
opsonophagocytosis.  
The complement system is an important part of the humoral mechanism of defense 
against bacterial invasion, and is composed of many distinct proteins which react with 
one another sequentially to induce inflammatory responses. The complement system 
can be activated through three pathways: the classical pathway, the alternative 
pathway, and the lectin pathway. Each pathway follows a sequence of reactions to 
generate a key protease called C3 convertase. The complement system prevents 
infection by three steps; opsonisation of pathogens so that they are engulfed by 
phagocytes bearing receptors for complement (C3b, C3bi), recruitment of 
inflammatory cells (C3a, C5a) or direct killing of pathogens by creating pores at the 
bacterial membrane (C5b, C6, C7, C8, C9) (5). 
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Figure 1.2 Schematic representation of the complement pathways.  
Figure from (6) 
 
The clearance of encapsulated bacteria is also dependent on the production of a 
humoral response, a response which unvaccinated children under 2 years are unable 
to produce, leaving them very vulnerable to infection. Between 0.8-1 million children 
under the age of 5 die from pneumoccoal disease annually (7) and Hib and 
meningococcus are thought to account for approximately 400,000 and 50,000 deaths 
respectively each year (2, 8). According to recent research (9, 10) these pathogens are 
responsible for as many child deaths as HIV/AIDS, malaria and tuberculosis combined, 
despite the development of safe and effective vaccines against common serotypes of 
all three (11). 
 
31 
 
S. pneumoniae is an encapsulated diplococcus and is divided into at least 91 serotypes. 
The classification of the serotypes is based on the chemical structure of the capsular 
PS. It can cause  pneumonia, meningitis and septicaemia, and also cause disease in the 
form of otitis media, sinusitis and bronchitis (9). Increasing resistance of S. pneumoniae 
to common antibiotics is a growing problem, which increases pressure to prevent 
disease by immunisation (12-15). Studies of community-based incidence studies of 
invasive pneumococcal disease (IPD) suggest there are approximately 814,000 
pneumococcal deaths in children over the age of five years in developing countries 
each year (16, 17). 1-4 million cases of pneumococcal pneumonia are occurring in 
Africa alone. One vaccine targeting 7 pneumococcal serotypes was licensed for young 
children in 2000. In contrast to the 23-valent polysaccharide vaccine used in adults, the 
7-valent conjugate vaccine affects pneumococcal carriage and transmission. Early after 
its introduction, incidence of invasive pneumococcal disease declined among older 
adults, a group at high risk for pneumococcal disease (17). 
 
N. meningitidis is also a significant public health problem, particularly in developing 
countries. It is a leading cause of meningitis and fulminant septicaemia. Five of at least 
thirteen different PS serotypes cause approximately 90% of infections worldwide. 
Serogroups B and C are most prevalent in Europe, while serogroups A, C and W135 are 
responsible for most cases in Asia and Africa and serogroups B, C and Y predominate in 
the Americas (18). Unlike S. pneumoniae and Haemophilus influenzae type b (Hib), 
carriage rates of N meningitidis are highest amongst adults and adolescents and rare in 
those under 10 years of age. Polysaccharide vaccines against meningococcal 
serogroups A, C, Y and W135 have been available for decades, but have poor 
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immunogenicity in young children and little effect on nasopharyngeal carriage. 
However, the introduction of conjugate serogroup C meningococcal vaccine has 
dramatically decreased incidence of  the disease in industrialised nations. 
 
Haemophilus influenzae is a gram-negative rod-shaped bacterium. In 1931, Pittman 
showed that H. influenzae could be divided into two groups; the first encapsulated and 
able to cause invasive disease, and the other unencapsulated and not isolated from 
the blood or cerebrospinal fluid of patients with sepsis or meningtitis (19). The 
encapsulated group can be divided into six serotypes (a-f) based on capsule type and 
the untypeable isolate have no capsule. Serotype b (Hib) is by far the most common, 
and causes over 80% of invasive infections (20, 21). Unencapsulated strains are found 
in 95% of cases of Haemophilus influenzae nasopharyngeal carriage, with equal 
frequencies between the six serotypes in the remaining 5% (22).The type b capsule is 
composed of a polymer of polyribosyl-ribitol phosphate (23), which acts as the  main 
virulence factor of the bacteria (19, 24), whereas the other capsule types contain a 
hexose instead of a pentose (25, 26). 
 
Hib infection can cause a variety of diseases, such as osteomyelitis, septicaemia, 
cellulitis, epiglottitis, and septic arthritis but is particularly well known as a cause of 
bacterial meningitis and pneumonia. Treatment with antibiotics can cure the infection, 
but severe neurological sequelae occur in 15% to 30% of those who survive Hib 
disease.  
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The  bacterial capsule plays a role in helping it evade the immune system by 
preventing phagocytosis and activation of the alternative complement pathway. 
Therefore, the encapsulated bacteria to invade such systems as the blood and 
cerebrospinal fluid and cause severe infections. However, in the presence of anti-
capsular antibodies, both phagocytosis and bacteriolysis are induced.  
 
There are many bacterial pathogens which express a PS capsule, and the development 
of effective PS-based vaccines has had an important role in reducing the prevalence of 
related bacterial infections in countries where the vaccine has been included into the 
vaccination schedule. This project focuses on Hib infection as a model of infection by 
encapsulated bacteria. Although there is an efficacious vaccine currently available, its 
low uptake into the immunisation schedule in some countries has limited the 
worldwide prevention of Hib infection. 
 
1.2  Epidemiology of Hib 
 
Hib is a major cause of serious infections in children worldwide, though the rate of 
invasive Hib disease varies greatly between resource-poor and developed countries as 
shown in Figure 1 (27-29).  61% of Hib related infant deaths worldwide occur in just 
ten countries within Africa and Asia, as is shown by Figure 1.1. 
34 
 
Figure 1. Hib deaths per 100,000 in children aged 1-59 months (HIV-negative Hib 
deaths only).  Map from Watt et al. 2009 (10) 
In the year 2000, there were approximately 8.13 million serious Hib disease cases and 
371,000 deaths in children under 5 years of age, with HIV infected children under 5 
accounting for 2.1% of these deaths (10) . However, the true number of Hib disease 
cases are likely to be underestimated as many Hib meningitis cases go undiagnosed 
(10) and the incidence of Hib disease which is not meningitis or pneumonia also often 
gets underestimated. A high proportion of Hib disease (85%) occurs in young children 
under four years of age (30) and one third of the survivors of bacterial meningitis are 
left with long term neurologic complications, including sensorineural deafness, 
cerebral palsy and epilepsy (31).  
 
As Hib has no non-human hosts, pharyngeal carriage of the bacteria is the main source 
of infection (32). The highest rates of asymptomatic carriage are amongst toddlers 
(33), and this population acts as a reservoir for infection. Hib was recovered from 
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nasopharyngeal cultures in 30-50% of infants older than 6 months (34), but this level is 
markedly increased amongst those living in crowded conditions (35) and with larger 
numbers of siblings in the family (33). As most bacteria increasingly become antibiotic 
resistant, the use of vaccine becomes increasingly important to prevent infectious 
diseases. 
 
1.3  Polysaccharide-based vaccines against encapsulated bacteria 
As previously mentioned, PS capsules of S. pneumoniae, H. influenzae and N. 
meningitidis are virulence determinants that are made up of repeating saccharide 
units. The bacterial capsule has multiple functions which enable the bacteria to 
establish and maintain an infection in the human host (4). In naïve individuals, the 
alternative complement pathway is responsible for protection against invasion by 
bacteria. This occurs through the binding of the complement component C3b to the 
microbial cell wall which triggers the formation of the membrane attack complex that 
leads to swelling and bursting of the microbial cell. However, capsular PS inhibits 
deposition of complement on the cell membrane. In addition, interaction between the 
phagocytic cells’ complement receptors and the techoic acid-deposited C3b on the cell 
wall, or the cell wall itself are sterically hindered by the capsule (36, 37). 
 
Since the discovery that the capsule is one of the main virulence factors of these 
bacteria, polysaccharide vaccines were developed to protect against infection by 
encapsulated bacteria (38). The first large scale clinical trial in 1945 of a tetravalent 
pneumococcal polysaccharide vaccine demonstrated that the PS vaccine  was effective 
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in preventing disease in South African gold miners (38). Subsequently, the availability 
of antibiotics that were able to cure infections in a non-serotype specific manner 
delayed further research into vaccine design until the 1960s. However, it soon became 
clear that patients treated with antibiotics might still suffer from the effects of the 
infection due to the immune reaction to lysed cells and therefore development of a 
suitable vaccine became the focus of research. 
 
1.4  Hib polysaccharide vaccine 
PS antigens are T cell independent antigens (39), they induce short-lived B cell 
responses by cross-linkage of the B-cell receptor on marginal zone B cells. This cross 
linking drives the fast development of plasma cells and production of an antibody 
response, but without the generation of B memory cells, which necessitates 
vaccination at regular intervals to maintain the protective antibody level.  
 
By the late 1960s, the high fatality rate caused by invasive Hib infection, the high 
incidence of complications in meningitis survivors and the increasing antibiotic 
resistance in emerging strains meant that the development of a Hib vaccine was 
crucial. Human anti-PRP antibodies were shown to confer protection against infection 
by the bacterium, the purified capsular PS was trialled as a vaccine candidate (40) In a 
clinical trial in Finland where 100,00 children were immunised with the Hib capsular PS 
vaccine, interestingly an age-dependent antibody response was found. In children 
older than 18 months, the vaccination provided good protection against invasive Hib 
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disease, while the PS vaccine did not protect children under 18 months of age, even 
with a booster dose  (41).  
 
This age-dependent response to Hib polysaccharide is attributed to the nature of the 
polysaccharide, which is a linear polymer of ribose, ribitol and phosphate; a T cell 
independent antigen (23). Activation of B cells by PS is mediated by binding of 
polysaccharide to the B cell receptor (BCR) and of the complement component C3D to 
its receptor (CD21) which is expressed on marginal zone B cells (42-46). The marginal 
zone B cell repertoire has low-level of self-reactivity which allows them to remain in a 
constant pre-activated state. They can therefore respond rapidly to blood-borne 
pathogens that enter the spleen.  
 
The antibody responses induced by the marginal zone B cells do not need any T cell co-
operation and are therefore known as T-cell independent (TI) responses. The reason 
that infection is so high in infants less than two years of age, is due to the immaturity 
of their immune system; in particular to the low level of expression of CD21 on their 
marginal zone B cells and this also makes them unable to mount an antibody response 
to PS-based vaccine (10, 47). 
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Figure 1.3. Schematic presentation of Immune response to polysaccharide (a T cell 
independent response) 
Adapted from (48) 
 
1.5  Conjugate vaccines 
As mentioned earlier, Hib conjugate vaccine followed the use of the polysaccharide 
vaccine when introduced in 1985, but was withdrawn in 1988 due to limited efficacy in 
infants under 18 months old. (49). Due to the inability of the polysaccharide vaccine to 
induce protective immunity in infants younger than 18 months old, polysaccharide has 
been chemically conjugated to a protein carrier. This converts the polysaccharide to a 
T cell dependent antigen which is able to induce an antibody response in young 
infants. The serum antibody to the type b capsule confers protection against invasive 
Hib disease, and conjugate vaccination primes the follicular B cells for long-term 
immunologic memory to the Hib polysaccharide, which does not occur after either 
immunisation with the unconjugated polysaccharide, or even after recovery from 
invasive Hib infection. Since the licensing of Hib conjugate vaccines in 1987 there has 
been a huge fall in the number of cases of invasive Hib infections (20, 50). 
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Effective Hib conjugate vaccines were first licensed for use in US children greater than 
18 months old in December 1987 and for infants over 2 months old in October 1990. 
The success of the Hib conjugate vaccine was seen when the age-specific incidence of 
Hib disease among children less than 5 years old decreased by 71% from 37 per 
100,000 people in 1989 to 11 per 100 000 people in 1991, however Haemophilus 
influenzae meningitis incidence decreased by only 2% between 1951 and 1991 (51). An 
advantage of the conjugate vaccine is the enhanced IgG booster responses after 
repeated immunisation, something which does not occur with the unconjugated Hib 
polysaccharide (52).  
 
Furthermore, the antibodies generated by immunisation with the Hib conjugate 
undergo affinity maturation, which results in higher avidity antibodies which are more 
efficient at activating complement-mediated bacteriolysis or opsonisation of Hib. It has 
also been shown that immunisation with Hib conjugate vaccines lowers the rate of 
nasopharyngeal colonisation and transmission of Hib, thereby decreasing the incidence 
of Hib even amongst non-immunised individuals (53, 54). 
 
The success of the Hib conjugate vaccine was soon followed by protein conjugation of 
polysaccharides from S. pneumonia and N. meningitidis. These highly effective vaccines 
induce long-term immune responses as they promote the differentiation of B cells, 
into long-lived memory B cells in addition to antibody-secreting cells. The existence of 
memory B cells also results in an increase the magnitude of the antibody response 
when the vaccine is given as booster doses.  
 
40 
 
Studies of the incidence of invasive Hib disease within the various age groups in 
England and Wales was shown to drop soon after the introduction of the first 
conjugate vaccine, ActHIB in 1992. The rate of incidence went from 22.9 per 100,000 
1990 (the pre-vaccine era) to 0.65 per 100,000 in 1998. In the UK, the conjugate 
vaccine was administered as three doses at 2, 3 and 4 months of age, a booster dose 
was then introduced at 12-13 months of age (55). This led to a dramatic fall in the 
number of cases of invasive disease in children under 4 years of age (as shown in 
Figure 1.4). 
Until the year 2000, widespread use of Hib vaccine use was mainly limited to countries 
within Europe and the Americas. However, by 2006 several other countries had 
included the Hib vaccine into their vaccination routines  (56) and this has led to a 
massive reduction in Hib disease in those countries. This is due to the protection 
afforded by the vaccination of the individual as well as the reduction of asymptomatic 
nasopharyngeal carriage in the population. This herd immunity is vital for the 
protection of the unvaccinated population, even in areas with low coverage (57-60).  
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Figure 1.4 Number of diagnosed cases invasive Hib disease in different age groups in 
England and Wales from 1990-2010 (Data from UK Health Protection Agency) 
 
Hib conjugate vaccines were prepared from either the PRP polysaccharide or 
oligosaccharide which was conjugated to diphtheria toxoid (PRP-D), CRM197 (a 
modified non-toxic fragment of diphtheria toxin; PRP-HbOC), or to the outer 
membrane protein of Neisseria meningitidis (PRP-OMP) (61). It was subsequently 
found that conjugation of PRP to tetanus toxoid (TT) was as efficient at generating 
antibody responses as PRP-OMP, PRP-D and PRP-HbOC. The technology to conjugate 
PRP to tetanus toxoid was not protected by patent laws, and so TT became the most 
commonly used (62). It was also found that PRP-D did not produce as good a memory 
response compared to the other conjugates, and is no longer used (49, 63). 
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Table 1.1 The effectiveness of various Hib conjugate vaccines with different protein 
antigens. (64) 
Vaccine commercial name Protein Carrier Protective efficacy (%) 
(Ref) 
PRP-D Diptheria toxoid 90 (65) 
35 (63) 
87 (66) 
HbOC Mutant diphtheria toxin 
CRM197 
100 (67) 
95 (66) 
PRP-OMP (or –OMPC) Outer membrane protein 
complex 
95 (68) 
PRP-T Tetanus Toxoid 100 (69) 
 
As can be seen in Figure 1.4, there was a brief resurgence in Hib cases around the 
years 2000 to 2004. The incidence went from 0.65 per 100,000 in 1998 to 4.6 per 
100,000 in 2002 (70). The increase was identified as being caused by the use of of the 
DTaP-Hib combination vaccine (a 5-in-1 combination vaccine against Diptheria, 
Tetanus and Pertussis) which contains acellular components of pertussis, instead than 
the equivalent whole cell pertussis preparation (DTwP) (70). Although the protection 
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induced by conjugate vaccine is known to rely on the formation of immunological 
memory and pre-existing antibody, it was identified that there was an increased risk of 
Hib vaccine failure in fully immunised children who had received two or more doses of 
the trivalent DTaP vaccine (Infanrix) administered concurrently with the Hib-TT vaccine 
(71). 
It was found that although the DTaP vaccine administered in combination with Hib-TT 
produced lower antibody titres than when administered in combination with the 
DTwP, the nature (isotype and IgG subclasses) and function (avidity and opsonic 
activity) of the antibodies were the same with both the acellular- and the whole cell 
pertussis-combination vaccine. Hib immunological memory was also induced by both 
types of  combination vaccines and the sera from immune individuals was also able to 
protect rats against invasive disease after a passive transfer assay (72). These 
observations imply that the immunological response and formation of memory 
induced by these vaccines should be sufficient for protection against invasive Hib 
disease.  
There are many proposed mechanisms by which the DTaP vaccine might be interfering 
with the response to the Hib-TT conjugate. In a study by Dagan et al (73) it was seen 
that the reduction in the level of anti-PRP antibodies occurred when the PRP-TT 
conjugate was administered simultaneously with DTaP vaccine and a pneumococcal 
conjugate vaccine containing the same carrier protein (TT). It has also been noted that 
the decrease in the anti-PRP antibody response occurred with the highest dose of PncT 
(Pneumoccal and Tetanus toxoid) conjugate (within the combination). It is possible 
that the elevated concentration of antibodies to protein carrier could interfere with 
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conjugate immunogenicity through antigen capture and/or modulation of antigen 
presentation. When infants immunised with the Hib-TT were studied, it was also noted 
that the decrease in the level of the anti-PRP antibody response was proportional to 
the dose of TT injected from both vaccines.  
Other previous studies also indicated that the immune response to the carrier protein 
might interfere with and decrease the antibody response to the polysaccharide. It was 
found that pre-immunisation with the protein carrier can reduce the antibody 
responses to both the carrier and to PRP following immunisation with Hib-TT conjugate 
(74). A similar effect has also been described with other protein epitopes (75, 76). It 
was also demonstrated that the presence of maternal antibodies to the TT inhibited 
the response of infants to the PRP when immunised with the Hib conjugate vaccine.  
It is also possible that the suppression is mediated by the clonal dominance of B cells 
specific to the carrier epitopes. As the frequency of polysaccharide-specific B cells 
clones is much lower than the frequency of B cells specific to the carrier protein (77, 
78). The decrease in the response against the polysaccharide is proportional to the 
intensity of the immune response to the carrier and this effect is increased with 
polysaccharides with epitope for which a low frequency of B-cell precursors exist. 
A study by Fattom et al. (79) used two vaccines, a 12-valent E. coli vaccine and an 8-
valent S. aureus consisting of polysaccharides conjugated to the same carrier protein. 
It was found that when the two vaccines were administered together at the same site, 
there was a significant reduction in the antibodies against the polysaccharide 
compared to when the monovalent conjugates are administered separately.  
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The rising incidence of vaccine failure cases seen in Hib and Meningococcal serogroup 
C immunised individuals despite the presence of immunological memory (47) made it 
clear that the waning antibody titres are responsible for the vaccine failure. It was also 
demonstrated that even in individuals recently vaccinated with the conjugate vaccine 
there is a delay in the induction of a detectable increase in antibody concentration- 
leaving the individual vulnerable to invasive infection over the first few days following 
immunisation (80).  
As a result of the increase in Hib-cases, the DTaP-Hib combination vaccine (Infanrix) 
was withdrawn in 2003 and use of the DTwP-Hib combination vaccine was resumed. A 
Hib vaccination booster campaign was implemented from May to September 2003. In 
2004, the UK  switched to Pediacel- a combination containing DTaP, inactivated polio 
and Hib (but a different acellular pertussis component than that contained in the 
earlier vaccine), and was shown to induce a satisfactory immune response to the PRP 
(81). It was necessary to switch from the whole cell pertussis containing vaccine to one 
containing the acellular pertussis vaccine because of the reduced reactogenicity of the 
latter. In 2006, the Department of Health introduced a booster dose of a Hib and MenC 
combination vaccine (Menitorix) to infants at 12 months.  
1.6 Mechanisms of induction of antibody response to foreign 
antigen 
The initial step in a humoral response requires the acquisition of antigens by B cells via 
surface immunoglobulin. However, between the events of immunisation and 
production of an antibody response against the antigen, the vaccine or the pathogen 
will undergo trafficking through the lymphatics. A soluble antigen such as the 
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conjugate vaccine will passively diffuse through the blood stream or enter straight into 
the lymphatic vessels until it reaches a secondary or primary lymphoid organ, such as a 
lymph node or the spleen. The soluble antigens can diffuse directly from the lymph 
node the subcapsular sinus (SCS) in the lymph node follicle to be acquired by antigen-
specific B cells in the follicles (82). In the case of particulate antigens, transport is 
initially predominantly neutrophil uptake, and from 24 h to 72h by dendritic cells 
(DCs).  
1.7  Neutrophils 
Neutrophils are an abundant effector cell in the blood (40 to 75% of the white blood 
cell content in mammals) and play a vital role in phagocytosing and killing extracellular 
bacteria. Neutrophils start their existence in the bone marrow and continue circulating 
in the bloodstream until recruited in large numbers to a site of infection. They are one 
of the first inflammatory cells to migrate towards the site of injection due to local 
inflammatory signals. They migrate through blood vessels, then through interstitial 
tissue following chemical signals such as Interleukin-8, C5a, fMLP and Leukotriene B4 
(83). 
Phagocytosis by a neutrophil is the most likely outcome of introduction of a small 
particulate antigen at the site of immunisation. The particle may be recognised by 
being opsonized by antibodies (84). A neutrophil may phagocytose many particles, 
each phagocytic event results in the internalisation of the particle into a phagosome. 
Within the phagosome, the particle is exposed to reactive oxygen species and 
hydrolytic enzymes in an event known as the ‘respiratory burst’. 
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After the initial influx of neutrophils to the site of immunisation or infection, the 
neutrophils which have phagocytosed the particles proceed to migrate to draining 
lymph nodes and shortly undergo apoptosis. The cellular debris is then most likely to 
be either taken up by resident macrophages, and the antigens recognised and 
processed by circulating dendritic cells either in the local tissue or in the draining 
lymphoid organs (85).  
1.8  Dendritic Cells 
Dendritic cells (DCs) are the most functionally important cells in the trafficking of 
antigen to the lymph nodes, as well as presenting the antigen to other immune cells 
such as B cells. DCs can take up a wide range of antigens and present them  to T cells in 
the context of class I or II MHC. They are especially suited to stimulating naïve T cells, 
and are therefore crucial in the priming of a T cell dependent response against the 
conjugate vaccine.  
They exist in two main states in vivo; immature until they capture antigen and go 
through a maturation process that allows them more capacity for activating other 
immune cells.  Before activation, they exist in many non-lymphoid organs, but then can 
migrate to the afferent lymph or the T-cell dependent areas of the spleen. Immature 
DCs are common in the peripheral tissues and are adept at endocytosis and express 
relatively low levels of surface MHC class I and II molecules. MHC Class II molecules are 
synthesised by the cell, however it is sequestered intracellularly in endocytic 
compartments. Immature DCs readily take up antigen, which is then transferred to 
lysosomes containing MHC Class II, although these are used for use as immunogenic 
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peptides rather than to form complexes with MHC Class II (86, 87). The immature DCs 
are therefore less efficient at presenting antigen to T cells.  
In the mature state, DCs have much less of a capacity for antigen uptake, but an 
increased capacity for T cell stimulation. During the maturation process, the MHC 
CLASS II is redistributed from the intracellular compartments to the plasma membrane. 
Co-stimulatory molecules such as CD80, CD86, MHC I and T cell adhesion molecules 
are also upregulated. Any previously or newly internalised antigens are then able to 
form complexes with MHC Class II (86, 87). The structure of the cell changes, and long 
membrane folds of “dendritic” extensions act to increase T cell interactions.  
Dendritic cells can retain and transport intact antigen and present the antigen to naïve 
B cells (88). DCs can also give cell-bound signals essential for class switching, and this 
interaction can occur in a primary antibody response and is independent of T-cell 
intervention.  It has also been suggested that the  interaction of CD40L on the DC and 
CD40 on B cells also increases survival of the B cell (88).  
1.9  Macrophages 
Macrophages are large phagocytic cells that are found in essentially all tissues (89). 
Macrophages patrol of potential pathogens and play a critical role as part of the innate 
immune system. They also play a role in priming the adaptive immune response 
through recruiting other immune cells such as lymphocytes through inducing 
inflammation. A monocyte (the macrophage precursor) enters damaged tissue, such as 
that of an immunisation site, through extravasation through the endothelium of a 
blood vessel. Unlike neutrophils, macrophages can survive several months in the body. 
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In one study by Ambrosino et al (1992), the conjugate of the Hib capsular 
polysaccharide to OMP showed an increase in spleen size and number of 
macrophages, therefore concluding that the macrophage activation and cytokine 
release increased the immunogenicity of the Hib polysaccharide (90). 
After either endocytosis of foreign pathogen or vaccine antigen, the antigen presenting 
cell will require presentation in the context of a MHC class II molecule before 
recognition by the specific T cell receptor. 
1.10 Antigen processing and presentation by MHC Class II 
The MHC Class II is formed of a heavy and light chain in the endoplasmic reticulum. 
Initially it is associated with another peptide, the invariant chain, which guides the 
trafficking of the membrane bound complex from the endoplasmic reticulum into the 
endocytic pathway within a vesicle. The gradual acidification within the endocytic 
vesicle leads to activation of proteases, namely cathepsin S, which cleave the invariant 
chain in two locations. This process leaves the class II invariant associated chain 
peptide (CLIP) bound to the MHC class II groove, preventing binding by self-peptide 
fragments during transit.  
Foreign peptides such as pathogens or vaccine particles are engulfed by the cell into 
the endocytic pathway; here they also undergo a reduction in the pH which results in 
their degradation by acid activated proteases. Fusion of the endocytic vesicles 
containing the MHC class II and the pathogen or vaccine occurs, but the antigens 
cannot bind to the MHC class II groove until the HLA-DM molecules catalyses the 
removal of the CLIP from the groove, and also catalysing the binding of the foreign 
particles to the cleft. The vesicle is then trafficked to the cell surface where it fuses 
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with the phospholipid bilayer and the MHC class II associated antigens are exposed to 
the extracellular space. A schematic diagram of the intracellular trafficking of MHC is 
shown in Figure 1.5. 
 
 
Figure 1.5. Schematic representation of antigen uptake, processing and presentation 
in the context MHC Class I and MHC Class II.  
Image from (91) 
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1.11 Processing by B cells 
B cells have been shown to be able to prime naïve CD4+ T cells in both vitro and in vivo 
(92-94). Although B cells may not be essential for the priming of T cells (95, 96) in order 
to induce a protective humoral response, uptake of the antigen and involvement of the 
T cell is essential.   
B cells encounter antigen in secondary lymphoid organs after either diffusing there 
through the lymph or by trafficking by cells of the immune system in the case for 
soluble and particulate antigen respectively. Antigen-activated B cells and T cells 
migrate towards the borders of the B cell follicles and the T cell zones of secondary 
lymphoid organs, respectively. A schematic diagram of the cellular movement is shown 
in Figure 1.6.  B cell–T cell interactions occur and enable B cells to receive helper 
signals from cognate CD4+ T cells. Activated B cells and T cells then migrate to the outer 
follicles, where B cells undergo proliferation.  
Some of the proliferating B cells differentiate into short-lived plasma cells, which give 
rise to the extra-follicular foci, and some develop into memory B cells). Alternatively, 
the activated B cells can return to the follicle and can undergo rapid proliferation to 
form the germinal centre. In the dark zone of the germinal centre, the clonal expansion 
of antigen-specific B cells is accompanied by B cell receptor (BCR) diversification 
through somatic hyper-mutation.  
The B cells that exit the cell cycle relocate to the light zone, where affinity selection 
takes place through interaction with immune complex-coated follicular dendritic cells 
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(FDCs) and antigen-specific T follicular helper cells. The affinity-matured germinal 
centre B cells can re-enter the germinal centre cycle. Alternatively, these germinal 
centre B cells exit the germinal centre, either as memory B cells or as long-lived plasma 
cells that contribute to serological memory. The strength of signals that B cells receive 
is likely to determine their fate; stronger signals (indicated by bold arrows) favour 
development into plasma cells or germinal centre B cells, whereas weaker signals 
(indicated by narrow arrows) determine memory B cell differentiation.  
 
Figure 1.6 Schematic representation of the movement of the B cell within the 
secondary lymphoid organ 
Image taken from review by Kurosaki et al (97) 
In the immunologically naïve individual, the polysaccharide chain in a conjugate 
preparation binds to polysaccharide-specific membrane immunoglobulin expressed on 
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B cells (Figure 1.7). The conjugate is then internalized into the cell and the carrier 
protein is digested by proteases within an endosome. Resulting peptides are 
subsequently transported to the cell surface in association with the type II major 
histocompatibility complex (MHC Class II). Peptide specific T cells can then recognise 
the peptides presented on the B cells. This leads to activation of T cells and secretion 
of cytokines which lead to the maturation and differentiation of the polysaccharide 
recognising B-cells into specific plasma and memory B cells. Plasma cells undergo 
avidity maturation and isotype switching, producing IgG, IgA or IgE antibodies which 
have defined roles in the immune system (3, 48). Only after this process are the B-cells 
described as polysaccharide specific. 
 
 
Figure 1.7. Schematic representation of the induction of the anti-polysaccharide 
response by conjugate vaccines.  
Image taken from (48) 
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The two signals which are essential for T cell dependent naïve B cell activation are the 
BCR cross-linkage by the antigen (signal 1), and the cognate interaction with the helper 
T cells through the formation of an immunological synapse (signal 2). Upon formation 
of the immunological synapse the antigen specific T cells become activated and form 
CD40L-CD40 interactions as well as secrete cytokines to stimulate the B cells.  The 
binding of the antigen to the BCR forms a complex which is internalised and degraded 
in the endosomal pathway. This process initiates activation of the B cell, which initiates 
a signalling cascade that leads to the up-regulation of co-stimulatory molecules and 
also increases the efficiency of antigen internalisation, processing and presentation of 
the antigenic peptides in the context of MHC class II molecules (98, 99).  
Isotype class switching (also referred to immunoglobulin class switching, or class 
switch recombination) is a mechanism that allows B cells to produce antibodies of a 
different class, for example IgG, instead of IgM. The differences induced by this process 
are in the constant portion of the antibody heavy chain, whereas the variable region, 
and therefore the specificity remains the same. The antibodies of different classes can 
interact with different effector cells; therefore daughter cells produced from the same 
activated B cells can produce both different isotypes and subtypes. The process of 
Class switch recombination (CSR) is responsible for the antibody-heavy chain locus to 
be removed from the chromosome and the surrounding gene segments to re-join, 
forming a new antibody gene which expresses a different isotype (48). 
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There is increasing evidence which indicates that other signals and cell types may play 
accessory roles in T cell dependent B cell responses. Toll-like-receptor (TLR) signals can 
enhance the activation of B cells in response to T cell dependent antigens (100).  
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1.12 Current Limitations for wide use of the Hib conjugate vaccine 
In 2003, it was estimated by WHO that 92% of the eligible population in the developed 
world was vaccinated against Hib, but in developing countries the coverage was 42% 
and as low as 8% in the poorest countries (101).  
Despite the high efficacy attributed to the conjugate vaccine, there are some 
drawbacks which limit more widespread use, especially in poor countries. The difficult 
and expensive conjugation chemistry requires a tight process control and further 
purification steps to remove impurities and unconjugated polysaccharide, leading to 
high manufacturing costs, which limits its availability in poorer countries.  
Another limitation is the additional cost of the cold chain for storing and transporting 
the vaccine. Globally, 50% of vaccines are wasted due to poor thermo-stability (102, 
103).  It is also estimated that 80% of the financial cost of vaccination is maintaining 
the cold chain (104). When combined with the high cost of manufacturing, widespread 
vaccination with the Hib conjugate vaccine becomes unfeasible in some countries, 
particularly those with underdeveloped infrastructure. 
Despite the high cost, there have been recent efforts to increase the uptake of Hib 
conjugate vaccines in developing countries though the Global Alliance for Vaccines and 
Immunization (GAVI) -funded Hib initiative. Whilst this work is of incredible value, 
finding a replacement for the conjugate vaccine which is cheaper to produce and 
thermally stable would encourage even more countries to introduce the Hib vaccine 
into their national immunisation programmes. 
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Thus, in this project our aim is to investigate the possibility of a replacement Hib 
vaccine candidate which would remove the need for expensive chemical conjugation 
of the polysaccharide to the protein carrier by co-adsorbing the polysaccharide and the 
carrier protein onto a protein-based microcrystal, producing a virtual conjugation. 
A pilot study using Protein Coated Microcrystals (PCMCs) loaded with PRP, TT and CpG-
ODN (as an adjuvant) produced an anti-PRP IgG response in 3/8 animals following 3 
immunisations (Figure 1.8). This preliminary data formed the basis of this project. 
 
 
 
Figure 1.8. Anti-PRP response induced by PCMCs loaded with TT, PRP and CpG.  
Rats were immunised with a PRP equivalent dose of 6µg in CaP-PCMCs on days 0, and a PRP dose of 
1.2µg of CaP-PCMCs on days 28 and 56. Test bleeds were taken on days 28, 42 and 56. Serum anti-PRP 
IgG response was measured by ELISA. Levels of anti-PRP responses were determined by parallel line 
analysis relative to an immune serum from animals immunised with a Hib-TT conjugate vaccine with an 
assigned titre of 5000. 
Response from individual animals is shown as green diamonds and the geometric mean titre of the 
group is shown as a red horizontal bar. 
 
Number of immunisations 
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Thermostable vaccine delivery approaches 
As discussed earlier, the removal of the requirement for the cold chain can improve 
the cost and ability of the vaccine to be delivered to areas with restricted 
infrastructure. Much research has therefore been focussed on developing formulations 
for stabilising biological molecules such as vaccines and antibiotics. Such methods 
include the use of nanoparticles, micro-encapsulation, and liposomes (104) and are 
discussed below.  
Micro-encapsulation 
Tiny particles or droplets are surrounded by a coating to give small capsules of useful 
properties- a process which allows the stabilisation of the particle contained within the 
capsule. This process has been used to produce formulations which can decrease 
dosing frequency and prevent the degradation of the pharmaceutical. Most 
microcapsules have cores with diameters between a few micrometres and millimetres. 
Biodegradable polymer microspheres have been developed for the controlled release 
of antigens. This reduces the number of doses needed for primary immunization a 
single dose. A variety of vaccine antigens have been formulated into microspheres 
usually composed of PLGA. Depending on the size of the microspheres, molecular 
weight of polymer and ratio of lactic to glycolic acid in the polymer, the antigen can be 
targeted to various cells of the immune system or act as a depot a the injection site. 
However, problems in developing controlled-release vaccines have included instability 
of vaccine antigens during micro-encapsulation, storage and hydration pre-injection 
(105). 
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One material used for microencapsulation is silk fibroin. Silk is a biologically derived 
protein polymer purified from domesticated silkworm (Bombyx mori). The advantages 
of this material for use within pharmaceutical applications are that it is biocompatible, 
it has robust mechanical strength and it has a slow, controlled degradation (106, 107). 
The silk is processed entirely in an aqueous environment, using mild ambient 
conditions in terms of temperature and pressure. These conditions allow the use of 
labile biomolecules without compromising their bioactivity (108, 109). 
Silk has been used to stabilise the live measles, mumps and rubella vaccine (MMR). 
The commercial MMR contains protein and salt stabilisers, but still remains susceptible 
to degradation when exposed to variations in temperature (110). However upon 
microencapsulation within silk microspheres the vaccine remained viable for up to six 
weeks at 60° Celsius.  
A study by Gupta et al (105) used tetanus toxoid (TT) and PRP conjugated to TT (Hib-T) 
inside PLGA microspheres as a vaccine. The antibody levels in mice were evaluated and 
it was found that a single injection of these micro-encapsulated vaccines induced 
increased antibody levels which persisted for several months,  antibody levels were the 
same or high than those induced by immunisation of conventional formulations of 
AIPO4-adsorbed TT or soluble Hib-T conjugate vaccine. 
Nanoparticles 
Nanoparticles have an advantage of being a similar size to cellular components, 
allowing them to enter living cells using cellular endocytosis mechanism (111). 
Nanoparticles have qualities that lend themselves to vaccine formulation. They 
increase antigen stability, can improve immunogenicity and can be used for targeted 
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delivery and slow release (112, 113). In particular, the use of biodegradable polymeric 
nanoparticles with entrapped antigens such as proteins, peptides, or DNA are being 
investigated as a method for controlling the release of antigens, as well as controlling 
the type of immune response by targeting antigen-presenting cells (APCs). The delivery 
of the antigen to the APCs, such as dendritic cells (DCs) is vital for the production of an 
effective immune response to the vaccine.  
Nanoparticles have been increasingly used for vaccine formulations (Figure 1.9). 
Nanoparticles work well as a delivery system, to enhance processing and also can be 
used as an immune-stimulant to enhance immunity. Nanoparticles have been used for 
both therapeutic (114, 115) and prophylactic vaccines (116-118).  
 
Figure 1.9. Number of publications returned using the search terms “nanoparticle* 
and vaccin*” from Web of Science (http://apps.webofknowledge.com/; results for a 
search conducted on 29 July 2013). Taken from (112) 
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Nanoparticles can be made from synthetic polymers which give slow degradation rates 
such as: 
 Poly (D L-lactide-co-glycolide) (PLG) 
 Poly (D L-lactic-coglycolic acid) (PLGA) 
 Poly (g-glutamic acid) (g-PGA) 
 Poly(ethylene glycol) (PEG) 
 Polystyrene 
These polymers have also been used to synthesize hydrogel nanoparticles; a 
type of nano-sized hydrophilic three-dimensional polymer network. Nano-gels 
have the advantage of flexible mesh size, large surface area for multivalent 
conjugation, high water content, and potential for high antigen-loading (119).  
Natural polymers based on polysaccharides have been used. Examples include: 
 Pullulan (120, 121) 
 Alginate (122) 
 Inulin (123, 124)  
 Chitosan (125, 126) 
As well as vaccines, natural polymers such as chitosan are used for prolonged 
controlled release drug delivery systems, wound dressing, blood anticoagulants and 
bone tissue engineering scaffolds.  Chitosan-based nanoparticles have been a focus of 
recent studies due to good biocompatibility, biodegradability, nontoxicity and ability to 
control morphology (127-129). Chitosan has been used in the preparation of various 
nanoparticle vaccines including HBV vaccines (130), Newcastle disease vaccines (131), 
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and DNA vaccines (128, 132-134). Inulin acts through the activation of 
complement via the alternative pathway (135), and therefore has the advantage of 
being an adjuvant. Chitosan nanogels have also been used as a vaccine 
against Clostridium botulinum type-A neurotoxin subunit antigen Hc for an adjuvant-
free intranasal vaccine (136) and recombinant NcPDI antigen for Neospora caninum 
vaccination (137). There are also adjuvants derived from inulin, such as Advax™, a 
nanoparticle suspension. Use of Advax™ has shown enhancement of immune response 
in vaccines against various viruses including influenza (123) and hepatitis B (124). 
As well as natural polymers, synthetic substances for nanoparticle vaccines have also 
been used for vaccination. Although non-biodegradable, synthetic materials have an 
advantage in that they have a rigid structure and highly controllable synthesis (138). 
One of the most researched inorganic materials for nanoparticle vaccines is Silica. 
 Silica-based nanoparticles (SiNPs) are biocompatible and act as excellent nanocarriers 
for applications such as selective tumor targeting (139), real-time multimodal imaging 
(140), and vaccine delivery. The SiNPs can be prepared with tunable structural 
parameters. The particle size and shape of SiNPs can also be controlled to change the 
manner in which they interact with cells (141), an important advantage in vaccine 
design. The abundant surface silanol groups are also able to be modified to increase 
functions such as cell recognition, absorption of specific biomolecules, improved 
interaction with cells, and enhancement of cellular uptake (142-145). 
One form of nanoparticle formulation that is used for stabilisation of vaccines is the 
liposome. The liposome has been identified as a potential adjuvant since 1974 (146). 
Liposomes and liposome-derived nano-vesicles such as archaeosomes and virosomes 
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are increasingly investigated as potential carriers of antigen in vaccine development. 
Liposome based vaccine delivery systems are highly versatile, as their preparation and 
composition can be adapted to produce the desired properties. Hydrophilic 
components can be entrapped within the liposome, whereas the lipid-soluble 
components can be integrated into the lipid bilayer or linked to the surface of the 
liposome by chemical linkages.  
The liposome approach was also used to replace the need for conjugation of 
oligosaccharide to a carrier protein as shown in a study by Deng et al (147). A self-
assembling liposome containing pneumococcal oligosaccharides  (serotpye 14) and 
NKT cell adjuvant was used to successfully induce a natural killer T cell response that 
mediated the production of high titres of polysaccharide-specific IgG  response, 
comparable to level of response induced in animals immunised with the pneumococcal 
conjugate vaccine (Prevnar) in a non-liposomal form.  
 
1.13 Our approach to producing a more economic thermo-stable 
vaccine against Hib 
1.13.3  Protein coated microcrystals (PCMCs) 
Microcrystals can be engineered to stabilise a wide range of biomolecules including 
proteins, peptides, DNA/RNA and polysaccharides onto a core crystalline material.  
Small microcrystals made up of protein, sugar or salt can be produced by the rapid 
dehydration of an aqueous solution to produce self-assembled micro-particles, which 
can be coated with other particles such as antigens. The inert crystalline water-soluble 
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core is around 3-5µms in diameter and can be coated with one or a combination of 
proteins. These are therefore known as protein coated microcrystals. These crystals 
can also be coated with a thin layer of Calcium Phosphate (CaP), the thickness of which 
can be varied by the preparation process. In an aqueous environment, this CaP layer 
dissolves slowly and therefore allows a suspension of the PCMCs to be made until the 
CaP layer gradually erodes and leaves the crystals to dissolve.  Representative images 
of the PCMC forms are displayed in Figure 1.10. 
The PCMCs are prepared by dissolution of the excipient, along with the biomolecule of 
interest into an aqueous solution. This aqueous solution is rapidly dehydrated when 
added to a water miscible organic solvent. The PCMCs are immediately formed with 
the biomolecule immobilised on the surface of the excipient and can be dried to form 
a free-flowing powder. The final qualities of the PCMCs such as morphology, size and 
biomolecule loading can be adjusted by altering the dehydration conditions.  
 
 
Figure 1.  Preparation of CaP-PCMC 
PCMC prepared with inclusion of
phosphate buffer
Suspended In solvent
CaCl2
dissolved in solvent
PCMC coated with thin layer 
of calcium phosphate
CaP-PCMC
highly soluble in aqueous sustained release formulation   
Figure 1.10 Preparation of PCMC and CaP-PCMCs.  
Yellow spheres represent the protein adsorbed to the surface of the (blue) microcrystal. Orange spheres 
represent CaP coated biological molecule adsorbed to the surface of the microcrystal.   
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The advantages of PCMCs are summarized in Table 1.2.  
Table 1.2 The advantages of the PCMC technology. 
 High dosage delivery Can remain as a stable solid in suspension at high 
concentration.  
The viscosity still allows delivery through a 27 gauge 
needle 
Osmolarity applicable for subcutaneous 
administration 
 Sustained-release of 
biologics 
The release of the active pharmaceutical ingredient 
from the crystal can be controlled by the dissolution 
of calcium phosphate. This is easy to include in the 
normal production process. 
 Co-delivery of antigens 
and immune-stimulants 
to cells 
Immobilisation of the adjuvant onto the same 
crystal as the antigen allows simultaneous uptake 
and processing. 
The similarity of the particle size to a bacterial 
pathogen may also act with the adjuvant to imitate a 
bacterial pathogen. 
 Elimination of the cold-
chain requirement 
Active ingredients can be stabilised onto the crystal 
and the bioactivity is retained. 
 Possible for pulmonary 
delivery of biologics 
Can be handled as a powder to deliver multiple 
active ingredients simultaneously 
 Can use continuous 
manufacture 
The manufacturing method of the PCMC can be 
adapted for larger continuous production of the 
formulation. 
(From(148)) 
Work using the PCMC technology has resulted in products for the pulmonary 
administration of medicines which can contain more than one active agent, allowing 
the simultaneous administration of drug and a secondary agent such as an adjuvant. 
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The ratio of the multiple active agents adsorbed on the PCMCs can be specified, which 
may be crucial to the action of the components. PCMCs also have high thermostability 
which allows easy storage without the necessity for the cold-chain (149).  
Adenylate cyclase (Cya) toxin from Bordatella pertussis immobilised onto PCMCs in 
combination with calmodulin (CaM) or bovine serum albumin (BSA) was formed to 
retain its enzymatic activity, even when kept as a dry powder at 37°C for 2 weeks 
(150). Diptheria toxoid was immobilised onto PCMCs and the immunogenic activity 
was found to be retained in immunogenicity studies in mice, although it was reduced 
when the PCMCs were stored at 45°C for 4 weeks (149). 
In this project, new formulations of PCMC that contain L-glutamine microcrystals 
coated with the Hib polysaccharide PRP and TT antigen will be prepared and evaluated 
both in vivo and in vitro. Characteristics of the formulated PCMCs will need to be 
considered and the manufacturing processes that affect these characteristics will need 
to be understood. Properties of the existing conjugate vaccine may give a guide as to 
suitable characteristics that are required in the PCMC vaccine.  
The immune response required to produce adequate protection and memory will need 
to be characterised and considered in order to formulate an effective vaccine. Previous 
studies have showed that anti-PRP antibody titres  could  be used as  a correlate of 
immunity for the Haemophilus influenzae type b (Hib) polysaccharide (21). A study in 
unvaccinated population in Finland showed a decrease in age-specific incidence of Hib 
disease when the majority of the population had antibody concentrations of 0.15 µg or 
more; and in the efficacy study of PRP vaccine,  (151) age-specific vaccine efficacy 
correlated with the induction of 1.0 µg of antibody post-vaccination, therefore an 
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antibody level of 0.15 µg is probably protective against bacteraemia. In this study, the 
antibody titres will be measured and compared to existing Hib-TT conjugate 
immunised groups. 
 It has been shown that the rat model would be the most appropriate model to use to 
study antibody response to Hib conjugate vaccines. When immunised with Hib 
polysaccharide alone, both rats and guinea pigs fail to induce a memory response 
compared to when immunised with the Hib-TT conjugate. Mice have been tried as a 
model, however they mounted similar antibody responses to Hib when immunised 
with PRP alone or with the Hib-TT conjugate (152). Therefore, a rat model will be used 
in the study to assess antibody responses to immunisation with the formulation.  
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Chapter 2. Aim and Objectives 
Induction of an anti-PRP IgG response has been demonstrated after immunisation with 
a PRP-TT-CpG-CaP-PCMC formulation.  This demonstrates the ability of the formulation 
to act as a virtual conjugate of both the PRP and the protein antigen.  However, only 
three out of eight animals responded to three doses of the crystal formulation. The 
aim of this project is therefore to investigate the qualities of the CaP-PCMC to enhance 
the ability of the CaP-PCMCs to induce an anti-PRP response to a level similar to that 
induced by the conjugate vaccine.  
Specifically, the objectives were to: 
 Characterise the crystals and determine how the changes to the preparation 
procedure affects the morphology of the crystals. 
 Evaluate the immunogenicity of selected CaP-PCMC formulations in terms of 
anti-PRP, anti-TT responses, as well as splenocyte proliferation in response to 
TT and bactericidal qualities of the serum from immunised animals. 
 Understand the interaction of the CaP-PCMCs with cells of the immune system 
by co-incubation of cell cultures of neutrophils, dendritic cells and B cells with 
fluorescently labelled CaP-PCMCs.  
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Chapter 3. Investigation into Preparation Parameters on 
Physico-chemical properties of CaP-PCMCs 
3.1.  Introduction 
To create a virtual conjugate of the polysaccharide PRP and the protein TT antigens 
using the Protein Coated Microcrystal (PCMC) technology, it is necessary to 
understand the characteristics of the PCMCs prepared under various experimental 
conditions as they are likely to affect the immunogenicity of the crystals. 
The advantage of using a particle vaccine compared to soluble vaccinesis a much 
higher rate of antigen presenting cell (APC) uptake (153, 154). Once taken up by an 
APC, the antigen can be trafficked to the draining lymph nodes, as well as being 
presented within the major histocompatibility complex (MHC) class I or II for activation 
of T cells.  
Uptake of the particulate formulation into APCs is dependent on the physico-chemical 
characteristics of the particle. These can include size, surface charge, as well as 
hydrophobicity. Uptake into the APCs might also be through different mechanisms 
such as receptor mediated endocytosis, micropinocytosis and phagocytosis, which 
depends on the nature of the antigen(154-157).  
At this point, it is not fully understood how the changes in shape or size of the crystals 
may affect the immunogenicity of a given formulation. However, it is important to 
consider that the PCMCs need to be delivered to the draining lymph nodes for 
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recognition by B cells. Trafficking of the PCMCs may occur by circulating dendritic cells 
or other cell types such as neutrophils. Using polystyrene particles of various sizes and 
shapes, Champion et al. (2006) reported that particle shape, and not size, plays a 
dominant role in particle uptake and phagocytosis by alveolar macrophages (158). In 
particular, the local particle shape at the point of initial contact dictates whether 
macrophages initiate phagocytosis or simply physically spread onto the particles. 
The aim of the work in this chapter is to understand the formation of the CaP-PCMCs 
and optimise the preparation process to control the size and morphology of the 
crystals. PCMCs were prepared under varying conditions to determine how these 
influence the characteristics of the crystals formed. These were analysed for physical 
properties, such as shape and size. Antigen loading and immunological characteristics 
are discussed in later chapters. 
PCMCs are produced by firstly dissolving the L-glutamine, the PRP, TT and the adjuvant 
CpG in an aqueous solution and then precipitating these together by addition into a 
large volume of Isopropanal (IPA) in which these are not soluble. Water-insoluble 
PCMCs where the antigens, adjuvant and L-glutamine, are prepared with a Calcium 
Phosphate layer (CaP) is formed by reacting the Sodium Phosphate (dissolved in the 
aqueous solution) and Calcium Chloride which is added one min after the aqueous 
solution has been added to the IPA (for two step preparation, Figure 3.2) or in the 
Isopropanal on the magnetic stirrer (for the one step preparation, Figure 3.1). The 
quantity of Calcium Chloride needed is calculated from the reaction: 
CaCl2 + 2 NaH2PO4 = Ca(H2PO4)2 + 2 NaCl 
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It can be seen from the equation that half a mole of calcium chloride was needed for 
each mole of sodium phosphate. In our experiments the Calcium Chloride was added 
at a molar ratio of 1:1 or 5:2 with the Sodium Phosphate in order to achieve a 2x or 5x 
excess respectively, to investigate the influence of the extent of calcium chloride 
excess. 
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Small volume of aqueous solution containing the antigen, L-
glutamine and NaH
2
PO
4
 
Large volume of IPA containing CaCl
2
 
Figure 3.1. Schematic representation of the CaP-PCMC production 
Figure 3.2 Schematic presentation of the PCMC preparation in 2-steps. 
 
  
 
Small volume of aqueous 
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NaH
2
PO
4
 
Large volume of IPA 
 
  
 Small volume of CaCl2 in IPA 
added after 1 min of adding 
aqueous components 
Step 1 Step 2 
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3.2. Aims and objectives 
The preparation protocol can be varied to alter the formation of the crystals. It is 
known that crystal size would increase given factors that would slow crystal 
precipitation. This would include water content of the IPA/water mixture or the 
temperature of the solvent when the L-glutamine and antigen solution is added. The 
factors that were chosen to be investigated are listed in Table 3.1.  
 
To thoroughly investigate the effect of every preparation parameter, a systematic 
multi-factorial investigation would have to be carried out, which would not be practical 
due to the time and cost required to produce every sample and carry out full 
characterisation of each combination of parameters. Instead, this investigation relies 
on the experience and advice of XstalBio who provided a focussed range of factors that 
were most likely to change the morphology of the crystals.  
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Table 3.1 Parameters that were varied during the preparation of PCMCs 
Parameters of CaP-PCMC preparation Expected effect on crystal formation 
Solvent Temperature (°C) 4, 20, 50 
Increased temperature might increase the 
speed of crystal formation and result in 
smaller crystals or a difference in CaP layer 
Water content (aqueous volume as 
percentage of total mixture volume, 
v/v %) 
3, 5, 7 
Decreasing water content may increase the 
dehydration of the aqeous components and 
speed of precipitation and therefore smaller 
crystals 
Number of steps to form CaP layer 1, 2 
Adding the CaCl2 in a second step allows the 
L-glutamine and antigens to precipitate 
before the CaP and therefore may result in a 
different CaP structure 
Mixing Time (min) 1, 16 
A shorter mixing time may prevent further 
deposition of the CaP, or antigens on the 
surface of the forming crystal shape and 
result in smaller crystals but higher loss of 
material during the process 
NaH2PO4:CaCl2 ratio (CaCl2 excess) 1:1, 5:2 (2x, 5x) 
Increasing CaCl2 excess may increase the 
speed of its reaction with NaH2PO4 and 
increase the speed of formation of the CaP 
layer which might result in smaller crystals or 
a less formed CaP layer 
CaP Loading (%) 10, 15 
Increasing CaP loading maay decrease the 
solubility of the CaP-PCMC 
PRP Loading (%) 0, 0.25, 0.5 PRP and TT loading and ratio may alter the 
immunogenicity of the PCMCs 
TT Loading (%) 0, 0.05, 0.5 
CpG Loading (%) 0, 0.5 
CpG presence increases the immunogenicity 
of the CaP-PCMCs 
75 
 
 
 
3.3.  Materials and Methods 
3.3.1. Materials 
The following materials were used in the study: 
 
CaCl2 (Sigma, Dorset, UK)  
L-Glutamine (Sigma, Dorset, UK) 
Isopropanal (IPA, VWR, UK) 
NaH2PO4 (Sigma, Dorset, UK) 
CpG (Cambridge Biosciences, UK) 
PRP (NIBSC code 02/208, Potters Bar, UK) 
TT (NIBSC code 04/150, Potters Bar, UK) 
3.3.2. Preparation of the stock solutions for PCMC preparation 
A stock solution of CaCl2 was prepared at 20mg/ml in IPA and placed on a rotator 
overnight at room temperature to ensure full dissolution. Subsequently this stock 
solution is diluted with IPA to achieve the required CaCl2 concentrations. 
The following day, a stock solution of L-glutamine and NaH2PO4 is made with distilled 
water at the desired concentration. This was mixed for approximately 30 min on a 
rotator at room temperature. This stock was then used to prepare the PRP and TT 
solution with or without adjuvant such as CpG at the concentration required for the 
formulation.  
To prepare the PCMCs, 2-3mL of an aqueous solution of L-glutamine, antigens, CpG 
and Sodium Phosphate were added into 40-60mL of IPA and the mixture is stirred for 
16 min (unless stated otherwise). The resulting suspension of PCMCs was filtered 
through a 45µm nylon filter fitted in a glass scinter vial (both Millipore). The filter onto 
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which the PCMC were collected was left to dry at room temperature overnight. The 
filter and the dried residue were weighed before the PCMCs were removed from the 
filter and placed into a storage container. The solid recovery (%)  was calculated from 
this weight. The PCMCs might be milled down into a finer powder if required for 
analysis or if being mixed with another formulation.  
To prepare the CaP-PCMCs with a 2-step method, the same procedure was followed as 
for production of the 1-step precipitation with the exception of the CaCl2 which was 
made up in a separate more concentrated aqueous solution and was added 1 min after 
the antigen and L-glutamine whilst stirring. 
 
3.3.3. Influence of PCMC preparation conditions on PCMC morphology, 
solid recovery and crystallinity 
Formulations with varying preparation parameters were prepared at the School of 
Pharmacy.  The preparation conditions chosen are shown in Table 3.2. 
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Table 3.2. Preparation parameters of CaP-PCMC formulations prepared at XstalBio 
Sample 
I.D.  
TT load 
(%)  
PRP 
load 
(%)  
CaP 
load 
(%)  
Process  
Water 
Content 
(%)  
Mixing 
time 
(min) 
Temperature 
(°C) 
CaCl2 
excess 
1 
0.5 0 9.4 
2-step 
4.8 16 20 2 
2 1-step 
3 
0.5 0 9.4 1-step 
3 1 
20 2 
4 7 1 
5 3 16 
6 7 16 
7 
0.5 0 9.4 1-step 5 
1 
20 
2 
8 16 2 
9 1 5 
10 16 5 
11 
0.5 0 9.4 1-step 5 
1 
4 
2 
12 16 
13 1 
50 
14 16 
15 0.05 
0.5 9.4 1-step 5 16 20 2 
16 0.5 
 
A second batch of samples were prepared to study the effect of antigen/adjuvant load 
on the morphology of the CaP-PCMCs. Antigen-free and CaP-free samples were also 
produced to determine the effects of antigen and CaP layer inclusion on PCMC shape. 
The details of this second batch of crystals are shown in Table 3.3. 
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Table 3.3 Formulation details CaP-PCMC formulations prepared with varying process 
steps and antigen loadings 
Sample I.D.  
TT load 
(%w/w)  
PRP (%w/w)  
CpG load 
(%w/w)  
CaP (%)  Process  
Water 
Content 
(%v/v) 
17 
0 0 0 
0 
1-step 
5 
18 
9.4 
19 0.05 
0.5 0 1-step 
20 0.5 
21 
0.05 0.5 0.5 
2-step 
22 1-step 
23 
0.025 0.25 0 
2-step 
24 1-step 
 
A third batch of samples was prepared at the School of Pharmacy with varying TT, CpG 
and PRP, the details of which are shown in Table 3.4. These were prepared with the 
intention of checking the solid recovery and for antigen quantification in Chapter4.  
Table 3.4. Details of CaP-PCMC formulations which vary in antigen loading 
Sample I.D.  
TT load 
(%w/w)  
PRP (%w/w)  
CpG load 
(%w/w)  
CaP (%w/w)  Process  
Water 
Content 
(%v/v) 
25 0 0 
0 
9.4 1-step  5 
26 0.05 
0.5 
27 0.5 
28 
0.05 
0.5 
0.5 
29 0.05 
30 0 0.5 
31 0.5 0.5 
0.05 
32 0.05 0.25 
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3.3.4. Morphology of the PCMCs 
The shape of the PCMCs were determined by using Scanning Electron Microscopy 
(SEM) and light microscopy. 
SEM:  PCMCs were sputter-coated with 10nm gold using a Quorum Q150 Sputter 
coater, and analysed with a Quanta 200F scanning electron microscope (FEI, UK). 
Light microscopy: A small amount of PCMCs were placed sparingly on a standard glass 
microscope slide using a small paintbrush. Images were then taken at 10x 
magnification. To image the change in crystal shape whilst in suspension, a droplet of 
water was added to the PCMCs, a coverslip was then placed on top. Images were taken 
at various time points without moving the slide. 
3.3.1.3 Xray Diffraction Analysis 
Powder X-ray diffraction patterns of the particles were collected using an X-ray 
diffractometer (Philips PW3170 Scanning X-Ray Diffractometer, Philips, Cambridge, UK) 
equipped with a Cu K target. The X-rays were generated at 45kV and 30mA. The 
sample was gently compressed into the sample holder and the powder surface was 
smoothed with a flat Perspex block. The samples were loaded onto the diffractometer 
and scanned over a range of 2Ɵ values, from 5° to 50° at a scan rate of 1.0° 2Ɵ/s. 
3.3.1.3 Micro Flow Imagingto measure particle size 
A CaP-PCMC suspension was prepared at 10µg/mL in PBS immediately before its 
placement into the entry portal on the Micro-flow imaging unit (Protein Simple™, 
California, US). The images were collected at a flow rate of 0.1mL/min.  
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3.4. Results and Discussion 
 
To investigate the effect of preparation parameters on CaP-PCMC structure, 
formulations with varying preparation parameters were prepared and are shown in 
Table 3.2. 
3.4.1. Solid Recoveries  
Solid recovery, calculated from the mass of the crystals recovered on the filter, was 
analysed to determine if the formulations are feasible to prepare. In these 
formulations, the solid recovery levels of the CaP-PCMC samples were between 71% 
and 87% (Figure 3.3), these values are sufficiently high to make preparation feasible. 
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Figure 3.3. Solid recovery of material during the production of the first series of CaP-
PCMCs.  
CaP-PCMCs were prepared at XstalBio with differing preparation parameters (A), 
different antigen loadings (B and C). The details of the formulations can be seen in 
Table 3.2, Table 3.3 and Table 3.4. 
A 
B 
C 
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Values shown for solid recovery were never 100%, because of the nature of the 
preparation process. Some material was lost in the soluble form and was not 
harvested on the filter. Most of the loss occurred when the precipitated crystals 
remained stuck to the glassware after the preparation and could not be collected. 
As the investigations later on in this project are going to be focussed on formulations 
which contain antigen. The solid recoveries of the formulations prepared with various 
antigen loadings can be seen in part B of Figure 3.3. 
Solid recoveries were found to range from 77% to 88%, similar to recoveries shown in 
Figure 3.3. This indicates that antigen loading did not influence solid recovery, this 
could be due to the very low proportion of antigen compared to the other PCMC 
components. The large quantity of material lost in sample 18, was due to material 
being stuck on the glassware and not being collected on the filter. 
Solid recovery in the third series (shown in part C of Figure 3.3) was similar to the 
previous series, with all samples recovering between 85% and 89% of the theoretical 
mass, with a mean of 87% which shows a consistently satisfactory level of recovery. 
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3.4.2. Influence of formulation parameters on the shape of the PCMCs 
Representative SEM images from the first batch of samples are shown in Figure 3.4. 
Overall, the SEM appeared to confirm that factors which would increase the rate of 
precipitation of the PCMCs decreased the size and smoothness of the crystal shape. 
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Figure 3.4. SEM images of the samples of CaP-PCMCs prepared with varying 
preparation parameters. Sample numbers that refer to details shown in Table 3.1 
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Although many of the formulations have been screened by SEM, the limitations of 
imaging by SEM is that the formulations were imaged as a dry powder. As a vaccine 
candidate, these formulations will be reconstituted in a buffer and administered as a 
suspension, making dry imaging of limited relevance. It is possible that upon particle 
suspension in an aqueous medium, gradual dissolution of the PCMCs might occur 
resulting in the release of the smaller particles that are adhered to the larger plate like 
crystals, and that these particles are taken up by cells and serve as an antigen depot 
for gradual release. This slow and extended release may improve the quality of the 
immune response (159). Nevertheless, the SEM is the most effective way, that is 
available, of determining the morphology of the crystals produced with the different 
formulations.  
3.4.3. Influence of process step  
The size and shape of CaP-PCMC samples 1 and 2 are shown in Figure 3.5, both 
methods produce PCMCs that are quite large in the micrometer size range. The PCMCs 
formed by the 1 step method appear to be more rod shaped, irregular, and tend to be 
aggregated, whereas the crystals produced by the 2-step method appear much flatter, 
and more plate shaped. 
Addition of the calcium chloride in a second step, after the L-glutamine, antigens and 
sodium phosphate have precipitated (for 1 min) may result in a CaP layer that forms 
more on the surface of the crystal. However if the sodium phosphate precipitates 
within the L-glutamine, it might not come into contact with the calcium chloride and 
therefore might not have the opportunity to react and form the CaP layer. From 
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experience, however, we think that the sodium phosphate does not precipitate out in 
the IPA and that it does not react with the calcium chloride to form the CaP layer. 
1-step 2-step 
 
Figure 3.5. SEM images of formulations made using  1 (left) 
or 2- (right) process steps 
 
3.4.4. Influence of water content  
The shapes and sizes of four samples prepared with either 3%  or 7% water content 
and either mixed for 1 min or 16 min are shown in Figure 3.6. The crystals formed with 
only 3% water content appear much smaller and irregular, and also formed tighter 
clusters. In contrast, the crystals formed with 7% water content appear much larger in 
size. In addition, the presence of small surface particles on the surface of the plate-like 
particles can be seen, which could be adsorbed antigen or CaP particles. The surfaces 
of the PCMCs are smoother and flatter, and they are not flake-like. 
2µm 2µm S1 S2 
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 1 min mixing 16 min mixing 
3% 
water 
content 
  
7% 
water 
content 
 
Figure 3.6. SEM images of CaP-PCMCs prepared at different water contents and 
mixing times.  
Samples 3-6 shown, prepared with a 1-step process. 
 
This result was as expected, as larger crystals are often formed from slower 
precipitations. At a higher aqueous content during the precipitation process, the 
increased solubility of the crystal components in the mixture of IPA and water will slow 
the crystal formation and produce crystals with the larger, planar morphologies seen in 
Figure 3.6. 
2µm 
5µm 
2µm 2µm 
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The One or 16 min mixing times did not seem to influence particles morphology. This 
shows that PCMC formation occurs fairly rapidly, once the aqeous phase is added to 
the organic solvent.  
3.4.5. Influence of CaCl2:NaH2PO4  ratio  
To form the CaP on the PCMCs, the CaCl2 was added in excess to make sure that all of 
the NaH2PO4 was reacted. The shape and size of four samples produced with either 2x 
or 5x CaCl2 excess (molar rations of 1:1 and 5:2 CaCl2:NaH2PO4 respectively) and mixed 
for either 1 min or 16 min are shown in Figure 3.7. The crystals that were produced in a 
5x excess of CaCl2 for 1 min appear to be much larger than the crystals produced under 
the other three conditions. There also seems to be fewer of the small surface particles. 
Apart from this, the crystals produced in a 5x CaCl2 excess for 16 min mixing duration 
do not appear to differ greatly from the PCMCs prepared in 2x excess of CaCl2 for 16 
min. Although crystals prepared from the 1min mix in 2x CaCl2 excess appear similar in 
morphology to the 16 min in 2x CaCl2 excess, the former seem to show a slightly flatter 
and thinner morphology and have fewer small surface particles like the PCMCs 
produced under the other conditions.  In this case, there seems to be a combined 
influence of mixing time and amount of calcium chloride excess on crystal shape. 
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 1 min mixing 16 min mixing 
2x CaCl2 
excess 
 
5x CaCl2 
excess 
Figure 3.7. SEM images of formulations made at varying CaCl2 excesses and mixing 
time. 
 Samples 7-10 shown, prepared with a 1-step process. Scale bar applies to all four images. 
 
2µm 
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3.4.6. Influence of Temperature  
The particles that were produced in IPA heated or cooled to 50°C  and  4°C are shown 
in Figure 3.8.  Temperature has a significant influence on the size of the crystals, as 
they appear to increase at the higher temperature, which was expected as this would 
increase the solubility of the PCMC components and thereby slow down their 
precipitation, which results in the growth of larger crystals. In addition the crystals 
prepared in IPA at 50°C appear to have more of the small particles adhering to their 
surface. In this case, there does not appear to be an effect of mixing time.  
 1 min mix 16 min mix 
4°C 
 
50°C 
Figure 3.8. SEM images of formulations made at varying solvent temperatures and 
mixing times. 
Samples 11-14 shown, prepared with a 1-step process. 
 
2µm 
2µm 
5µm 
2µm 2µm 
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3.4.7. Influence of TT loading in the presence of PRP 
Scanning Electron Micrographs of particles prepared with 0.05 or 0.5% TT are shown in 
Figure 3.9. The crystals seem to be relatively similar in shape and size to each other. 
This is most probably due to the small proportions of TT in the PCMCs. Thus, a change 
from 0.05% to 0.5% does not cause any significant change in the PCMC morphology 
when the majority of the PCMC components did not change.   
0.5% PRP loading 
 
0.05% TT loading 0.5% TT loading 
Figure 3.9.SEM images of formulations prepared two loadings of TT 
Ssamples 15 and 16 shown, prepared with a 1-step process 
 
3.4.8. The effect of CaP loading on the CaP-PCMC morphology  
PCMC formulations prepared with and without a CaP layer were analysed by SEM, the 
resulting images are shown in Figure 3.10. It can be seen that the two micrographs in 
Figure 3.10 look very different to each other. Images of PCMCs formulated with CaP 
show small particles on the PCMC surface, similar to those on the other CaP-PCMC 
samples, shown in Figure 3.4 to Figure 3.9. PCMCs prepared without appear to have a 
smooth surface and smooth edges, this suggests that some CaP remained in the 
2µm 2µm 
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suspension after the PCMCs are formed and then adsorbed to the surface, forming the 
small particles. These may be formed from excess CaP in suspension after the PCMCs 
are formed and adsorb to the already CaP-coated surface of the crystal.  
 
 
Figure 19. SEM Images showing the effect of CaP on shape and structure of PCMCs. 
 
Samples 17 and 18 shown. 
No CaP Cap 9.4% 
 
SWL_01 SWL_02
2µm 
Figure 3.10. SEM images showing the effect of CaP on the shape and structure of CaP-PCMCs 
S9 
2µm S10 
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3.4.9. Fate of CaP-PCMCs when made to contact an aqueous medium 
The effect of suspending PCMCs in water on their shape was observed using light 
microscopy (Figure 3.11). After 18 hours in suspension at room temperature, the 
crystals were visible in the same viewing field and displayed no signs of fragmentation, 
but some aggregation seems to have occurred possibly due to water evaporation, 
shown by the red arrows. In these images, the CaP-PCMCs seem to be stable in an 
aqueous medium.  
  
10 min in suspension >18 hr in suspension 
Figure 3.11. Effect of time in suspension on the morphology of the PCMCs (100x 
magnification) 
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3.4.10. PCMC particle size, evaluated by MFI 
Micro-flow imaging can be used to determine the particle size in a suspension. The 
distribution of particle sizes measured on a CaP-PCMC formulation prepared with 0.5% 
PRP, 0.05% TT, 0.5% CpG and 9.4% CaP (with 5 x CaCl2 excess) is shown Figure 3.12. 
The minimum size this technique is able to measure is 1µm diameter. This analysis 
indicated that a majority of the particle sizes are below 1µm in equivalent circular 
diameter. However, it must be remembered that this technique assumes a spherical 
shape, and our PCMCs are obviously not spherical, as shown in the scanning electron 
micrographs.  
 
Figure 3.12. MFI analysis of particle size in a suspension.  
Concentration of particles for each Equivalent Circular Diameter is shown.  
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It was also seen in the previous SEM images that the sizes of the crystals was 
consistently around 2-5µm in contrast to the 1µm or less being given by the MFI.. This 
may be either because the ‘diameter’ being measured is narrow due to the rod-like 
structure of the crystals which is not taken into account by the software. Another 
explanation could be that the crystal is broken into smaller pieces by the physical 
stresses when made into a suspension and forced to flow through a narrow tube 
during MFI measurement.  
3.4.11. Comparison of shape of the two samples produced at 
different locations 
Two formulations were prepared both at XstalBio and at the UCL School of Pharmacy 
to determine if there are differences in the set-ups at the two locations that could 
affect the morphology of the crystals.  These formulations had TT loadings of 0.5% and 
0.05%, and a PRP loading of 0.5% and are displayed in Figure 14. 
In setting up the crystal preparation in multiple labs, it was a risk that the formulations 
produced would be different to those previously prepared at XstalBio. Figure 3.13 
shows that the PCMCs produced at XstalBio had more of a rod like morphology, 
compared to the thinner plate-like structure seen in the two samples produced at the 
School of Pharmacy. These differences in morphology occurred despite the fact that 
the same preparation parameters had been used at the two sites and indicate that the 
preparation set up has an effect on the morphology of the crystals. This to be taken 
into consideration during formulation production. 
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Samples 26 and 27 shown.  
 
 
3.4.12. Determinationation of crystallinity/amorphpous nature 
of CaP-PCMC particles by X-Ray Diffraction (XRD) analysis 
To confirm that the PCMCs formed by the precipitation process have a crystalline 
nature, a formulation was prepared with 0.5% PRP, 0.05% TT, 0.5% CpG and 9.4% CaP 
with a 5:2 NaH2PO4:CaCl2 ratio and was analysed by XRD.  
The spectra (Figure 3.14) produced by the Xray diffraction has clear sharp peaks, which 
indicates a crystalline material. Therefore, it can be confirmed that the PCMCs 
prepared in our experiments are crystalline in nature. 
5µm 
SWL_03 SWL_04
TT loading 0.5% TT loading 0.05% 
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Figure 3.13. SEM images of samples prepared at XstalBio and the School of 
Pharmacy 
5µm 5µm 
5µm 5µm 
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Figure 3.14. Intensity counts from Xray Diffraction analysis. 
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3.5. Conclusions  
First, PCMCs were successfully prepared at all three locations; XstalBio, School of 
Pharmacy and NIBSC. They are in the micrometer size range, are crystalline in nature 
and rod-like or plate-like shapes. SEM images of the dry formulations (Figure 3.4 - 
Figure 3.8)  suggest that the preparation coniditons had some influence on particle 
morphology. In particular, the water content seems to have the biggest effect on the 
CaP-PCMC shape and size. Other factors that may affect the formuation of the CaP-
PCMCs are the temperature and the process step, although not to such an obvious 
degree.  
It is not fully understood how the changes in shape or size of the CaP-PCMCs might 
affect the immunogenicity of each formulations. However, it is important to consider 
that the CaP-PCMCs need to be delivered to the draining lymph nodes for recognition 
by B cells. Previous studies have shown that particle shape, and not size, plays a 
dominant role in particle uptake and phagocytosis by alveolar macrophages (157, 158), 
in particular the local particle shape at the point of initial contact seems to dictate 
whether macrophages initiate phagocytosis or simply spread onto the particles. 
However, there is also evidence that size, as well as a positive surface charge can affect 
uptake of particles by circulating dendritic cells (160). Surface charge and 
hydrophobicity are also factors which can affect the magnitude of the immune 
response to an antigen. It has been demonstrated that hydrophobic surfaces, such as 
those exposed on mis-folded protein molecules, can improve antigen immunogenicity 
(161). Future investigation of the electric charge on the PCMC by zetasizer should be 
performed to help understand factors that could also increase CaP-PCMC 
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immunogenicity by changing charge, however there is no evidence if uptake by the 
dendritic cells might actually increase the magnitude of the antibody response.  
 
In order to create a virtual conjugate vaccine using the PCMC technology, it is very 
important that the PCMCs are able to hold the two antigens together for processing by 
the B cell. The stability of the crystals in suspension is expected to be increased by the 
CaP loading. To determine the stability of the crystals in suspension, the antigen 
release profile can be studied. 
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Chapter 4. Quantification and immune characterisation of 
the antigens adsorbed to the CaP-PCMC 
4.1. Introduction 
The immunological properties of a vaccine rely on the quality and quantity of the 
antigens themselves. In the case of conjugate vaccines, where an immune response to 
the polysaccharide antigen is desired, the characteristics of the polysaccharide antigen 
are critical. The antigen has to reach the specific B cells whilst in virtual or real 
conjugation to the protein antigen. The presence of ‘free’ un-conjugated 
polysaccharide can be detrimental to the efficacy of a conjugate vaccine. If free 
polysaccharide was to reach the B cell before the protein conjugated gets access to the 
B Cell Receptor (BCR), this may induce anergy (52). The production of memory B cells 
and antibody producing plasma cells relies on full activation of the B cell through co-
stimulation by a T cell dependent response (48, 162). Early vaccines consisting of pure 
PRP failed to stimulate any response in infants under two years of age.  
There has been considerable research on reliable and sensitive techniques for the 
determination of conjugated and unconjugated PRP in protein-polysaccharide 
conjugate vaccines. The World Health Organisation has published details on the testing 
of Hib, meningococcal and pneumococcal conjugate vaccines in a Technical Report 
Series (TRS). The currently manufactured conjugate vaccines are assayed for levels of 
‘free’ soluble polysaccharide that are not conjugated to the  protein. The accurate 
determination of unconjugated polysaccharides has improved greatly with modern 
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physicochemical methods, based on the structure of the active ingredient. These 
techniques include optical spectroscopy (circular dichroism and fluorescence 
spectroscopy), size exclusion, and mass spectrometry. The saccharide component of a 
glycoconjugate can also be analysed through high performance anion exchange 
chromatography (163, 164). 
The antigenic quality of the polysaccharide antigen needs to be assessed during and 
after the conjugate vaccine preparation process because activation of the 
polysaccharide prior to conjugation can shorten or degrade the saccharide chain (165). 
The structure of the polysaccharide antigen has to be maintained, as the epitope 
exposed to be recognised by specific B cells has to correspond to the epitope that 
would be found in the bacteria for anti-polysaccharide antibodies to be protective in 
vivo. 
In the development of CaP-PCMC formulations, the assessment of the immunological 
characteristics of the polysaccharide antigen is extremely important, as preparation 
techniques may alter the epitopes of the polysaccharide in unknown ways. For these 
assessments ELISA is a useful tool. It is also possible that during the PCMC preparation 
process, not all the available antigen adsorbs onto the PCMC before formation of the 
CaP component. Some antigen may remain dissolved in the solvent and some antigen 
may adsorb after the CaP formation, the latter would become immediately soluble 
upon re-suspension of the PCMCs resulting in ‘free’ antigen. In this chapter, the quality 
of the PRP epitopes on the CaP-PCMC formulations were assessed, partly, by the 
detection of the antigens on the crystals through ELISAs, as well as through chemical 
assays which were also able to measure the soluble polysaccharide. 
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The presence of the protein antigen must be analysed as it is essential in recruiting T 
cells for the full activation of the specific B cell. The protein antigen should also ideally 
be immunogenic enough to stimulate protection, although this function is secondary. 
In this investigation, the highly immunogenic Tetanus Toxoid along with an adjuvant, 
CpG, were used for the virtual conjugation. It is hypothesised that the polysaccharide, 
TT and CpG combination would ensure an adequate immune response if all three are 
co-immobilised onto PCMCs, such that they are all ‘virtually’ conjugated. 
4.2. Aims and Objectives 
The aim of the work discussed in this chapter was to quantify the PRP, TT and CpG 
loading of the CaP-PCMCs. The PRP content of the crystals were determined using 
Orcinol assays and ELISA. Orcinol was essential for quantifying the chemical presence 
of PRP, whereas ELISAs and NMR were conducted to confirm/test that the antigenicity 
of PRP is retained after formulation. ELISA results show a low PRP concentration 
compared to Orcinol assay. The lower PRP concentrations measured by ELISA were 
thought to be caused by a change in the PRP conformation during the CaP-PCMC 
formulation. In order to investigate this, a series of investigations were conducted to 
determine the possible formulation parameters which could have caused a 
conformation change.  
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4.3. Materials and Methods 
4.3.1. Materials 
The following materials were used in the study: 
 
Anti-TT rat monoclonal antibody (NIBSC 10/134, Potters Bar, UK) 
Guinea pig anti-TT detection Antibody (NIBSC 10/132, Potters Bar, UK) 
Anti-Guinea Pig IgG-horseradish peroxidase conjugate (detection antibody, Sigma) 
Rabbit polyclonal IgG anti-PRP-HRP(detection antibody, NIBSC, Potters Bar, UK) 
 
Hib oligosaccharide conjugated to human serum albumin (HBO-HA, NIBSC, Potters Bar, 
UK) 
TT standard (NIBSC code 04/150) 
 
Carbonate Buffer (0.159% Sodium carbonate w/v, 0.293% Sodium hydrogen carbonate 
w/v pH 9.5-9.7) 
Assay Diluent for TT ELISA (20% w/v Marvel Milk powder in PBS, UK)  
Assay Diluent for PRP ELISA and anti-PRP antibody ELISAs (1% BSA w/v, 0.5% Tween20 
w/v in PBS) 
Tris/50mM Citrate/1mM EDTA buffer (pH7.4, all from Sigma, UK) 
Sigmafast o-Phenylenediamene dihydrochloride (OPD) substrate (Sigma, UK) 
2,2’-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt substrate 
(ABTS, Sigma, UK) 
Citric Acid Substrate Buffer (10.51% w/v Citrate monohydrate in water)  
H2O2 (CalbioChem, UK) 
Iron Chloride in Hydrochloric acid (FeCl3-HCl) solution (1.8mM FeCl3 in 36% HCl) 
Orcinol-ethanol solution (0.7M Orcinol in absolute ethanol, Sigma, UK) 
1st International PRP standard in Sodium Chloride (NIBSC code 02/208, Potters Bar, UK) 
SilverXpress silver staining kit (Invitrogen, UK) 
Micro BCA protein assay kit  (Life Sciences, UK) 
4.3.2. Formulations prepared  
Three CaP-PCMC formulations were prepared as before, and production parameters of 
the formulations are detailed in Table 4.1. The antigen loadings were selected using 
fixed values from a previous sample used by XstalBio in the pilot study which was 
previously shown to be partially immunogenic. The CaCl2:NaH2PO4 ratio was varied in 
these formulations  
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Table 4.1. Details of the CaP-PCMC formulations produced. 
Formulatio
n 
PRP 
loading 
(%, w/w) 
TT loading 
(%, w/w) 
CpG loading 
(%, w/w) 
CaP loading 
(%, w/w) 
CaCl2:NaH2PO4 
(CaCl2 excess) 
1 0 0 0 9.4 5:2 (5) 
2 0.5 0.05 0.5 9.4 1:1 (2) 
3 0.5 0.05 0 9.4 5:2 (5) 
4.3.3. Preparation of the CaP-PCMC formulations for 
measurement of total and free PRP CaP-PCMC 
To confirm the PRP retained its antigenicity after formulation, the PRP content was 
assessed using 2 immunoassays. A Sandwich ELISA using rabbit polyclonal antibody 
(raised in rabbits with PRP-KLH conjugate) was used for coating and for detection and 
an inhibition ELISA where anti-PRP immune serum (generated from rats immunised 
with Hib-TT conjugate vaccine) as follows: 
 Sandwich ELISA on page 105 
 Inhibition ELISA on page 106 
 To measure the total PRP in the CaP-PCMC formulation, CaP-PCMCs were dissolved in 
the Tris/citrate/EDTA buffer at a concentration of 5-10mg/mL, unless otherwise 
specified.  
To measure the ‘free’ or soluble PRP, CaP-PCMCs were suspended at a concentration 
of 10mg/mL (unless otherwise specified) in PBS (pH 7.5). The suspension was left to 
stand for 15 min on the bench at room temperature before centrifugation at 12000 
rpm for 2 min in a micro-centrifuge. 1mL of supernatant was collected for use in the 
assays for PRP quantification described below. In initial assays, the pellet was also 
collected for analysis.  
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The total PRP content was calculated using a standard curve of various dilutions of the 
PRP standard. The percentage of free PRP was calculated relative to the total PRP 
content.  
4.3.4. PRP Quantification by Orcinol Assay 
To determine the total and the amount of PRP in the formulation, CaP-PCMCs 
containing PRP were prepared as in Chapter 3 in triplicate, with the exception that the 
1mL supernatant was collected and dilution 1:1 in PBS to provide adequate volume for 
the assay. 500µL of this solution was mixed with 500µL of FeCl3-HCl solution. 50µL of 
Orcinol-ethanol solution was added to the mixture and incubated for 20 min at 100°C 
in an oil bath. The glass vials were then added to ice and the optical density was 
measured at 670nm using a UV-vis spectrophotometer (Perkin Elmer Lambda 800, 
Waltham, Massachusetts, USA). Optical density was converted to PRP concentration 
using a standard curve that was prepared with PRP standards in triplicate. 
4.3.5. Immune assays to check antigenicity of the formulation 
 Sandwich ELISA 
A sandwich ELISA was used to measure the total and free of PRP based on interaction 
between antigen and antibodies generated from rabbits immunised with PRP-KLH 
conjugate.  
96-well flat bottom plates were coated with 100µL/well of rabbit polyclonal anti-PRP 
antibody diluted to 1/200 in carbonate buffer and incubated for 90 min at 37°C.  Non-
specific binding sites were blocked with 100µL/well assay diluent and incubated for 1hr 
at 37°C after which they were washed three times. The first well of each row was filled 
with 200µL/well of the CaP-PCMC samples dissolved in Tris/Citrate/EDTA at 5mg/mL 
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crystal concentration. The samples were diluted across the 96-well plates in serial two-
fold dilutions, and the plates incubated again for 90 min at 37°C. After washing (3x) the 
plates, a HRP-conjugate rabbit polyclonal anti-PRP detection antibody was added at 
100µL/well and the plate incubated for 2 hr at room temperature. The plates were 
washed and then 100µL of the OPD substrate was added to each well in the dark. The 
OPD substrate was prepared according to manufacturer’s instructions. The reaction 
was stopped with 50µL/well of 3M HCl. Optical densities were read at 492nm and the 
concentration of the PRP in the PCMC samples was determined by comparison with a 
standard curve generated by serial two-fold dilutions of PRP standard on the same 
plate.  
 Inhibition ELISA 
An inhibition ELISA was used to measure the specificity of binding between the PRP 
and antibodies from rats immunised with Hib-TT conjugate. 
PRP was diluted in assay diluent to a concentration of  4-40µg/mL of PRP (to give a 
final concentration of 2-20µg/mL). CaP-PCMCs were dissolved in Tris/Citrate/EDTA at a 
concentration of 10mg/mL (an equivalent of 5µg/mL of PRP) and then diluted in AD to 
0.4mg/mL (a PRP equivalent of 2µg/mL). To each tube, 0.5mL of immune serum from 
rats immunised with Hib-conjugate vaccine in assay diluent was added and these were 
incubated at 4°C overnight. 
The following day, ELISA plates pre-coated with 50µL/well of 1µg/mL of HbO-HA in PBS 
were washed and blocked with 100µL/well of Assay Diluent for 30 min at 37°C. 100µLs 
of each sample was added to duplicate wells of the ELISA plate and incubated for 90 
min at room temperature. Plates were washed and 100µL/well of anti-rat IgG:HRP 
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conjugate (at 1/2000 dilution) in Assay Diluent was incubated for 90 min at 37°C.  
Plates were washed and 100µL/well OPD substrate was added for 15 min at room 
temperature in the dark. The reaction was stopped with 50µL/well 0.1M HCl and the 
colour change was measured at 492nm. 
 
4.3.6. Quantification of TT content in CaP-PCMCs 
The loading of TT on the formulations needed to be determined to be sure that the 
CaP-PCMCs would be delivering the protein antigen alongside the polysaccharide 
antigen. The amount of  TT in the formulation was quantified using different ELISA 
assays, SDS-Page or a BCA protein assay. 
4.3.6.1 ELISA  
Tetanus toxoid content of the PCMCs was quantified using a sandwich ELISA. Plates 
were coated with 100µl/well of an anti-tetanus toxoid monoclonal antibody diluted to 
1:200 in carbonate buffer and incubated at 4°C overnight.  Non-specific binding sites 
were blocked with 150µL/well Assay Diluent and incubated for 1 h at 37°C. After 
washing, 100µL volumes of CaP-PCMC samples (initially dissolved in Tris/Citrate/EDTA 
buffer) were added to the plate in serial two-fold dilutions and incubated for 90 min at 
37°C. After washing (3x), a guinea pig polyclonal anti-TT antibody was added at 
100µL/well and the plate incubated for 2 hr at 37°C. To detect levels of binding, the 
plates were washed and then 100µL/well of anti-guinea pig IgG-HRP (1:2000) was 
incubated for 1hr at 37°C. The substrate ABTS was prepared according to 
manufacturer’s instructions in citric acid substrate buffer and added to the plate at 
100µL/well.  ODs at 405nm was measured after 30 min at room temperature. 
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Concentration of the TT on the PCMC samples was determined by comparison to a 
standard curve generated by TT standard in the same ELISA. 
4.3.6.2 SDS-Page  
To quantify the total TT on the CaP-PCMC formulation SDS-PAGE analysis was carried 
out. A 10mg/mL CaP-PCMC solution in Tris/Citrate/EDTA buffer was prepared, and 
65µL of CaP-PCMC sample was added to 25µL of LDS sample buffer and 10µL of DL-
dithiothreitol solution (DTT). The resulting mixture was shaken, before heating at 70°C 
for 10 min. Ten 10µL volumes were loaded  into wells on a 4-12% Bis-Tris gel with a 
MES running buffer. After running, the gel was then stained using silver staining 
staining kit according to the manufacturer’s instructions. The gel was analysed using a 
Bio-Rad GS-800 densitometer and Quantity One software.  
4.3.6.3 Micro BCA protein assay for quantification of TT content 
in CaP-PCMCs 
 
To measure the total TT on the CaP-PCMC samples, the crystals were dissolved at 
10mg/mL in Tris/Citrate/EDTA buffer. To measure the soluble TT on the CaP-PCMC 
sample, the suspension was prepared as before in section 4.3.3, but at a crystal 
concentration of 100mg/mL. 
In eppendorfs, 1mL of CaP-PCMC sample was added in duplicate to 1mL of the BCA 
protein assay kit working reagent prepared according to the manufacturer’s 
instructions. The mixture was then incubated at 60°C for 1 h in a heating block before 
being left to cool to room temperature. The ODs were then read at 562nm. The 
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concentration was determined by comparison to a standard curve generated by 
varying concentrations of the TT standard. 
4.3.7. Quantification of CpG by UV spectroscopy 
To determine the quantity of CpG in the CaP-PCMCs, the microcrystals were prepared 
as in section 4.3.3 and optical density was measured at 280nm. The optical density of 
the samples and standards were also measured at 330nm to take into account light 
scattering by particulates in suspension. CpG concentration was calculated by 
comparison against a standard curve generated from various concentrations of CpG. 
The standard curve can be seen in Figure 4.15. The absorption was corrected using the 
equation ABSprotein = ABS280 – (1.929*ABS330)  
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4.4. Results and Discussion 
4.4.1. Quantification and characterisation of PRP in CaP-PCMC 
formulation 
Initial formulations were tested for total and free PRP at XstalBio in a water 
suspension, rather than PBS. The release of soluble PRP from the CaP-PCMCs was 
found to be low in water, and so the first formulations were tested in immunogenicity 
studies. Once new formulations were prepared at NIBSC it became a priority to test 
the soluble PRP content prior to use in the immunogenicity studies.  
The PRP content in the formulation as well as the soluble PRP was measured by both a 
chemical Orcinol assay and by ELISA. It was essential to set up assays with which to 
accurately measure the levels of antigen recovery, as potential loss of antigen during 
the formulation process would make the CaP-PCMC formulation both inefficient to 
produce and non-immunogenic. 
The antigenicity of the PRP when it is a component of the CaP-PCMC formulation is 
also important to measure in this context. It is for this reason that we cannot solely 
rely on Orcinol results providing evidence of the chemical presence of PRP. The ELISA 
to quantify PRP was used in these experiments to investigate if the PRP retained its 
antigenic form post-formulation. The detection of the PRP in this assay depends on 
antibodies, which are specific for PRP in the Hib-TT conjugate and known to be 
effective at killing bacterium [ref], to bind to the same epitope on the CaP-PCMC. 
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Without this antigenicity, it would be impossible for the CaP-PCMC formulation to 
induce a protective anti-PRP response.  
 
4.4.2. Orcinol assay for quantification of total and soluble PRP 
in CaP-PCMC formulation 
To determine if the Orcinol assay could be used to accurately quantify PRP content in 
the presence of CaP-PCMC formulation, an assay was carried out with the standard 
PRP in the presence and absence of blank (i.e. without PRP) CaP-PCMC. 
As seen in Figure 4.1, the relationship between the ODs and the PRP concentration is 
linear. It can also be noted that the ODs measured at the various PRP concentrations 
are not affected by the presence of CaP-PCMC. This indicates that the CaP-PCMC 
formulation does not interfere with the quantification of PRP by this method. 
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Figure 4.1.  Optical density of various concentrations of PRP stock after testing by 
Orcinol assay 
Optical density measurements at multiple concentrations of PRP with and without 
CaP-PCMC formulation (black and grey lines respectively). Error bars represent 
standard deviation of the ODs between the three replicates at each concentration. 
 
The Orcinol assay was used to measure the total PRP content in various batches of 
CaP-PCMC formulation 3 (Table 4.1) after formulation as well as the soluble PRP. 
Examples of total PRP content and soluble values are presented in Table 4.2. The total 
recovery was higher than expected, 112% of the expected quantity of PRP was found 
in the CaP-PCMC formulation. However, it was found that 69.9% of this was lost as 
soluble PRP when in a suspension of PBS.  
From these results, we conclude there is a high rate of release of PRP from this 
formulation. Positively, the closeness of the calculated percentages from the pellet and 
the supernatant to the total measured PRP indicate that this is a reliable assay. 
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Table 4.2. Total and soluble PRP measurements from CaP-PCMC formulation 
 
Percentage of 
total PRP content 
Percent of 
expected 
Supernatant 69.9 - 
Pellet 27.5 - 
Total - 112 
Total and free PRP in PBS was measured CaP-PCMC as measured by Orcinol assay. 
 
This assay was repeated multiple times, measuring the release of soluble PRP from the 
CaP-PCMC suspension and calculating it against the total PRP content shown in Table 
4.2. The values of the soluble PRP release vary from 62.4 to 80.8%. This variation could 
come from heterogeneity in the crystal suspension, if there was clumping of the 
crystals or variations in the agitation to form the suspension. However in all the assays, 
over half the PRP was found to be soluble in PBS. Interestingly, this formulation was 
found to have a <5% release in water when tested by XstalBio (data not shown). This 
could be due to the breakdown of the CaP layer in the presence of salt.  
Table 4.3. Percentage release of soluble PRP from CaP-PCMC formulation.  
Assay 
no. 
Percentage free 
(%) 
1 69.9 
2 80.8 
3 70.3 
4 80.4 
5 62.4 
Mean 72.8 
Multiple suspensions were measured for soluble PRP release by Orcinol assay. The percentage was 
calculated from the measured total from a previous assay. 
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Before further testing in immunogenicity studies, a new CaP-PCMC formulation will 
need to be developedBoth the recovery of PRP on the CaP-PCMC formulation and the 
low levels of soluble PRP released in suspension are vital for the success of a 
formulation. Just as the conjugate vaccines are tested for low ‘free’ polysaccharide, 
this measurement will need to be taken with every new batch of formulations 
prepared, particularly those tested in immunogenicity experiments.  
4.4.3. Kinetics of soluble polysaccharide release from CaP-
PCMC suspension, and effect of CaCl2:NaH2PO4 ratio, over time 
Two formulations were developed at XstalBio by screening a variety of preparation 
parameters for low soluble PRP, the parameters can be seen in Table 4.4. 
Table 4.4. Formulations developed by XstalBio which have low PRP release.  
Formulation 
PRP 
 Loading 
 (%, w/w) 
TT loading 
 (%, w/w) 
CpG loading  
(%, w/w) 
CaP loading  
(%, w/w) 
CaCl2:NaH2PO4  
(CaCl2 excess) 
Process 
step 
1 0.5 0.05 0.5 10 5:2 (5) 1 
2 0.5 0.05 0.5 10 5:2 (5) 2 
Multiple formulations with varying preparation parameters were screened for low 
soluble PRP content in a PBS suspension. The two formulations with the lowest soluble 
PRP content were both produced with a 5:2 CaCl2:NaH2PO4 excess and produced in 
both 1 and 2 process steps. 
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To monitor the release of soluble PRP from the CaP-PCMCs while in suspension over 
time, it was decided to test the soluble PRP at different time intervals. The rate of 
release of PRP from the formulation was investigated in suspensions in two different 
ways: 
1. CaP-PCMC suspensions (1.5mL) which were replenished with 1mL of PBS after 
the harvesting of 1mL supernatant. 
2. Individual CaP-PCMC suspensions prepared used for each time point 
The two methods were used on the two formulations and the suspensions were kept 
both on the rotator for constant resuspension of the CaP-PCMCs and on the bench 
where the suspensions were left to settle. 
The soluble PRP from both formulations on the rotator are shown in Figure 4.2. It can 
be seen that the initial release of soluble PRP from the crystals was 5.7% and 32.6% of 
the total from the formulation prepared with monobasic and dibasic sodium 
phosphate. The monobasic formulation shows a steady increase of cumulative PRP 
release to 26% after an hour, 61% after two hours, 89% after three, and up to 109% 
after four hours when the suspension was centrifuged, the supernatant harvested and 
the pellet resuspended with PBS. However, the suspensions that were kept for the 
different time points and had the supernatant harvested once, showed low PRP 
release, showing a peak of only 14% after 4 hours. 
The dibasic formulation showed similar patterns, but with increased PRP release from 
both suspensions. After only 1 h, there was over a two-fold increase at 79% soluble 
PRP content, which increased to 88% after 2, 96% after 3 and 99% after 4 h in the 
replenished suspension. Again with the individual suspensions, the soluble PRP was 
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found to be greatest at the first time point with 33%, and remains at the same level, 
with soluble PRP values only dropping to 20%.  
The data shows a clear effect of the PBS supernatant replenishment. In both 
formulations, the individual aliquots showed minimal influences of time on the soluble 
PRP content. Variations in these results are likely due to the variations in the crystals 
within each suspension. It is also clear, that the replenishment of the supernatant with 
PBS drives the release of more soluble PRP from the crystals. These results would 
indicate that the presence of the Phosphate and Saline may act to dissolve the Calcium 
Phosphate layer and release more soluble PRP.  
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Figure 4.2 Release of soluble PRP from the CaP-PCMC over time from two 
formulations in a rotating suspension 
PRP release from CaP-PCMC formulation prepared with monobasic sodium phosphate (A, formulation 1) 
and dibasic sodium phosphate (B, formulation 2) and left on a rotator. The release from crystals which 
had the buffer replenished (black line) is shown against separate samples for each timepoint  (grey line).  
 
To investigate the effect of the rotation on the release of PRP from the CaP-PCMCs, 
the same experiments were carried out but without any movement which acts to 
continually resuspend the crystals in the PBS. The release of soluble PRP from the 
stationary CaP-PCMC suspensions over time is shown in Figure 4.3. The initial release 
Formulation 1 
Formulation 2 
A 
B 
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was found to be 12 and 51% in the formulations prepared with the monobasic and 
dibasic sodium phosphate respectively. Although higher, these results are similar to 
the previous experiment, and indicate that Formulation 1 which was prepared with the 
monobasic Sodium Phosphate has a much lower soluble PRP content than the 
formulation prepared with the dibasic Sodium Phosphate.  
The release of soluble PRP from the individual suspensions on the bench showed no 
effect of time on the release of soluble PRP from the CaP-PCMCs, as seen with the 
rotated suspensions in Figure 4.2. The formulation with the monobasic Sodium 
Phosphate (Formulation 1) has a maximum release at 3 h with 23% of the PRP in the 
formulation released as soluble. The replenished sample, again, showed increasing 
proportions of the PRP lost from the crystal. The values increase six-fold from 12% to 
76% after the first hour. The release continued to increase steadily between 1 and 4 h, 
reaching 108%. 
Formulation 2, which had an initial soluble PRP content of 51%, showed a similarly 
constant release rate at all time points when measured from separate suspensions, 
reaching a minimum at 3 h of 43% and a maximum of 59% at 4 h. The same 
formulation showed an increase of 33% between 1 and 2 h and the cumulative release 
continues to increase steadily to 101% at 4 h. 
The similarity between the release of soluble PRP from samples from both the 
stationary suspensions and the rotated suspensions indicates that the physical 
agitation of the crystals is unlikely to be the driving factor in the release, and the 
presence of the phosphate and saline is increasing the release. 
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Formulation 1 
Formulation 2 
Figure 4.3 Release of soluble PRP from the CaP-PCMC over time from two formulations in a 
stationary suspension 
PRP release from CaP-PCMC formulation prepared with monobasic sodium phosphate (A, 
formulation 1) and dibasic sodium phosphate (B, formulation 2) and left on a the bench. The release 
from crystals which had the buffer replenished (black line) is shown against separate samples 
harvested for each timepoint (grey line).  
 
B 
A 
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4.4.4. Quantification and characterisation of antigenicity of PRP 
in CaP-PCMC formulation by ELISA 
The ELISA has the advantage over the Orcinol assay of being more sensitive, being able 
to quantify PRP concentrations as low as  and also being able to measure the 
antigenically recognisable PRP. A standard curve generated by testing different 
concentrations of the PRP standard measured by ELISA is presented in Figure 4.4.  
 
Figure 4.4. Titration curve of PRP standard measured by sandwich ELISA 
ODs generated from duplicate wells of an ELISA carried out on serial two-fold dilutions 
of the PRP standard. 
 
To investigate the potential for CaP-PCMCs to interfere with the PRP quantification by 
ELISA. A CaP-PCMC formulation with no PRP was added to the PRP standard and added 
to the plate. As shown in Figure 4.5, there was no significant difference between the 
titration curves generated in the presence or absence of CaP-PCMC. This result would 
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indicate that there is no interference with the ELISA from the components or physical 
presence of the CaP-PCMCs. 
 
Figure 4.5. Titration curve of PRP standard with and without CaP-PCMCs measured 
by sandwich ELISA 
ODs generated by ELISA to quantify PRP in CaP-PCMC formulation and PRP standard 
with and without non-PRP CaP-PCMC formulation (grey and black lines, respectively). 
Points shown are mean values from duplicate wells. 
 
To quantify the PRP on the CaP-PCMC, the CaP-PCMC and PRP standard were titrated 
together across the ELISA plate and the PRP content of the CaP-PCMC was calculated. 
The curves are shown in Figure 4.6. The sample, which had previously been shown to 
have 112% recovery by Orcinol assay (Table 4.2), was shown to have a much lower OD 
compared to the PRP standard, although not as low as the negative control. The 
negative control, blank CaP-PCMCs, appear to have very low levels of binding at the 
highest two PRP concentrations, however these levels are barely above the 
background level seen at the other concentrations and therefore do not indicate any 
presence of PRP. The low detection of PRP on the PRP CaP-PCMC sample indicates that 
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only when the PRP is formulated as part of the CaP-PCMC, the ability to bind to either 
the capture or detection antibody is decreased.  
 
Figure 4.6. Titration curves of PRP-CaP-PCMCs against PRP standard 
PRP-CaP-PCMCs were titrated against PRP standard with and without CaP-PCMCs as 
well as blank CaP-PCMCs. ODs shown are from duplicate wells on PRP ELISA. n=2. 
 
Changes in the antigenicity of PRP leading to failure of recognition by the detection 
antibodies used in the assays indicate that we cannot solely rely on Orcinol results 
providing evidence of the chemical presence of PRP. There is either a difference in the 
interfering capabilities of the CaP-PCMC formulation when formulated with the 
antigen, or more likely, that the formulation of the PRP has somehow changed the PRP 
so that it is no longer detectable by the ELISA. This could be due to a conformational 
change of some of the PRP polysaccharide in a way that does not allow the same level 
of binding by the anti-PRP detection antibodies in the rabbit serum from PRP-KLH 
immunisation.  
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The detection of the PRP in this assay depends on antibodies, which are specific for 
PRP in the PRP-KLH conjugate, to bind to the same epitope on the CaP-PCMC. Without 
this antigenicity, it would be impossible for the CaP-PCMC formulation to induce a 
protective anti-PRP response. It is not clear if these changes could affect the 
immunogenicity of the CaP-PCMC. 
The sandwich PRP ELISA was used to measure the total and soluble PRP content of 
Formulation 1 (refer to Table 4.1), the assay was carried out on two dates and both 
sets of results are shown in Table 4.5. The pellet was also analysed in these samples. 
Similar values were obtained when the assays was repeated on two different days.  
It was found that the total PRP content was 28% of the expected in the first assay, and 
only 6% of expected in the second. The PRP measured on the supernatant was 23% in 
the first assay and 5% in the second, which equates to 82% and 75% of the total PRP 
measured. The PRP in the pellet was found to be 18% and 2% of the total expected in 
the two assays, which equates to 64% and 30% of the total measured PRP content.  
The low recovery of the PRP measured on this sample which had previously been 
shown to have 112% of PRP by Orcinol assay (Table 4.2) demonstrates that the ELISA is 
not able to detect 72-94% of the PRP that is present on the CaP-PCMCs. The measured 
PRP in the supernatant might indicate that the soluble PRP can be quantified by the 
sandwich ELISA, but a conclusion is hard to draw, as the soluble PRP was measured 
between 6-12% as measured by Orcinol assay.  
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Table 4.5. The concentration of PRP in the CaP-PCMC formulation were analysed 
twice by ELISA 
 
First Assay Second Assay 
 
Conc (ng/mL) 
Actual recovery (% 
of theoretical) Conc (ng/mL) 
Actual recovery (% 
of theoretical) 
Total 2.80 28.03 0.67 6.71 
Supernatant 2.26 22.55 0.50 5.01 
Pellet 1.83 18.28 0.20 2.00 
 
The initial experiment (Table 4.2) appears to demonstrate that the presence of the 
CaP-PCMC itself is not the cause of the low detection of PRP by ELISA, and rather, it is a 
change that is occurring as part of the formulation process. Interestingly, when the 
measurement of the free and CaP-PCMC polysaccharide was carried out by ELISA 
(Table 4.5), the proportions of the PRP in the supernatant was similar, although the 
quantities varied considerably. This may indicate that the proportion of epitopes on 
individual polysaccharide chains might be affected, rather than proportion of the total 
PRP.   
 
4.4.5. Quantification of PRP mixed with IPA and CaCl2 
combinations by ELISA 
To understand which component of the CaP-PCMC preparation process could have 
altered PRP and resulted in reduced binding in the ELISA, the PRP standard was mixed 
with Isopropanal (IPA), IPA and CaCl2, or CaCl2 in water and mixtures were titrated 
straight onto the plate coated with rabbit anti-PRP antibodies, and the assay carried on 
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as before. Results shown in Figure 4.7 indicate that exposure of PRP to IPA did not alter 
the ability of the PRP to bind to the detection antibody.  
These results indicate that there does not seem to be an alteration of the binding 
epitopes by treatment of PRP with IPA, CaCl2 or the combination of both.  
 
Figure 4.7. Titration curves of PRP treated with IPA and CaCl2 individually and in 
combination  
The PRP standard was mixed with CaCl2  and IPA individually or in combination were 
titrated against PRP standard. ODs shown are from duplicate wells on PRP ELISA. n=2 
 
Although the PRP standard treatment do not indicate whether the CaCl2 or the IPA are 
responsible for the decrease in PRP detection when formulated into CaP-PCMCs, the 
results indicate that the effect is the results of the  preparation process. Therefore, it 
was decided to test the effect of different processes on the antigenicity of PRP by 
ELISA to determine the factors responsible. 
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4.4.6. ELISA to quantify PRP on soluble PCMC preparation 
prepared at XstalBio 
To determine if the PRP has endured any changes during the formulation process, a 
range of formulations were produced by XstalBio. These formulations were designed 
with the aim of isolating the factor that may be causing the potential epitope change. 
Due to the effect of the reduced binding seen only in CaP-PCMC samples and not in 
soluble samples prepared without the CaP layer (data not shown), the factors that 
these samples focus on are related to the formation of the CaP layer. 
 As the use of a core protein is necessary for the formation of the crystals, the L-
glutamine was replaced with histidine in two samples to investigate the role of the 
effect of the L-glutamine on the CaP layer. Other factors include the presence of 
NaH2PO4 and CaCl2 in combination with solvent. 
The details of the formulations are shown in 
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Table 4.6. The titration curves from ELISA analysis are shown in Figure 4.8 and Figure 
4.9. The ELISA method was carried out at NIBSC and the Orcinol assay was carried out 
by staff at XstalBio. A comparison and summary of all the values are shown in Table 
4.7. 
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Table 4.6. PCMC formulations prepared with different core proteins and CaP-PCMC 
component 
Formulation 
number Core CaP component 
1 L-glutamine NaH2PO4 
2 L-glutamine none 
3 L-glutamine NaH2PO4 and solvent 
4 L-glutamine CaCl2 in solvent 
5 Histidine NaH2PO4 
6 Histidine none 
Six formulations were prepared with either L-glutamine or Histadine as the main component, and with different 
combinations of NaH2PO4, or CaCl2 with and without extra solvent. The PRP and TT loadings were kept at 0.5% or 
0.05% respectively to reflect previous formulations. 
 
 
It can be seen that the Orcinol results show close to the expected 100% recovery of 
PRP in all samples, with the percentages ranging from 74-106. Slightly lower values are 
expected in soluble (without CaP) PCMCs due to higher loss to glassware. However, it 
was seen that the percentage of PRP quantified by ELISA was much higher in the two 
samples which contained NaH2PO4 (Formulation 1 and 5). This result was unexpected, 
as high quantification by ELISA had not previously been seen. This effect might be due 
to interference by un-reacted NaH2PO4 with the binding of the capture antibody, 
however it is not of direct relevance, as in the CaP-PCMCs, there is an excess of CaCl2 
and therefore it is unlikely there is unreacted NaH2PO4 remaining in the formulation. 
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Figure 4.8. Titration curves of PRP-PCMC formulation against PRP standard 
PRP-PCMC formulations detailed in 
Formulation 1 
Formulation 2 
Formulation 3 
Formulation 4 
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Table 4.6 were titrated against the PRP standard. ODs shown are means of replicate 
ELISA wells of sample. The PRP content of the PCMC (black line) was calculated against 
the PRP standard (grey line). n=2 and n=3 for the standard and the sample wells 
respectively. 
It was also seen that only the sample containing the CaCl2 (Formulation 4) was found 
to have a much lower PRP quantity by ELISA, with only 9.9% of expected compared to 
109.6% in the formulation without the CaCl2 (Formulation 2). It is evident that 
inclusion of CaCl2 was responsible for the low PRP detection by ELISA.  
The two samples prepared with histidine instead of glutamine did not show a large 
difference in PRP quantification by ELISA, with PRP values of 203.1% and 122.1% 
compared to 215.8% and 109.6% in the corresponding glutamine samples.  
 
 
Figure 4.9. Titration curves of PRP-PCMC formulation against PRP standard 
PRP-PCMC Formulation 5 and 6 detailed in 
Formulation 5 
Formulation 6 
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Table 4.6 were titrated against the PRP standard. ODs shown are means of replicate 
ELISA wells of sample. The PRP content of the PCMC (black line) was calculated against 
the PRP standard (grey line). n=2 and n=3 for the standard and the sample wells 
respectively. 
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 Table 4.7. The PRP as measured by ELISA compared to the values measured by 
Orcinol assay at XstalBio. The values of PRP detection by ELISA were calculated by 
parallel line analysis. 
Formulation 
no. PCMC components 
% of expected by 
ELISA 
% of expected by 
Orcinol 
1 
TT, PRP, glutamine, NaH2PO4 215.8 74 
2 TT, PRP, glutamine 109.6 88 
3 
TT, PRP, glutamine, NaH2PO4 (with solvent shot) 154.4 92 
4 
TT, PRP, glutamine (with solvent shot containing CaCl2) 9.9 106 
5 
TT, PRP, histidine, NaH2PO4 203.1 90 
6 TT, PRP, histidine 122.1 82 
 
The specificity was also investigated by using soluble formulations produced with only 
one of either CaCl2 or NaH2PO4 in combination with either L-glutamine or histidine. The 
inhibition ELISA titration curves are shown in Figure 4.10.  
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Table 4.8. PCMC formulations prepared with different core proteins and CaP-PCMC 
component 
Formulation no. PCMC components 
7 TT, PRP, glutamine 
8 TT, PRP, glutamine (with solvent shot containing CaCl2) 
9 TT, PRP, glutamine (with solvent shot containing NaH2PO4) 
10 TT, PRP, histidine, solvent shot 
11 TT, PRP, histidine (with solvent shot containing CaCl2) 
12 TT, PRP, histidine, NaH2PO4 (with solvent shot containing CaCl2) 
Six formulations were prepared with either L-glutamine or Histadine as the main component, and with different 
combinations of NaH2PO4, or CaCl2. CaCl2 was added dissolved in a ‘shot’ of Isopropanal 1 min after the aqueous 
components were added.  The PRP and TT loadings were kept at 0.5% or 0.05% respectively to reflect previous 
formulations 
 
It can be seen that the glutamine samples with and without NaH2PO4 did not show a 
large difference in binding from that of the PRP standard, indicating a similar 
antigenicity. However, Formulation 8, which contained CaCl2 showed a decrease in 
binding. These results confirm the previous finding that the antigenicity of the PRP is 
affected by the CaCl2 during the preparation process.  
However, in Formulations 11 and 12, CaCl2 was included in the formulations and it was 
seen that there was no decreased specificity of the anti-PRP detection antibodies. 
These results show that the decrease in antigenicity by CaCl2 in the CaP-PCMC 
formulations is dependent on the protein core. Unfortunately, histidine is not suitable 
for use as a protein core in CaP-PCMCs, as previous samples used by XstalBio were 
found to have high levels of solubility in a water suspension.  
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Figure 4.10. The specificity of binding of the anti-PRP antibody from a Hib-TT 
immunised animal to PRP in different PCMC formulations with NaH2PO4 or CaCl2 in 
formulations with glutamine or histidine. 
The antigenicity of the PRP in formulations with glutamine and histidine (A and B) which were prepared with 
NaH2PO4  and CaCl2 at doubling dilutions. The points show means from duplicate wells on the ELISA plate.  
A 
B 
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Once the CaCl2 has been shown to cause a loss of antigenic PRP, a concern is that in 
immunogenicity investigations, that the CaP-PCMC immunisations might be inducing a 
specific antibody response against the conformationally altered PRP, which may not be 
protective.   
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4.4.7. Investigation into change of PRP conformation of PRP 
using NMR 
Nuclear magnetic resonance (NMR) spectroscopy can be used to detect changes in the 
PRP structure after formulation. As indicated by results in section 4.4.6, there may be a 
conformational change induced by a binding of calcium to the PRP. 
The main purpose of the NMR experiment was to determine if there was a change in 
PRP conformation induced by binding of Calcium. After consultation with a 
polysaccharide NMR expert, the resulting spectra, shown in Figure 4.11, there would 
be three peaks that are absent, in a location indicated by the green arrows. 
 
Figure 4.11. NMR of CaP-PCMC sample (blue) overlayed with NMR of two 
unformulated PRP samples (red and green) 
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The NMR spectra shown in Figure 4.11 shows that there is a large peak of resonance  
present on the CaP-PCMC spectra which can attributed to the presence of a large 
quantity of glutamine present in the formulation. Unfortunately, it is a change in the 
smaller peaks that a consequently masked by the glutamine peak, that would indicate 
changes in the structure of PRP. 
There also appears to be a slight shift and sharpness of the spectra from the CaP-PCMC 
formulation which is due to the presence of NaCl (from the PRP used in the 
formulation).  
 
4.4.8. TT ELISA for quantification of TT on CaP-PCMC 
formulation 
In contrast to PRP, the antigenicity of the TT is of less importance than that of the PRP. 
The presence of the TT is very important, as highlighted by the high ratio of TT to PRP 
in conjugate vaccines, however, the pure function of the TT in the conjugate is to 
recruit T cells to activate the follicular B cells. Therefore as long as there is some 
immunogenic protein presence of the TT, the necessary T cell dependent response 
could theoretically still be induced. 
ELISA was used to measure the antigenically recognisable TT on the four CaP-PCMC 
formulations prepared by XstalBio with either 0.05% or 0.5% TT. Determination of TT 
loading on PCMCs by ELISA showed very low level of TT recovery for one sample 
(0.12%) and none for another sample (Figure 4.12). This suggests that the ELISA 
method was not able to detect any TT on sample 15 which had the lower loading of 
0.05%. This is possibly due to a loss of TT during formulation or to changes in the 
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conformation of the TT during the production process, making it unrecognisable during 
the ELISA. 
 
 
Figure 4.12. TT loadings as measured by ELISA.  
Expected loading is shown in pale grey bars, against the loading measured by ELISA in 
darker grey. 
 
4.4.9. SDS-Page for quantification of TT on CaP-PCMC 
formulation 
SDS PAGE was used to measure the chemical presence of the TT on a range of 
formulations prepared at XstalBio. The intensity of the bands was used to quantify the 
TT using a densitometer.  
It can be seen in Figure 4.13 that three of the samples with 0.5 or 0.05% loading 
showed recoveries of 80.1-122%. However, there was one 0.05% loading which only 
had 11.9% of the expected TT and the two samples with 0.025% TT loading show low 
recoveries of TT (41.2 and 51.1%) however this can be attributed to the low 
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concentrations which are at the limit of detection for this assay. The first sample also 
shows low recovery of TT on the formulation. 
 
Figure 4.13. Percentage recovery of TT on six CaP-PCMC samples tested by XstalBio. 
Six formulations were prepared and tested for TT recovery using SDS-PAGE by XstalBio. 
The percentage of TT recovery calculated from the intensity of the bars shown on the 
gel.  
It is clear that there was either an issue with the ELISA for TT detection, or there was a 
problem with low recovery of TT on the CaP-PCMC. The conformation of TT was not 
investigated in a similar fashion to PRP, as any conformational change would not affect 
the immunogenicity of the overall formulation. 
4.4.10. BCA protein assay for quantification of TT on CaP-PCMC 
formulation 
The SDS Page, although more specific, is limited by its detection limit. The soluble TT is 
still important to measure to ensure that delivery of the TT reaches the polysaccharide 
B cells along with the PRP. To test the release and total recovery of TT in the 
formulation, a more sensitive BCA protein assay kit was used. A standard curve of TT 
concentrations  were tested, the relationship between the colour change and the TT 
concentration was found to be linear (Figure 4.14). 
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Figure 4.14. The OD generated by the BCA assay carried out on a standard curve of TT 
The BCA protein assay was used to quantify TT in different TT concentrations to produce a standard curve. OD 
points are from duplicate samples.  
 
The equation from the standard curve was used to calculate TT in the CaP-PCMC 
formulation as well as the TT released into soluble form when the CaP-PCMCs were 
suspended in PBS. The total recovery of TT was found to be 69.9% of the expected 
value, and of this, only 2% was found to be soluble.  
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The BCA assay was more successful in measuring the quantity of TT in the formulation 
as well as the release of the TT into soluble form when the crystals are suspended in 
PBS buffer. Although this assay is more sensitive, there is no confirmation of size of the 
measured protein as in the SDS-Page. The release of TT from the formulation is also 
very low, which indicates that the TT is stably adsorbed to the crystal surface and will 
be delivered to the final cellular target of the crystal. 
 
4.4.11. Quantification of CpG by UV spectroscopy 
CpG was added to the formulation to stimulate TLR9 which is present intra-cellularly in 
B Cells. Although CpG is not an essential antigen, the recovery of CpG on the 
formulation is important to stimulate the B cells. CpG is also costly and so it is of 
interest that as high a recovery is achieved in the formulation as possible.  
The CpG standard was diluted and tested to form a standard curve, shown in Figure 
4.15, and this was used to calculate the CpG recovery on two 0.5% CpG loaded CaP-
PCMC formulations (Table 4.9). The recovery of CpG was high, with 96.2 and 98.8% of 
the theoretical CpG measured adsorbed to the crystal.  
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Figure 4.15. Absorbtion at 330nm of different concentrations of CpG corrected for 
control absorbtion at 330nm 
 
CpG was quantified successfully by using UV spectroscopy (Table 4.9). Unfortunately, 
this assay required a large quantity of CpG to produce a reference standard for 
quantification of the sample CpG content. It is for this reason that this assay was not 
repeated with other formulations. 
The high recoveries on formulations from both the 1-step and 2-step protocols 
indicate that the CpG loss during the production process is not an issue with CaP-PCMC 
production. Collectively, these results indicate that the preparation of the CaP-PCMCs 
is successful in adsorbing good amounts of antigen to the crystal upon preparation. 
This is crucial to ascertain before any investigation moves into the in vivo system.  
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Table 4.9. The CpG measurement and percentage recovery of two formulations as 
determined by UV spectroscopy 
Formulation details CpG (µg/mL) Expected 
Percentage 
recovery 
0.5% CpG, 2-step 48.1 50.0 96.2 
0.5% CpG, 1-step 49.4 50.0 98.8 
 
 
4.5. Conclusions  
These experiments indicate that the PRP, TT and CpG are all chemically present on the 
crystals. However, the measurement by ELISA of both TT and PRP indicate that there is 
an issue with changes in the antigenicity of the antigens on the crystals after 
formulation. This is not a major concern with TT, however for a protective immune 
response against the Hib capsule to be induced by the CaP-PCMC immunisations, the 
epitope of the PRP needs to be recognised by the immune response. 
The analysis of the different PCMC formulations demonstrated that the inclusion of 
CaCl2 is changing the PRP on the CaP-PCMCs in a way that it cannot bind the detection 
antibodies generated against the PRP-KLH vaccine to the same level as PRP in PCMCs 
formulated without CaCl2. This may cause a decrease in the specificity of anti-PRP 
antibodies generated in animals immunised with the CaP-PCMC formulation, and this 
is investigated in the next chapter.  
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Chapter 5. Immunogenicity of CaP-PCMC and effect of 
various preparation parameters and adjuvants 
5.1. Introduction 
The pilot study with CaP-PCMCs demonstrated that the CaP-PCMC formulation was 
able to induce an anti-PRP immune response (52). The original PRP-TT-CpG CaP-PCMC 
formulation used had been prepared at XstalBio using a two-step process and the 
antigen, CpG, CaP loadings, and water content and molar ratio of CaCl2 to NaH2PO4 
used in the CaP-PCMC preparation are shown in Table 5.1 below.  
Table 5.1. The Preparation parameters of the pilot formulation 
  Antigen Loading 
CpG 
loading 
CaP 
loading 
Water 
content 
CaCl2:NaH2PO4 
ratio 
Number 
of 
Process 
steps   PRP TT 
Percentage 
Loading 
(%,w/w) 
0.5% 0.05% 0.5% 9.4% 5% 1:1 2 
 
The immunogenicity of this formulation had been tested in the rat model at NIBSC, 
where animals were immunised subcutaneously with three doses of the CaP-PCMC 
formulation. The immune responses following the primary and two booster doses are 
shown in Figure 1.8. The CaP-PCMC formulation was shown to be promising as it can 
be seen that three out of the eight rats given three doses of CaP-PCMC suspension 
generated substantial levels of anti-PRP antibodies.  
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Figure 5.1. Anti-PRP IgG response induced after 1, 2 and 3 doses of CaP-PCMCs 
loaded with TT, PRP and CpG.  
Rats were immunised with CaP-PCMCs with PRP equivalent dose of 6µg in CaP-PCMCs on days 0, and a 
PRP dose of 1.2µg on days 28 and 56. Test bleeds were taken on days 28, 42 and 56. Serum anti-PRP IgG 
response was measured by ELISA. Levels of anti-PRP responses were determined by parallel line analysis 
relative to an immune serum from animals immunised with a Hib-TT conjugate vaccine with an assigned 
titre of 5000. Responses from individual animals are shown as diamonds and the geometric mean titre 
of the group is shown as a red horizontal bar. 
5.2. Aims and Objectives 
The aim of the work discussed in this chapter: 
1. To investigate the effect of different preparation parameters on the 
immunogenicity of the crystals 
2. To investigate the effect of dose and dosage regimen on the immunogenicity of 
the crystals 
3. To investigate the effect of soluble adjuvant on enhancing the immunogenicity 
of the CaP-PCMC formulation 
4. To investigate the antigenicity of the PRP after the CaP-PCMC preparation 
process.  
Number of CaP-PCMC 
immunisations 
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The formulation used in the pilot study between NIBSC and XstalBio was used as a 
starting point. Thus, PRP, TT and CpG loadings in the CaP-PCMCs were maintained at 
levels shown in Table 5.1. The preparation conditions shown in Chapter 2 to influence 
the CaP-PCMC morphology were varied. The CaP loading, number of process steps and 
water content used during the preparation procedure were therefore varied. 
The influence of dosage regimen was tested to determine an optimum dose and 
dosage regimen using the doses used in the pilot study. As too high, as well as too low 
a dose can result in sub-optimal antibody responses (52), the original dosage regimen 
of 6µg followed by two doses of 1µg of PRP (a TT equivalent of 0.6µg, then two doses 
of 0.1µg) was increased as well as decreased.  
The effect of the adjuvants on the immunogenicity of the crystals was studied using 
Monophosphoryl Lipid A (MPLA), Pam2Csk4, Polyinosinic:polycytidylic acid (Poly(I:C)) 
and QuilA. MPLA, Pam2Csk4 and Poly(I:C) are Toll-like-receptor (TLR) agonists and can 
activate immune cells which express the specific TLRs. This action would promote 
inflammatory responses and recruit higher numbers of immune cells (166, 167) which 
may act to increase the immune response to the PCMCs and possibly enhance their 
uptake or stimulation of the B cells.  
MPLA  is a derivative of Lipid A from Salmonella and was chosen as an adjuvant as it 
binds to Toll-like receptor 4 (TLR4). It is a detoxified version of Lipopolysaccharide (LPS) 
and acts as an efficient immune-stimulant (168, 169).  
Pam2Csk4 which is a synthetic diacylated lipopeptide that is thought to signal through 
a TLR2 and TLR6 heterodimer, as it has both a lipid and peptide part (170). However, it 
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has also been reported to that Pam2Csk4 can also signal through a TLR6 independent 
manner (171). It has been shown that stimulation of TLR2 by Pam2Csk4 enhances the 
efficacy of vaccination against other bacterial infections (172). Furthermore, when 
combined with a TLR 9 agonist, present as CpG-ODN in the CaP-PCMC formulations, 
the Pam2Csk4 was found to promote resistance against bacterial pneumonia via the 
TLR2-Myd88-dependent pathway (170). 
Poly(I:C) is a synthetic analogue of double stranded RNA, which imitates viral infection. 
Poly(I:C) binds TLR3 and therefore can be used an immune stimulant (173, 174). Once 
bound, TLR3 activates the transcription factor interferon regulatory factor 3 (IRF3), 
which leads to the production of type 1 Interferons (IFNs), such as IFN-β.  Activation 
also triggers the production of inflammatory cytokines and chemokines such as TNF-α, 
IL-6 and CXCL10 (167). 
QuilA is a derivative of a saponin from the Quillaja saponaria plant and  is not a TLR 
agonist. QuilA has been used with CpG-ODN, which is present in the CaP-PCMC 
formulation, as an adjuvant to enhance antibody response against viral proteins (175).  
 
 
148 
 
 
5.3. Materials and Methods 
5.3.1. Materials 
The following materials were used in the study: 
Plastic microtitre 96-well plates (Nunc Maxisorb, UK) 
Hib Oligosaccharide conjugated to Human Serum Albumin (HbO-HA, NIBSC, Potters 
Bar, UK) 
Wash Buffer (PBS containing 0.05% Tween 20 v/v) 
Assay Diluent (PBS containing 1% Bovine Serum Albumin, 0.05% Tween 20 and 3.8% 
Ethylenediaminetetraaectic acid, w/v) 
Detection Antibody (HRP-conjugated goat anti-rat IgG, 3030-05 Southern 
Biotechnology, UK) 
Sigmafast OPD substrate (Sigma, UK, prepared 30 min before use) 
TT In-house standard (NIBSC code 02/126, Potters Bar, UK) 
First International PRP standard (NIBSC code 02/208, Potters Bar, UK) 
5.3.2. Animals and immunisation 
Groups of 5-10 female, Sprague Dawley rats (aged 6-8 weeks) were immunised 
subcutaneously with 200µl of a CaP-PCMC formulation (equivalent of 6µg of PRP for 
first, and 1µg of PRP for second and third doses) per animal on days 0, 21 and 42 
unless otherwise specified. The equivalent TT doses were 0.6µg for the first dose, and 
0.1µg for the second and third dose. PRP & TT doses were varied by adjusting te mass 
of CaP-PCMCs used to immunise the rats. The positive control group received 1/25th of 
the Single Human Dose (SHD) of a Hib-TT conjugate vaccine (0.4µg of PRP and 0.8µg of 
TT per dose in 200µL volume) subcutaneously on the same days as the CaP-PCMCs, as 
this was previously determined to be the optimum dose for immunogenicity in the rat 
model (52). 
Animals were bled from the tail vein on days -1, 20 and 41 to determine baseline, 
primary and secondary IgG responses. The experiments were terminated 
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approximately 2 weeks after the 3rd immunisation. When blood was collected, it was 
kept overnight at 4°C before centrifugation at 10,000rpm for 10 min. Serum was 
collected and stored at  -20°C in single use aliquots until tested for antibody responses 
by ELISA. 
5.3.3. Quantification of anti-PRP antibody response by ELISA 
Plastic microtitre plates were coated with 100µL/well of 1µg/mL of Hib capsular 
oligosaccharide conjugated to HbO-HA in PBS and incubated for 2 h at 37°C, then 
overnight at 4°C. The following day, plates were washed three times before being 
blocked using assay diluent for 45 min at 37°C. Rat sera were diluted 1/25- 1/50 in 
assay diluent and added at 100µl/well volumes to duplicate wells and incubated for 90 
min at room temperature. 
After washing the plates, 100µl of 1/1000 dilution of detection antibody in assay 
diluent was added to each well and the plate was incubated for 90 min at room 
temperature. After washing, 100µL/well of the Sigmafast OPD substrate, prepared 
according to manufacturer’s instructions, was added and the plates were incubated for 
15 min at room temperature in the dark. The colour change reaction was stopped with 
50µL/well of 3M HCl and optical density (OD) was read at 492 nm using an automated 
reader (Labsystems Multiscan, MS, UK) and Genesis software. Data from the ELISA was 
presented as mean OD values for each serum sample tested. 
5.3.4. Quantification of anti-TT antibody response by ELISA 
 Plates were coated with a 100µl/well of 0.5Lf/mL TT and incubated overnight at 4°C. 
The following day, the plates were washed before being blocked for 45 min at 37° with 
100µL/well of assay diluent. After washing, rat sera were diluted 1/1000 in assay 
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diluent and added, in 200µl volumes to duplicate wells in the first column on the plate, 
then 10 two-fold dilutions were carried  out across the plate except for the final 
column which contained Assay Diluent and served as a blank. The plates were then 
incubated for 90 min at room temperature.  
After washing, 100µl of a 1/1000 dilution of detection antibody in assay diluent was 
added per well and the plate was incubated for 90 min at room temperature. After 
washing, 100µL/well of the Sigmafast OPD substrate was added and plate incubated 
for 15 min at room temperature in the dark. The colour change reaction was stopped 
with 50µL/well of 3M HCl and optical density measured at 492 nm using an automated 
reader as in Chapter 4. 
The titre of an anti-TT IgG response in the immune sera  samples was calculated 
relative to a reference serum with an assigned titre of 10,000 using in-house parallel 
line bioassay programme (Combistats) which relates the logarithm of the assay 
responses (OD) to the logarithm of the dose, using at least 3 points on the linear 
portion of the dilution curve.  
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5.3.5. Preparations of CaP-PCMC formulations used in the 
immunogenicity studies 
In this Chapter, three immunogenicity studies were conducted. The details of CaP-
PCMC preparations are shown below.  
5.3.5.1. Investigation into the influence of CaP-PCMC preparation 
parameters 
Seven CaP-PCMC formulations were prepared under aseptic conditions with variations 
in the preparation parameters. The CaP loading, the water content and the number of 
steps in which the solutes are added (process steps) were varied, as shown in Table 
5.2.  
 
 
Table 5.2. Details of CaP-PCMC formulations prepared at XstalBio with varying CaP 
load, Water content and process step.  
PCMC Sample ID 
TT load 
(%w/w) 
PRP 
load 
(%w/w) 
CpG 
load 
(%w/w) 
CaP 
load 
(%w/w) 
Water 
Content 
(%v/v) 
Process 
Mixing 
Time 
(min) 
Solid 
recovery 
(%) 
1 
0.05 0.5 0.5 
10 
5 
1-step 
16 
80 
2 7 76 
3 10 83 
4 
5 
2-step 
88 
5 15 81 
6 20 74 
7 10 3 81 
 
5.3.5.2. Investigation into the influence of dose and dosage 
regimen 
Based on results of the immunogenicity of CaP-PCMC prepared with different 
preparation parameters, two formulations were chosen, details are shown in Table 
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5.3. The two formulations were prepared, and the powders mixed in a 1:1 ration on a 
rotator for 3 h.  
Table 5.3. Two formulations  prepared and combined for immunogenicity studies on 
dose and adjuvant 
Sample ID 
TT 
(%w/w) 
PRP 
(%w/w) 
CpG 
(%w/w) 
CaP 
load 
(%w/w) 
Water 
Content 
(%v/v) Process 
Mixing 
Time 
(min) 
CaP-PCMC A 0.05 0.5 0.5 10 7 1-step 16 
CaP-PCMC B 0.05 0.5 0.5 10 10 1-step 16 
 
TheCaP-PCMC concentration in the suspension were adjusted to give different dosages 
and dosage regimens. The three chosen regimens are shown in Table 5.1. 
Table 5.4. Dose and regimen of PRP and TT given in the three different dosage 
patterns tested 
Dosage Regimen Theoretical PRP content (µg) Theoretical TT content (µg) 
1 1, 1, 1 0.1, 0.1, 0.1 
2 6, 1, 1 0.6, 0.1, 0.1 
3 6, 6, 6 0.6, 0.6, 0.6 
 
5.3.5.3. Investigation into the influence of soluble adjuvant 
To investigate the effect of soluble adjuvant administered at the same time as the CaP-
PCMCs, the suspension for injection was prepared as above, from formulations shown 
in Table 5.3. The soluble adjuvant was then added to the suspension prior to injection. 
The doses of each adjuvant were chosen based on those used in previous literature. 
Details of the adjuvant doses are shown in Table 5.5. The doses were kept the same for 
each specific adjuvant whether used singly or in combination. 
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Table 5.5. Dosage details for each of the four adjuvants administered in soluble form 
simultaneously with the CaP-PCMC suspension 
Adjuvant 
Dose/rat 
(µg) Agonist References 
MPLA 10 TLR 4  (176) 
PAM2CSK4 5 TLRs 2, 6  (172) 
Poly(I:C) 25 TLR 3  (174) 
QuilA 20 NLRP3  (177) 
 
Soluble PCMCs were prepared (without the addition of CaCl2 and NaH2PO4) and mixed 
with soluble PRP, TT and CpG and used as a negative control for the components of the 
CaP-PCMCs. Hib-TT conjugate was used as a positive control.  
5.3.6. Investigation into the antigenicity of PRP 
To investigate if any changes in PRP are caused by  conditions it encounters during the 
CaP-PCMC preparation process, the antigenicity was assessed through its ability to 
bind anti-PRP antibodies which were generated against the Hib-TT conjugate.  
The influence of Isopropanal (IPA) and CaCl2 were investigated as experiments 
discussed in Chapter 3 indicated that the combination of these during the preparation 
process as responsible for a change in the PRP which limits its detection by ELISA. The 
effect of CaCl2 and IPA individually and in combination were investigated by incubation 
of CaCl2 in assay diluent, CaCl2 in IPA and IPA on antigen coated plates. The assay was 
carried out as for the anti-PRP ELISA, with the addition of an extra step of plate-
treatment before adding immune serum. 
HbO-HA was necessary to use as the PRP is a carbohydrate, and therefore lacks the 
ability to adhere to the plate surface without conjugation to a protein, in this case, 
154 
 
Human Serum Albumin. Although it should be noted that there may be differences 
between the Hib Oligosaccharide in HBO-HA that  
Duplicate rows on the HbO-HA coated plates were exposed to conditions for 16 min, 
similar to the preparation process. The conditions were as follows: 
 IPA (5% water content) 
 CaCl2 dissolved in H2O (0.3mg/mL) 
 CaCl2 dissolved in IPA(at a water content of 5%, CaCl2 at 0.3mg/mL) 
5.3.7. Statistical Analysis 
To analyse the influence of treatment group on the immune response generated in the 
animal (either anti-PRP response or anti-TT titre), One way Analysis of Variance 
(ANOVA) was conducted on the data from the ELISA. To analyse the influence of 
number of immunisations among groups, a Repeated Measures ANOVA was 
conducted. 
SPSS 21 was used for all statistical calculations.  The nature of test used in stated in the 
text.
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5.4. Results and Discussion  
5.4.1. Effect of formulation parameters on the immunogenicity of CaP-
PCMCs 
To study the effect of the preparation parameters on the CaP-PCMCs’ immunogenicity, 
seven different formulations were prepared (Table 5.2) under aseptic conditions, 
based on the PRP-TT-CpG-CaP-PCMC formulation in the pilot study, but with variations 
in water content, CaP loading, process step (ie. One or two step process) and CaP 
loading, as these parameters were seen to have a visible effect on the crystal 
morphology. A Hib-TT conjugate vaccine was used as a positive control. 
The solid recoveries for the different formulations were high (between 74% and 88%), 
with a mean of 80% which was similar to the recoveries of the formulations prepared 
under non-aseptic conditions shown in Chapters 2 and 3.  
4.3.2.1 The anti-PRP antibody response 
Figure 5.2 shows the anti-PRP responses before and after three doses of each 
formulation tested. An animal was considered a responder if the anti-PRP response 
was greater than the mean IgG response in pre-immune sera + 3 standard deviations. 
It was found that there were no significant differences between the groups prior to 
immunisation, as expected (ANOVA, p<0.05). The geometric mean pre-immunisation 
responses of the groups were low, at 0.7-0.8 OD, which confirms that the rats were 
naïve and had not been exposed to any PRP or polysaccharide that could induce cross-
reactive antibodies. 
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The IgG responses post-immunisation were found to be significantly different to the 
responses prior to immunisation (repeated measures ANOVA, p<0.05), however the 
post-immunisation OD means vary between 0.9 and 0.22 in the CaP-PCMC immunised 
groups which is low, and therefore may indicate that there is a very low response 
generated against the CaP-PCMCs.  
However, there was no significant difference between the groups after immunisation 
(ANOVA, p<0.05). Although it can be noted that the highest means, both over 0.2 OD, 
were from the groups administered with Formulations 2 and 3, prepared with 7 and 
10% water content, respectively. The highest anti-PRP response (OD of 1.4) was 
induced in one rat in the group immunised with PCMC Formulation 2. Two other 
weakly responding animals were from the group immunised with Formulation 3 (ODs 
of 0.8 and 0.3). In the responses seen in the pilot study, the formulation parameters 
were altered. However, as can be seen in Figure 5.2, this did not enhance the 
immunogenicity of the CaP-PCMCs. It seems that the CaP-PCMCs are not acting as a 
virtual conjugate of PRP with TT. 
As seen in the SEM images in Chapter 2, the increase in the water content from 5% to 
7% resulted in larger flatter crystal shape. The CaP-PCMCs prepared with a 7 or 10% 
water content were not imaged. It appears that the increase in the water content may 
act to increase the immunogenicity of the formulation and this may be due to a slightly 
more immunogenic shape which allows better targeting of the follicular B cells.  
4.3.2.1 Kinetics of the anti-PRP response in three responding animals 
In order to understand if the high responders had generated the anti-PRP response in a 
T cell dependent manner, the sera from the three individual rats (circled in orange in 
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Figure 5.2) with the highest anti-PRP responses were further analysed to determine 
the kinetics of the anti-PRP response after sequential dose of antigen (Figure 5.3). It 
can be seen that the responding animal immunised with Formulation 2 mounted a 
clear booster response after the second and third immunisations, indicating the 
generation a T cell dependent response and the priming of B cells for a memory 
response. 
In contrast, the two animals immunised with Formulation 3 show responses that are 
less indicative of a memory response. One animal shows an increase in the OD from 
the first to the second immunisation of 0.13 to 0.34, while the other shows an increase 
after the second immunisation from 0.08 to 0.38 OD. In the first case, the lower dose 
of CaP-PCMCs may not have reached the follicular B cells, and in the second case, it 
may be that the first dose of CaP-PCMCs did not reach the cells. If none of the first 
dose of CaP-PCMCs were able to reach the follicular B cells to initiate the 
differentiation into memory B cell, the next dose will not induce a memory, boosted, 
response, but instead act to prime the B cells.  
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Figure 5.2. Anti-PRP IgG response after 3 doses of different formulations of CaP-PCMCs 
Animals were immunised with 3 doses of various CaP-PCMC formulations containing 6µg of PRP/rat for the initial dose (1.2mg of CaP-PCMC) and 1µg/rat for the booster doses 
(0.2mg of CaP-PCMC). Animals in the control group were immunised with a Hib-TT conjugate containing the equivalent of 0.4µg PRP/dose. Sera obtained before (-) or after 3 
immunisations (+) were tested at a dilution of 1/25. The anti-PRP response is presented as OD of individual animal sera (diamonds) and geometric mean of the group (red 
horizontal bars; n=5). A two-way ANOVA was carried out and there was no significant difference between the CaP-PCMC groups or between immunisations. The orange circles 
show the IgG titres of the highest responders which were selected for further analysis described in the following section. 
1 
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Figure 5.3. Kinetics of anti-PRP IgG responses in responding animals.  
Animals were immunised with 3 doses of two different CaP-PCMC formulations 
containing the equivalent of 6µg of PRP/rat for the initial dose and 1µg/rat for the 
subsequent two doses. Sera were tested after each immunisation at a dilution of 
1/25.Mean OD readings from triplicate wells are shown (error bars indicate 1 standard 
deviation) 
 
4.3.2.2 The anti-TT antibody response 
In contrast to the low anti-PRP responses, substantial primary and memory antibody 
responses were generated against TT, as shown in Figure 5.4 and Figure 5.5. After each 
successive immunisation the anti-TT titre increased significantly (repeated measures 
ANOVA, p<0.05).  However, the primary, secondary and tertiary IgG responses did not 
differ significantly among groups (ANOVA, p<0.05) 
 In addition, irrespective of the PCMC formulation used, all animals immunised with 
CaP-PCMCs had anti-TT responses that were similar or higher than the response 
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induced by the Hib-TT conjugate, the TT dose in the Hib-TT conjugate (4µg) was higher 
than in the CaP-PCMC (0.6µg then twice at 0.1µg) and this was most probably due to 
the inclusion of the adjuvant CpG in the CaP-PCMC formulation.  
Interestingly, the three animals which mounted good anti-PRP response, shown in 
Figure 5.3, also had the highest anti-TT responses compared to other animals in their 
group (data not shown). This not only indicates that the antibody response to TT does 
not interfere with the induction of an anti-PRP response, but that there may be a 
correlation between the responses. 
Influence of number of steps in preparation process on anti-TT response 
The effect of number of process steps on the immunogenicity of the CaP-PCMCs was 
investigated, as there is likely to be differences in the nature of the CaP formation on 
the crystal. The CaP layer may or may not cover the antigens and the core of the 
microcrystal, and therefore might affect the antigen exposure and recognition by B 
cells. Data presented in Figure 5.4 showed that the primary response induced by 
immunisation with Formulation 1, prepared by 1 –step process was much higher than 
the response induced by the equivalent formulation prepared using a 2-step process 
(Formulation 4). However, the difference disappeared after subsequent 
immunisations. The difference may be due to variations in the crystal morphology that 
affected the ability of the crystal to prime the initial response. Subsequent doses may 
require lower levels of TT than the priming dose, due to increased pools of anti-TT T 
cells, which may explain why the final doses even out. 
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Influence of CaP loading on anti-TT response 
The effect of CaP loading on the anti-TT response was investigated in groups 
immunised with Formulations 4, 5 and 6, where the CaP-PCMCs used were loaded with 
either 10%, 15% or 20% CaP respectively (Table 5.2). The animals immunised with 
Formulations 5 and 6 show very similar levels of anti-TT IgG titre at all three doses 
(p>0.05; ANOVA, post hoc Tukey). The animals administered Formulation 4 (the lowest 
CaP-loading of the three groups) showed a significantly lower anti-TT titre after the 
first dose but not the second or third doses compared to groups given 15% and 20% 
CaP-loaded crystals (ANOVA, p<0.05) . It is possible that the increased CaP loading  in 
Formulation 5 and 6 would have an effect on the antigen release rate and stability of 
the microcrystals, and therefore have a possible effect on the immunogenicity of these 
particles. However this may only have an effect on the priming dose, or at the higher 
concentration of CaP-PCMCs administered.  
Influence of  water content on anti-TT response 
The effect of water content on the anti-TT response generated by the CaP-PCMCs was 
investigated with formulations prepared with a 5%, 7% and 10% 
The primary anti-TT response in the group immunised with the formulation prepared 
with a 10% water content (Formulation 3) had similar titres after the first dose as the 
titre from animals administered CaP-PCMCs prepared with a 5% and 7% water content 
(Formulations 1 and 2). This result may indicate that the water content does not play a 
part in altering the immunogenicity of the CaP-PCMCs, at least in terms of the anti-TT 
responses generated.
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Figure 5.4 Anti-TT IgG antibody responses after the first, second and third (1, 2 ,3 on x axis) doses of  different  CaP-PCMCs 
formulations.  
Animals were immunised with 3 doses of different CaP-PCMC formulations containing 0.6µg of TT/rat (1.2mg of CaP-PCMCs) for the 
initial dose and 0.1µg/rat (0.2mg of CaP-PCMCs) for the booster doses. Animals in the control group were immunised with a Hib-TT 
conjugate containing the equivalent of 4µg TT/dose. Sera were tested after each immunisations  at a dilution of 1/1000. The anti-TT 
response is presented as geometric mean titre (n=5) and error bars indicate the 95% confidence interval.
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Figure 5.5 Anti-TT IgG antibody responses after the first, second and third (1, 2 ,3 on 
x axis) doses of  different  CaP-PCMCs formulations. The data is the same as in Figure 
5.4 but presented to visualise the differences among the different groups 
Animals were immunised with 3 doses of different CaP-PCMC formulations containing 0.6µg of TT/rat 
(1.2mg of CaP-PCMCs) for the initial dose and 0.1µg/rat (0.2mg of CaP-PCMCs) for the booster doses. 
Animals in the control group were immunised with a Hib-TT conjugate containing the equivalent of 4µg 
TT/dose. Sera were tested after each immunisation at a dilution of 1/1000. The anti-TT response is 
presented as geometric mean titre (n=5). 
 
5.4.2. The influence of antigen dose and dosage regimen on the 
immunogenicity of the PCMCs 
As the only responding animals were from groups immunised with a formulation 
prepared with a water content of 7% or 10%, it was decided that two new batches of 
CaP-PCMCs would be prepared with the parameters shown in Table 5.2, the first with 
7% and the second with 10% water content (Table 5.3). The two batches were 
combined at a mass ratio of 1:1 for further immunogenicity studies in an attempt to 
increase the immunogenicity of the CaP-PCMCs. 
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5.4.2.1. The anti-PRP antibody response 
To investigate the effect of antigen dose and dosage regimen on the antibody 
responses, animals were immunised with the doses and regimens seen in Table 5.4. 
Anti-PRP and anti-TT responses were assessed after the third immunisation and the 
data is presented in Figure 5.6. It was found that none of the animals in any of the 
groups had any significant anti-PRP IgG responses that were above the background 
level (pre-immunisation). Changing the PRP dose and dosage regimen did not increase 
anti-PRP titre. The low immune responses seen in Figure 5.6 may be due to a too low 
or too high (ie. Non-optimum) antigen dose, or due to the fact that the CaP-PCMCs are 
inherently poorly immunogenic.   
 
 
Figure 5.6. Anti-PRP response in terminal sera of groups given different dosage 
regimens of PRP 
Rats were administered with CaP-PCMC dosage regimens shown in Table 5.2 Diamonds represent the 
mean of readings from duplicate wells of individual serum samples at 1/25 dilution. Geometric mean of 
the group shown as red horizontal bars  (n=5). Two way ANOVA was carried out and it was found that 
there was no significant difference between groups.  
165 
 
5.4.2.2. The anti-TT antibody response 
The anti-TT response (as shown in Figure 5.7) indicate that an influence of antigen 
dose was found, with animals receiving the lowest dose (0.1µg TT for all three 
immunisations) showing the lowest titres which were statistically significant for the 
primary response (ANOVA, p<0.05). 
After the second immunisation a greater than two-fold effect of the dosage difference 
is seen when boosted with the lower dose (ANOVA, p<0.05). After the third 
immunisation the group boosted with the 0.6µg of TT dose had a five-times greater 
response than the group boosted with the 0.1µg of TT, which was significantly 
different (ANOVA, p<0.05). The group which was given the highest dose of 0.6µg of TT 
at each immunisation showed higher anti-TT responses to the group given 0.6µg of TT 
followed by 0.1µg of TT for the third immunisations (ANOVA, p<0.05). These results 
indicate that the dosage can make a large difference in the magnitude of the anti-TT 
response induced, especially for the priming dose.  
These results correspond to previous findings by Katere et al (178) who found that the 
increase in antigen load of TT on polymer particles was found to have positive 
influence on generation of antibody titres. This study showed increasing anti-TT titres 
after a single immunisation with micro-particles loaded with increasing TT 
concentrations. However it is not known whether increasing the  antigen loading acts 
differently to adjusting the TT dose through increase particle dose. 
 
166 
 
 
Figure 5.7. Anti-TT responses in groups given different dosages.  
Animals were immunised with 3 doses of CaP-PCMC suspension with the dosage regimens shown 
inTable 5.4. Sera were tested after each immunisation at a dilution of 1/1000. The anti-TT response is 
presented as a geometric mean titre of th egroup (n=5), bars indicate 1 standard deviation. 
 
5.4.3. The influence of soluble adjuvants on the antibody response to 
PRP and TT 
To study the effect of soluble adjuvant on the CaP-PCMCs’ immunogenicity, the same 
combination of formulations were used as in the previous section except for the 
addition of soluble adjuvants singly or in combination as shown Table 5.5. 
5.4.3.1. The anti-PRP response 
The anti-PRP IgG responses are shown in Figure 5.8. The figure shows the CaP-PCMC 
suspensions remain poorly immunogenic even in the presence of different well-known 
adjuvant, whether these were used singly or in combination. In all groups immunised 
with the CaP-PCMCs, the geometric mean responses were low, ranging from 0.07-0.17, 
compared to a mean of 0.8 in the positive control, and 0.09 in the negative control 
group immunised with soluble PCMCs and antigens, where PRP and TT are co-
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immobilised. Similar responses for the CaP-PCMCs and the negative control further 
confirms that the CaP-PCMCs are not acting as a virtual conjugate and the PRP is being 
presented to the appropriate immune cells (B cells) as an antigen.  
There were few animals which had a substantial anti-PRP IgG responses (circled on 
Figure 5.8). These rats were from the groups which had both MPLA and Pam2Csk4, 
QuilA and MPLA, Poly(I:C) and Pam2Csk4 as well as Poly(I:C) and MPLA combinations. 
As seen in Figure 5.2, a few animals respond and show that in isolated instances, the 
CaP-PCMCs act as a virtual PRP-TT conjugate.  
CpG was present in all the CaP-PCMCs used in the immunisation, however it is evident 
that there is no adjuvant effect of this. The responses were low, and similar to the 
group dosed with soluble PCMCs and antigen without CpG. To properly control for the 
adjuvant effect of CpG, however, a group immunised with CpG-less CaP-PCMCs should 
be used.  
Sera that was collected after the first and second immunisations of animals which 
showed high anti-PRP responses (circled in orange in Figure 5.8) were further analysed. 
The kinetics are shown in Figure 5.9. The highest response was seen in an animal from 
a group which was administered with a combination of MPLA, Pam2Csk4 with the CaP-
PCMC suspension; this immune did show a very clear anti-PRP booster response after 
the booster doses. The OD increased after each dose, from 0.4, to 1.8, to 3, which 
indicates the successful generation of PRP specific memory B cells. This may suggest 
that the stimulation of the TLR 4 (by MPLA), TLR2 and TLR 6 (both by Pam2Csk4) and 
TLR9 (from the CpG adsorbed to the crystal) might be useful to induce the production 
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of a T cell-dependent anti-PRP response. However, the results are not conclusive as 
only one animal from the group of five responded.  
Another responding sera was from an animal immunised with the CaP-PCMC 
suspensions with Poly(I:C) and MPLA, the OD increased 8-fold from 0.17 after the first 
immunisation to 1.4 after the third. The next highest responder was from an animal 
immunised with QuilA and MPLA. The increase was from 0.1 after the first dose to 0.4 
after the third. In these two animals however, these increases may not be the 
formation of a memory response, as after the second dose the OD values are close to 
the background level. If it is the case that there is a very low anti-PRP response after 
the second dose, the addition of the TLR agonists could help to boost a low, but 
existing memory B cell pool.  
The anti-PRP responses shown in Figure 5.2 demonstrate that there are only a few 
responding animals even in the group administered the same formulation as that in 
the pilot study (Formulation 1, Table 5.2).  
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Figure 5.8. Anti-PRP responses after immunisation with CaP-PCMC formulations in combination with different soluble adjuvants.  
Animals were immunised with 3 doses of various CaP-PCMC formulations with the equivalent PRP dose of 6µg of PRP/rat for the initial dose and 1µg/rat for the booster doses. 
Animals in the control group were immunised with a Hib-TT conjugate containing 0.4µg PRP/dose, a negative control group were immunised with soluble PCMCs with 6µg of PRP, 
followed by 1µg in the following two doses. Sera were tested after 3 immunisations at a dilution of 1/25. The anti-PRP response is presented as OD of individual animal sera and 
geometric mean response of the group (red horizontal bars; n=5). Data was tested by two-way ANOVA and it was found that there was no significant difference between each 
group. The orange circles show the IgG titres of the highest responders which were selected for further analysis described in the following section.
A 
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 Figure 5.9. The kinetics of the anti-PRP IgG response in the high responding animals administered with a combination of CaP-PCMC suspension 
and soluble adjuvants 
Animals were immunised with 3 doses of various CaP-PCMC formulations containing 6µg of PRP/rat for the initial dose and 1µg/rat for the booster doses. Animals in the control 
group were immunised with a Hib-TT conjugate containing 0.4µg PRP/dose. Sera were tested after each of 3 immuniseations at a dilution of 1/25. The anti-PRP response is 
presented as mean OD of two readings form the ELISA plate.  
A 
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5.4.3.2. The anti-TT response  
The anti-TT titre in the sera of animals immunised with CaP-PCMC suspension in 
combination with the soluble adjuvants is shown in Figure 5.10.  
The titres of anti-TT antibodies were high in every group tested, with titres ranging 
from 21500 to 362000. It was found that there was a significant effect of subsequent 
immunisations on the anti-TT response which showed significant increases in titre after 
each immunisation (repeated measures ANOVA, p<0.05), indicative of the generation 
of a memory response. However, there were no significant differences between the 
groups given different adjuvants or groups given no adjuvant (ANOVA, p<0.05). 
It is interesting that the same group which had the highest anti-PRP responder in the 
previous section was in the group immunised with Pam2Csk4. This would confirm that 
the generation of the anti-TT response may positively correlate with the generation of 
the anti-PRP response. 
The anti-TT responses were higher in the animals immunised with the CaP-PCMCs 
compared to the two groups which were administered the soluble PCMCs and the Hib-
TT conjugate (neither containing the TLR9 agonist, CpG). This result shows that the 
CpG may increase the anti-TT response generated, even though it does not increase 
the anti-PRP response, although the results are not significant.  
A big difference between the CpG-less control groups is the low titre after the priming 
dose. The mean titres from the groups given the Hib-TT conjugate and the soluble 
PCMCs with TT had mean titres of 87 and 8 after the first dose. However this then 
increased 90-fold and 642 fold with the booster dose, indicating that even with a low 
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titre generated by animals in the control group, a memory response was still evident, 
demonstrating that CpG is not crucial for the development of the memory response. 
There has been a lot of previous studies that use the encapsulation of TT in particles to 
reduce the number of doses needed (179-181), and it was found that the sustained 
release of TT from particles was able to boost the antibody response. In this case, a 
slower release of TT from the CaP-PCMCs, which may be determined by the quality of 
the CaP-layer, may have acted to increase the anti-TT titre compared to the soluble 
PCMCs or the Hib-TT conjugate.  
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Figure 5.10. Anti-TT responses induced by immunisation with CaP-PCMC formulations in combination with different soluble adjuvants after 1, 2 
and 3 immunisations.  
Rats were administered with the TT equivalent dose of 0.6µg for the first, followed by two doses of 0.1µg. Soluble adjuvants were mixed with CaP-PCMC suspension. Sera was 
tested at a 1/1000 dilution after 1, 2 and 3 immunisations (1, 2 and 3 on x axis). Grey bars represent the geometric mean titre of the responses from each group (n=5), and error 
bars represent a 95% confidence interval. Two-way ANOVA was carried out on the data and it was found that there was a significant difference between sequential immunisations, 
but not between groups. Pediacel vaccine Hib component was run as a positive control (Hib-TT conjugate).  
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Figure 5.11. Overlayed Anti-TT responses induced by immunisation with CaP-PCMC 
formulations in combination with different soluble adjuvants after 1, 2 and 3 
immunisations. 
The data is the same as in Figure 5.10 but presented to visualise the differences among the different 
groups. Rats were administered with the TT equivalent dose of 0.6µg for the first, followed by two doses 
of 0.1µg. Soluble adjuvants were mixed with CaP-PCMC suspension. Sera was tested at a 1/1000 dilution 
after 1, 2 and 3 immunisations (1, 2 and 3 on x axis). Points represent the geometric mean titre of the 
responses from each group (n=5). Pediacel vaccine Hib component was run as a positive control (Hib-TT 
conjugate). 
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5.4.4. Investigation into  PRP antigenicity  
The low anti-PRP responses seen in Figure 1.8, Figure 5.6 and Figure 5.8 could be due 
to either a low PRP response generated by immunisation with the CaP-PCMCs, or 
possibly due to a change in the PRP that occurs during the CaP-PCMC preparation. Any 
change in the PRP conformation could lead to generation of different anti-PRP 
antibodies not detectable by antibodies generated against the Hib-TT conjugate.  
To investigate this, PRP was exposed to the various conditions it encounters during the 
CaP-PCMC preparation process. After exposure, its antigenicity was assessed through 
its ability to bind to anti-PRP antibodies which were generated against the Hib-TT 
conjugate. To mimic the exposure of PRP to different conditions it was necessary to 
use HbO-HA instead of PRP which is a carbohydrate, and therefore lacks the ability to 
adhere to the plate surface without conjugation to a protein. 
Immune sera from the Hib-TT immunised animals as well as two immune sera from 
CaP-PCMC immunised animals that are known to have high anti-PRP antibody titres 
were used.  
The binding of antibodies generated against Hib-TT conjugate to the HbO-HA coated 
plate exposed to IPA and CaCl2 are shown in Figure 5.12. It can be seen that the 
titration curves of the antibody binding were similar whether or not the plate was 
treated with CaCl2, IPA or the combination of the two. This suggests that the exposure 
did not result in a different antigenicity of the Hib oligosaccharide (HbO-HA) on the 
plate. However, it must be noted that the anti-PRP antibodies used were those that 
had been generated against Hib-TT conjugate.
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Figure 5.12. The effect of exposure of HbO-HA to different conditions on its binding 
to anti-PRP antibodies  
ELISA plates were coated with HbO-HA and then duplicate rows were treated with 
CaCl2 in H2O, CaCl2 in IPA or IPA for 16 min. Duplicate control rows were treated with 
assay diluent. Sera from immune animals immunised with Hib-TT conjugate was used 
at a 1/100 dilution. Points shown are means of duplicate wells on the plate. 
 
It is possible that during the CaP-PCMC preparation, the conformation of the PRP 
exposed to IPA and CaCl2 was changed and that this altered epitope induced a 
different antibody response. In this case, the new antibody would bind less to 
untreated HbO-HA and more to HbO-HA treated with the substance that altered the 
epitope during the preparation process. 
In order to test this hypothesis, the binding between HbO-HA exposed to IPA and CaCl2 
individually and in combination and antibodies in sera from animals immunised with 
the CaP-PCMC suspension was measured and is shown in Figure 5.13. The sera from 
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CaP-PCMC immunised rats bound at similar levels to the HbO-HA when exposed to any 
of the treatments, at all dilutions of sera. There is a small decrease in the readings 
from wells treated with either IPA or IPA and CaCl2, although the difference is small 
and disappears at higher serum dilutions.  
These results indicate that the exposure of the PRP to the IPA and CaCl2 does not alter 
the PRP sufficiently to change the binding of anti-PRP antibodies. However, it must be 
remembered that as PRP could not coat the ELISA plates by itself HbO-HA was used. 
Therefore, HbO-HA may be more resistant to changes than the unconjugated PRP 
molecules to IPA or CaCl2 in the production process, which would explain the results. 
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Figure 5.13. The effect of different treatments of HbO-HA on binding of anti-PRP antibodies from CaP-PCMC immunisation.  
Duplicate rows of HbO-HA coated wells were treated with IPA, CaCl2 and the combination for 16 min before addition of immune sera 
from animals immunised three times with CaP-PCMC suspension. The two sera used (A and B) were from an animal immunised with CaP-
PCMCs with 7% water content, 2 x CaCl2 excess and 9.4% CaP loading (A) and an animal immunised with CaP-PCMCs with 7% water 
content, 2 x CaCl2 excess and 9.4% CaP loading alongside soluble MPLA and Pam2Csk4 (B) . The data represent the mean of duplicate 
readings from ELISA plates
A B 
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5.4.4.1. Investigation into specificity of anti-PRP antibodies 
generated by CaP-PCMC immunisation 
The ability of antibodies generated by immunised with the CaP-PCMCs to bind to PRP 
itself was tested in an Inhibition ELISA. Both the native PRP and the PRP forming part 
of a CaP-PCMC formulation were used. The results are shown in Figure 5.14. The data 
shows a slightly lower inhibition of HbO-HA binding by the PRP in the CaP-PCMCs was 
shown at all but one of the serum dilutions 
The decrease in binding, however, is not low enough to indicate that there would be 
an anti-PRP response generated by CaP-PCMC immunisation which is undetectable in 
the anti-PRP ELISAs from the immunogenicity studies.  
 
Figure 5.14 Specificity of the binding of anti-PRP generated against the CaP-PCMC 
formulation to formulated and native PRP.  
The percentage inhibition of the anti-PRP antibody from a Hib-TT immunised animal to the HbO-HA at 
different dilutions of unformulated PRP (black line) or as a component of a CaP-PCMC (grey line). Values 
shown are mean of duplicate readings on plate. 
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5.5. Conclusions 
Generally, the immune response to the CaP-PCMC (prepared using different 
experimental conditions) was low. Only a few animals from a few groups responded. It 
seems that the PRP is not being delivered to or recognised by the follicular B cells 
when present on the CaP-PCMCs.  
CpG, a commonly used TLR9 agonist, was present in the CaP-PCMC. Despite this, the 
CaP-PCMCs were not immunogenic for PRP. Other adjuvants tested; MPLA, Pam2Csk4, 
Poly(I:C) and QuilA were also unsuccessful in enhancing the immunogenicity of the 
CaP-PCMCs..  
In contrast to the low anti-PRP responses, anti-TT titres were high, whether the TT was 
administered in the soluble form, adsorbed on CaP-PCMCs or whether soluble 
adjuvants were used. It is clear that the generation of the memory response is not 
dependent on the TT being adsorbed to a CaP-PCMC formulation.  
It was hypothesised that the poor immune responses to PRP could be due to the 
alterations in PRP conformation (and thereby epitope), during the CaP-PCMC 
preparation process, such that different anti-PRP antibodies were generated in vivo 
and that these antibodies would not bind to the detection antibody used in the antigen 
assays. However, exposure of HbO-HA to IPA and CaCl2 did not show any altered 
binding by immune serum from animals immunised with the Hib-TT sera or sera from 
animals immunised with CaP-PCMCs. It was also demonstrated that the anti-PRP 
antibodies were still specific for the PRP in the CaP-PCMCs and the standard ‘native’ 
conformation of PRP.  
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Having established that the PRP in the crystal formulation is not inducing an anti-PRP 
response, the next investigations need to focus on the PRP delivery in vivo to the B 
cells. This may not be occurring for a number of reasons, and the retention of the PRP 
on the crystals needs to be confirmed to increase the likelihood of the CaP-PCMC 
acting as a virtual conjugate. 
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Chapter 6.  Immunogenicity of CaP-PCMC formulations in 
differing pH and with varying administration routes 
6.1. Introduction 
The low levels of anti-PRP response induced by the CaP-PCMC formulations indicate 
that there may be a problem with the antigenicity of the crystals. In chapter 5, it was 
shown that the changes in the PRP, if any, do not affect the specificity of the antibody 
response generated by the crystals. This would indicate that the low immunogenicity 
may be due to an inability of the formulation to deliver the antigens to the PRP specific 
B cells in a fashion similar to what happens with the conjugate vaccine. 
Previously used formulations were tested for PRP release by XstalBio and results 
indicated that less than 5% of total PRP is soluble and released into water in the 
formulation used in the pilot study. As the testing conditions for the PRP did not mimic 
physiological conditions as they were tested in water, it was important to find out if 
results were different when the free PRP released when the free PRP was measured 
from suspensions of the CaP-PCMCs in more physiological buffers such as PBS. For this 
reason, the formulations prepared under the same conditions as those used in Chapter 
4 were tested in PBS.  
However, when a similar formulation was tested in an isotonic solution, PBS, the 
results indicated that over 70% of the total PRP content was released as soluble PRP in 
the supernatant when the CaP-PCMC suspension was pelleted by centrifugation. This 
test was repeated four times and the release ranged between 70-81% with a mean of 
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77%. This high level of free PRP might be the reason for the low immunogenicity seen 
in the studies in Chapter 4.  
Therefore, the high rate of soluble PRP in the PBS was addressed by XstalBio and 
various CaP-PCMC preparation parameters were screened and two new formulations 
with low levels of soluble PRP were prepared. The difference being the change in the 
CaCl2:NaH2PO4 ratio, from 1:1 to 5:2. The two formulations varied in the form of 
Sodium Phosphate used and both were investigated for the ability to induce an anti-
PRP response. The details of the formulations are presented in Table 6.1 . 
Table 6.1  Preparation parameters of the two formulations prepared at XstalBio  
  
Percentage Antigen 
Loading 
CpG 
loadin
g 
CaP 
loadin
g 
Water 
conten
t 
CaCl2:NaH2PO4 
ratio 
Sodium 
Phosphat
e form   PRP TT 
Formulation 
1 
0.5% 0.05% 0.5% 9.4% 5% 5:2 Monobasic 
Formulation 
2 
0.5% 0.05% 0.5% 9.4% 5% 5:2 Dibasic 
All percentages are w/w. Soluble PRP was measured from a CaP-PCMC suspension in PBS. 
The formulations were evaluated for the ability to induce an anti-PRP antibody 
response in the immunogenicity studies using different dosages. The effect of the 
administration route, either subcutaneous or intraperitoneal was also evaluated. 
Intra-peritoneal routes of immunisation of the CaP-PCMC suspensions were 
investigated because this route may offer better trafficking of a particulate suspension. 
Subcutaneous immunisation may results in a ‘depot’ of crystals due to physical inability 
of the particulate form to move from the site of injection. This may result in the 
release and trafficking of only the soluble antigen from the formulation which will fail 
to induce a T cell dependent antibody response. Intra-peritoneal routes may be 
advantageous because the structure of this space is less restrictive to larger sized 
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particles. Previous studies have shown increased immunogenicity from particulate 
vaccines administered intraperitoneally (182). 
In addition, the adjuvants used in the previous chapter (MPLA, QuilA and Poly(I:C)), the 
effect of aluminium-based adjuvant insoluble or “Alum” on the CaP-PCMC 
immunogenicity was investigated. Aluminium salts have been shown to enhance the 
generation of a Th2 response, due to the provision of local inflammation and 
recruitment and activation of antigen presenting cells at the site of injection (183). It 
has also been shown that alum induces chemokine secretion and results in priming of 
Th2 cells, and secretion of IL-4, IL-5 and IL-10 (184).  
The effect of Addavax, a squalene-in-water based adjuvant similar to MF59 (Novartis) 
(185), on the immunogenicity of the CaP-PCMC was also investigated. MF59 has been 
widely used in Europe with the seasonal flu vaccines and has a good safety profile 
(186, 187). The MF59 emulsions, as well as  the similar adjuvant AS03 
(GlaxoSmithKline) stimulate stronger antibody responses, permit fewer doses and 
antigen dose sparing, and generate marked memory responses, with a mixed Th1-Th2 
cell phenotype (188).  
6.2. Aims and Objectives 
In this Chapter, it was important to determine not only if the CaP-PCMCs were 
immunogenic, but if they failed to induce an IgG response against the PRP. 
Two formulations were selected by XstalBio with low free PRP content. The 
assumption that with high retention of the PRP on the crystal, it is more likely that the 
crystals will behave like a virtual conjugate and deliver the PRP and TT on the crystals 
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to PRP specific B cells leading to induction of an anti-PRP antibody response. The two 
formulations were tested in the rat model at different dosages administered through 
both the subcutaneous or intra-peritoneal routes. 
Combinations of the CaP-PCMC suspensions and adjuvants that can improve the 
‘depot’ effect of the crystals such as Aluminium Hydroxide. Addaxax (MF59) and 
Aluminium Phosphate as well as the soluble adjuvant QuilA were also tested in an 
immunogenicity study. 
To investigate the effect of buffer on the immunogenicity of the formulation, a 
phosphate buffer was used which did not contain any saline to try to reduce any 
changes in pH after injection, this could increase the soluble PRP. Water was also used 
in two immunogenicity studies to try to reduce the release of soluble PRP from the 
crystal formulation.  
The antibody response to PRP is dependent on T cell help and therefore a study was 
designed to investigate if the poor antibody response to PRP is due to a deficient T cell 
response. Splenocytes from animals immunised (intraperitoneally) with the CaP-PCMC 
suspension were also analysed for a proliferation response to stimulation with TT, 
important for determining if the absence of a an adequate T cell help is responsible for 
the lack of antibody response. Sera from four animals immunised with the CaP-PCMC 
suspension were also tested for bactericidal function.  
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6.3. Materials and Methods 
6.3.1. Materials 
The following materials were used in the study: 
Phosphate Buffer for injection (pH 7.4) 
Phosphate Buffered Saline (pH7.4) 
RPMI for cellular proliferation (Invivogen, UK) 
Hank’s Buffered Saline Solution (HBSS, supplemented with 5% FCS, 1% Penicillin 
Streptomycin, 1% L-glutamine) 
RPMI (Sigma, UK) 
TT (NIBSC 04/150) 
Concanavalin A (Sigma, UK) 
Tritium Thymidine in RPMI  
Chocolate Agar plate (Blood Agar base no. 2, Oxoid, UK) 
Mueller Hinton Broth (supplemented with 10 μg/ml hemin and 1 μg/ml nicotine 
adenine dinucleotide (NAD)) 
Bactericidal Assay Diluent (1x Hanks Salt Solution, 10% FCS in H2O) 
Hanks Salt Solution (Sigma, UK) 
Thymidine Tritium (stock at 1mCi/mL in ethanol, Perkin Elmer, UK)  
6.3.2. Preparation of CaP-PCMCs 
Two formulations were selected by XstalBio by screening of a range of preparation 
parameters for crystals with a low soluble PRP content. The details of the formulations 
are seen in Table 6.2. 
Table 6.2. Details of preparation parameters used to produce the two CaP-PCMC 
formulations with low soluble PRP content, as tested by XstalBio 
 CaP-
Loading 
CaCl2:NaH2PO4 
molar ratio 
Number of 
process steps 
Sodium 
Phosphate form 
Formulation 1 
10 5:2 1 
Monobasic 
(NaH2PO4) 
Formulation 2  Dibasic 
(Na2HPO4) 
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6.3.3. Influence of adjuvants on immunogenicity of CaP-PCMCs 
Details of animal studies are shown in Chapter 5.  
Adjuvants MPLA, QuilA, Addavax, Al(OH)3 and AlPO4 were mixed with CaP-PCMC 
suspensions immediately prior to immunisations. All suspensions were prepared 
immediately before immunisation times, with the exception of Aluminium Hydroxide 
and Aluminium Phosphate which were prepared as a suspension with the CaP-PCMCs 
1 h prior to immunisation at a concentration of 1mg/mL.  
6.3.4. Influence of dosage of CaP-PCMC immunisation on 
induction of anti-PRP response 
To determine the optimum dosage of the two low-soluble PRP CaP-PCMC formulations 
(detailed in Table 6.2), three doses were investigated: 
 0.2µg of PRP per dose (0.02µg TT per dose, ) 
 1µg of PRP per dose (0.1µg of TT per dose) 
 5µg of PRP per dose (0.5µg of TT per dose) 
In another study, one formulation was selected and tested and used in combination 
with Aluminium hydroxide at the following doses: 
 0.4µg of PRP per dose (0.04µg TT per dose, ) 
 1µg of PRP per dose (0.1µg of TT per dose) 
 2.5µg of PRP per dose (0.25µg of TT per dose) 
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6.3.5. Influence of CaP-PCMC immunisation on the boosting of 
an existing anti-PRP response 
Five groups of five female Sprague-Dawley rats were injected subcutaneously with two 
0.4µg PRP equivalent doses of Hib-TT conjugate (Menitorix) three weeks apart. Test 
bleeds were taken on days 51, 62, 83, 104. Animals were immunised a third time on 
day 126 with a dose of CaP-PCMC suspension at a PRP equivalent of 1µg/rat. This 
dosage was selected from immunogenicity studies to optimise the dosage. Control 
groups were administered soluble PRP only, soluble PRP, TT and CpG, soluble PMCs 
formulated with PRP, TT and CpG and Menitorix (this group was given a dose of 
0.4µg/rat). 
6.3.6. Influence of CaP-PCMC immunisation on Splenocyte 
Proliferation in response to TT stimulation 
Cell-mediated immune function was assessed by measuring splenocyte proliferation in 
response to incubation with TT. Animals were killed two weeks after the third 
immunisation and spleens were harvested. A single cell suspension was prepared with 
the use of a cell sieve (Corning). The single cell suspension was washed in HBSS. Red 
blood cells were lysed with H2O and the resulting suspension washed in HBSS. The 
suspensions were adjusted to 2 x 105 cells/mL and 100µL added to rows on 96 well 
plates (Falcon). 100µL of TT in RPMI, RPMI without antigen was added to wells with 
cells and incubated for 4 days at 37°C and 5% CO2. Volumes of 10µL/well of Tritiated 
Thymidine in RPMI were added to the cells and incubated for 4 h. The cells were then 
harvested using a cell harvester onto glass fibre filtermats. The radioactive count for 
each well was recorded using radioactive count machine. 
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6.3.7. Investigation of Bactericidal Ability of serum from CaP-
PCMC immunised animals 
The bactericidal assay was used to assess the ability of the sera collected from 
immunised animals to kill a Hib culture, which would indicate protection against 
infection.  
Haemophilus influenzae type b strain (supplied by NIBSC) was stored in vials at -80°C 
and were streaked on chocolate agar plates after thawing. The streaked plates were 
incubated overnight at 37°C. The next day, 20 colonies were collected from the plate 
with a sterile loop and suspended together in 20mL of Mueller-Hinton broth in a 25mL 
conical flask and incubated for 4 h at 37°C. Terminal Serum from animals immunised 
with CaP-PCMC suspensions or with Hib-TT conjugates were incubated in 300µL 
volumes at 55°C for 30 min to deactivate complement.  The sera was then diluted in 
two-fold in triplicate, 9 times across a round bottomed 96-well plate into Mueller 
Hinton broth in 50µL volumes (50µL of broth added to wells in final column). 
Complement was then diluted 1:1 in broth and added in 30µL volumes to each well, 
leaving a final column without complement.  
20µL of the Hib bacterial suspension in Bactericidal assay diluent is then added to 
every column. The plate is then incubated for 1 hr at 37°C. 10µL volumes were taken 
from the triplicate wells on the plate and pipetted into a tilted chocolate agar plate. 
The three droplets were then allowed to run down the plate to evenly distribute the 
viable bacteria across the plate surface in three lines. The plates were then incubated 
overnight at 37°C. The following day, colony forming units (CFUs) were counted. The 
complement dependent bacterial killing was calculated as a percentage drop in the 
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CFUs of the serum mixed bacterial suspension compared to the CFUs on plates where 
only bacterial suspension had been used without complement. 
6.3.8. Measurement of tissue pH at the site of injection 
The pH at the site of the injection was measured following injection with 500µL of PBS 
into female Sprague-Dawley rats. The animals were terminated and the site was 
dissected 5 min and 30 min after injection via the intra-peritoneal and subcutaneous 
route. A contact pH probe (Mettler Toledo, Ohio, USA) was used to measure the pH in 
the space where the liquid had been injected.  
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6.4. Results and Discussion 
Two formulations prepared by XstalBio which showed low PRP soluble PRP release into 
PBS were prepared and tested at NIBSC for the low soluble PRP. The preparation 
parameters of these formulation is shown in Table 6.2. Both formulations were tested 
three times for the soluble PRP content. The results are shown in Table 6.3. The mean 
free PRP was found to be 13.2% and 25.3% in the two formulations. The upper limit for 
free PRP in the manufacture of the current conjugate vaccines is 20% (189). This would 
indicate that Formulation 2 may contain too much free PRP to initiate a T cell 
dependent response, however due to the different nature of the CaP-PCMC 
suspension, the formulation 2 was tested in an immunogenicity study.  
Table 6.3. Release of soluble PRP from CaP-PCMC suspensions as percentage of total 
PRP 
 
Soluble PRP (%) Mean (%) 
Formulation 1 
10.1 
13.2 5.7 
23.7 
Formulation 2 
22.2 
25.3 32.6 
21.1 
 
Formulation 1 was selected to be tested for release of soluble PRP in three buffers, 
PBS, Saline and H2O. The percentage release can be seen in Table 6.4. The levels were 
found to be lower in Saline than in PBS and lower in H2O than in Saline. These results 
indicate that the presence of both phosphate and Sodium Chloride increase the 
release of the soluble PRP from the new crystal formulation.  
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Table 6.4. Release of PRP from a new samples prepared with a 5:2 ratio of 
CaCl2:NaH2PO4, a 9.4% CaP, a 5% water content and a 1 step process 
CaCl2:NaH2PO4 ratio CaP loading (%, w/w) Process Step Buffer Release 
5:2 10 1 
PBS 13.2 
Saline 9.8 
H2O 1.8 
 
The low level of release of soluble PRP indicates that at least 86.8% of the PRP remains 
as part of the crystal. This level was thought to be enough to ensure that the PRP as 
part of the same crystals contained  
6.4.1. Immunogenicity of the CaP-PCMC formulation 
To investigate the optimum dose for the new CaP-PCMC formulation, three doses 
were investigated in an immunogenicity study. Each CaP-PCMC suspension tested at 
0.2, 1 and 5µg of PRP equivalent dose for all three immunisations. Anti-PRP responses 
after the second and third immunisations are shown in Figure 6.16.  
It was found that the responses induced in the animals given the Hib-TT conjugate 
vaccine were significantly higher than those in the animals immunised with the CaP-
PCMC formulation (repeated measures ANOVA, p<0.05). It was found that there was a 
significant increase of anti-PRP IgG titre between the second and third immunisation in 
all groups (repeated measures ANOVA, p<0.05). However, there were no differences in 
the anti-PRP IgG response generated among the groups immunised with the CaP-
PCMC formulations (ANOVA, p<0.05).  The highest anti-PRP response was seen in one 
animal from the group given 1µg of PRP dose of CaP-PCMC suspension (Formulation 
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1). After three doses this sera produced an OD of 1.3. The second highest anti-PRP 
response was also seen from this group, with a final OD of 0.3.  
It can be seen that the only group that had a responding animal produce an OD greater 
than 1 was immunised with Formulation 1 at a dose of 1µg of PRP, although it only 
induced an anti-PRP response in one animal. The lack of this response seen in groups 
immunised with formulation 2 may be due to the higher levels of soluble PRP seen in 
Table 6.3. As well as a decrease in the PRP able to act as part of the crystal structure 
like a virtual conjugate, the free PRP may act to decrease the response by inducing a T 
cell independent response.  
Low ODs in groups given 5µg PRP doses of the CaP-PCMC suspensions may be due to a 
higher than optimum dose, a similar effect to that seen with the conjugate vaccine. 
The lower dose of 0.2µg induced similar levels of low anti-PRP responses to the higher 
dose. Formulation 1 was therefore selected at a dosage of 1µg of PRP per dose (0.1µg 
of TT) for future immunogenicity studies with subcutaneous immunisations 
formulation and dosage in combination with routes and soluble adjuvants.  
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Figure 6.16 Anti-PRP IgG responses induced after the second and third immunisation (2 and 3) of two CaP-PCMC formulations at three 
dosages. 
Groups of rats were immunised subcutaneously with the CaP-PCMC suspension and sera was collected after three CaP-PCMC immunisations.  Individual responses from 
sera measured at 1/25 dilution shown as green diamonds. The anti-PRP in response in animals given the Hib-TT conjugate (positive control) of a PRP equivalent of 
0.4µg/dose of the Hib-TT conjugate. PRP dose was either 0.2, 1 or 5µg PRP/rat for all three immunisations. Geometric Mean of responses within the group shown as red 
horizontal bars (n=5). Two-way ANOVA was carried out and it was found that there was a significant effect of dose on all groups, however, there were no significant 
differences between groups. 
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6.4.2. Investigation of dose, route, and Aluminium 
Hydroxide on the immunogenicity of the CaP-PCMC 
formulation 
The combination of the intra-peritoneal route and the effect of aluminium 
phosphate were investigated in an immunogenicity study. Hib-TT conjugate 
(Menitorix) was also tested in three groups with the same PRP dosages. Sera from 
the animals after three immunisations were tested by ELISA and the results are 
shown in Figure 6.2. Although aluminium salts have a good safety profile, they can 
occasionally be associated with severe tissue reactions, induction of IgE and related 
allergic and hypersensitivity reactions (190). 
It was found that there was a significantly higher anti-PRP IgG response in the group 
immunised with the Hib-TT conjugate vaccine compared to the groups immunised 
with the CaP-PCMCs (ANOVA, p<0.05). However, there was no significant difference 
in the anti-PRP IgG response among the groups immunised with the CaP-PCMC. The 
highest responding animals were seen in the groups that were administered 1µg of 
PRP per dose administered without alum and intra-peritoneally. Within this group, 
two sera samples produced an OD of over 0.2, which is low, but might indicate the 
generation of a memory response. The highest responding animal in this group 
produced an OD of 0.49. The 1µg PRP dose of CaP-PCMC administered intra-
peritoneally without Aluminium Hydroxide did not show any responding animals, 
however the 5µg dose did induce one sera to give an OD of 0.27, similar to the 
second highest responder in the group administered the 1µg dose. 
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The group that was immunised intra-peritoneally in combination with Aluminium 
Hydroxide showed even lower numbers of responding animals and lower ODs. The 
1µg dose of the CaP-PCMC with this route and Aluminium Hydroxide combination 
had a serum sample produce an OD of 0.23. The lower dose of 0.4µg PRP of CaP-
PCMCs had a sera produce an OD of 0.18, which is higher than the equivalent dose 
without Aluminium Hydroxide. This small difference indicates there is no adjuvant 
effect of the aluminium hydroxide on the anti-PRP response.  
had sera samples with ODs greater than 0.2 was at the lower dosage of 0.4µg of 
PRP in CaP-PCMC suspension given without Aluminium Hydroxide. The sera 
produced an OD of 0.22. 4 animals produced an OD greater than this in the groups 
that were administered the CaP-PCMC suspension intra-peritoneally. 
The Hib-TT conjugate vaccine groups showed a high level of responses at all three 
dosages. The PRP dosage that had the highest geometric mean was the 1µg PRP 
dose, the mean OD was 2.7 compared to 2.2 in the 0.4µg dose and 2.5 in the 4µg 
dose. In each group there was one animal that had a sera OD that was much lower 
than the mean. This heterogeneity may be due to differences (genetic or 
environmental) between the animals within the group.  
This immunogenicity study indicates that the CaP-PCMC suspension may be able to 
act more immunogenically when administered through the intra-peritoneal route. 
However the number of responding animals and the low anti-PRP responses 
indicate that these CaP-PCMCs are not immunogenic, at least at these dosages and 
routes. There does not seem to be any effect of using Aluminium Hydroxide in 
combination with the CaP-PCMC suspension. 
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Figure 6.2. Anti-PRP IgG responses after 3 doses of CaP-PCMCs administered either intra-peritoneally, or subcutaneously, with and without 
aluminium hydroxide at three different doses. 
Groups of rats were immunised with either 2.5, 1 or 0.4µg of CaP-PCMC suspension in water. Six groups were given the CaP-PCMC suspension mixed with Aluminium 
Phosphate (Alum). Rats were immunised either intra-peritoneally or subcutaneously. Rats in the control group were given the PRP equivalent doses of the Hib-TT conjugate 
vaccine (Menitorix) subcutaneously. Individual responses from sera tested after three doses at a dilution of 1/50 The anti-PRP response is presented as OD of individual 
animal sera and geometric mean response of the group (green diamonds and red horizontal bars respectively, n=5). Two-Way ANOVA was carried out and it was found that 
there were no significant differences between groups. 
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6.4.3. Investigation of bactericidal ability of immune serum 
To confirm at the anti-PRP response generated is able to kill the Hib bacteria, a 
bactericidal assay was carried out on sera from responding animals. The immune 
sera from the immunogenicity study shown in Figure 6.2 was selected for testing.  
The percentage killing by ‘Positive serum’ from a Hib-TT immunised animal, non-
immune serum and serum from four animals selected from the CaP-PCMC 
immunised groups are shown in Figure 6.3. 
The positive serum showed a reduction in the percentage killing of over 60% at a 
1:1 dilution of serum to 0% at a 1/1024 dilution. The bactericidal effect of the sera 
from two animals immunised with the CaP-PCMC suspension intra-peritoneally are 
shown in graphs C and D. The percentage killing from these sera has a maximum of 
40-50% at a ½ sera dilution, which is surprising due to the low anti-PRP antibodies 
seen in the immunogenicity study. In animals which had been immunised with CaP-
PCMC suspension with Aluminium Hydroxide are shown in parts E and F. The 
maximum killing of these sera at a ½ serum dilution is around 50%. The differences 
between the animals immunised with and without aluminium hydroxide are not 
great, but the serum from the Hib-TT immunised animal had a higher percentage 
killing, which is not surprising as the positive sera from the Hib-TT immunised 
animals shows a much higher anti-PRP titre (Figure 6.2).  
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Figure 6.3.  Bactericidal effects of immune sera from CaP-PCMC immunisations 
were tested. 
 The immune serum from animals immunised with Hib-TT conjugate (A) and non-immune serum (B) 
were tested alongside immune serum from animals immunised intra-peritoneally with 1µg of PRP 
equivalent of CaP-PCMC suspension without and with aluminium hydroxide (C and D or E and F). 
Blue diamonds represent means of triplicate colony counts and error bars show standard deviation.  
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6.4.4. Investigation of immunogenicity of CaP-PCMC 
formulations administered intraperitoneally 
To confirm immunogenicity of the CaP-PCMC suspension administered at 1µg PRP 
of CaP-PCMC dose intraperitoneally, a larger group size was used. Negative controls 
included groups immunised with soluble PRP, soluble antigens (and CpG), soluble 
antigens (and CpG) with soluble PCMCs with soluble antigens (and CpG). The anti-
PRP IgG responses can be seen in Figure 6.4.  
Similarly to previous immunogenicity studies, the Hib-TT conjugate showed 
significantly higher anti-PRP IgG responses to those in the groups immunised with 
CaP-PCMCs (ANOVA, p<0.05). The animals in the positive control group in this 
experiment were immunised with a dose of Hiberix, a monovalent Hib conjugate 
vaccine. All 9 animals showed a high anti-PRP response with a geometric mean of 
2.3 within the group. 
There was no significant difference among the anti-PRP IgG responses in the groups 
immunised with CaP-PCMCs. The negative controls in this experiment all showed 
low anti-PRP responses. The highest response from a negative control group was 
from an animal immunised with soluble PCMCs formulated with PRP, TT and CpG. 
The OD on this animal was still low, at 0.141. The highest responder in this group 
showed an OD of 0.17, however, the 9 other animals showed lower ODs than the 
geometric mean of the group at 0.09. This response was much lower than the ODs 
from the previous immunogenicity study shown in Figure 6.2, which confirms the 
low immunogenicity of the crystals. 
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Figure 6.4. Anti-PRP IgG response after 3 CaP-PCMCs immunisations administered 
intra-peritoneally. 
Rats were immunised intra-peritoneally with three doses of CaP-PCMC suspensions (in water) 
containing 1µg of PRP per rat. Animals in control groups were given equivalent PRP doses of soluble 
PRP, soluble PRP with 0.1µg of TT and 1µg of CpG with and without soluble PCMCs (n=5) and a 
monovalent Hib conjugate (Hiberix, n=9).  Sera were tested after three immunisations at a dilution 
of 1/25. The anti-PRP response is presented as OD of individual animal sera and geometric mean 
response of the group (red horizontal bars; n=10). Two-Way ANOVA was used and it was shown that 
there was a significant increase in the group immunised with the Hib-Conjugate and all other groups. 
Hib-TT 
conjugate 
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6.4.5. Investigation of cellular response to CaP-PCMC 
immunisation  
The proliferation response of splenocytes in response to stimulation with TT was 
tested to determine if the low anti-PRP responses were due to a lack of cellular 
response to the TT. The indexes calculated from the tritium counts are shown in 
Figure 6.5. Index values greater than 1 indicate an increase in the proliferation in 
splenocytes stimulated with TT compared to unstimulated splenocytes. There was 
no significant difference between the indexes measured among the different 
groups.  
The high indexes in the group immunised with CaP-PCMC suspensions indicate that 
there is a successful induction of a T cell response to the TT in the CaP-PCMC 
formulation. Furthermore, all of the responses in this group were higher than 4 of 
the 5 indexes from the group immunised with Hib-TT conjugate. This increased 
response is most likely due to the inclusion of CpG in the CaP-PCMC formulation.  
In the 10 animals from the two negative control groups, all showed proliferation 
responses. The high index shown from one animal in the group immunised with 
soluble PRP, TT, and CpG was 16.6. The responses in these groups indicate that 
there is a response to soluble TT, which is due to the high immunogenicity of TT 
even when not part of a crystal formulation. However, there was a slight increase in 
the indexes from the CaP-PCMC immunised animals, the geometric mean was 5.3 
compared to 3.5 and 3.4 in the two negative control groups. 
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Figure 6.5. Stimulation index of splenocytes harvested after three immunisations 
of CaP-PCMC suspension.  
Rats were immunised intra-peritoneally with three doses of CaP-PCMC suspensions (in water) 
containing 1µg of PRP per rat. Animals in control groups were given equivalent PRP doses of soluble 
PRP, soluble PRP with 0.1µg of TT and 1µg of CpG with and without soluble PCMCs (n=5) and a 
monovalent Hib conjugate (Hiberix, n=9). Splenocytes were harvested after three immunisations and 
incubated for 4 days with and without Tetanus toxoid and then for 5 hours with Tritium-thymidine 
and uptake of tritium measured.  
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6.4.6. Investigation of soluble adjuvants on the 
immunogenicity of the CaP-PCMC suspension with and 
without CpG 
The immunogenicity of Formulation 1was investigated in combination with Addavax 
(MF59), AlPO4, MPLA and QuilA to improve the immunogenicity of the CaP-PCMC 
formulation to induce anti-PRP responses. Each adjuvant was made into a 
suspension with the CaP-PCMCs formulated with and without CpG to assess the 
adjuvant effect of CpG included in the formulations. The anti-PRP IgG responses 
from the groups are shown in Figure 6.6. 
The group immunised with the Hib-TT conjugate showed a significantly higher anti-
PRP response than all of the groups immunised with the CaP-PCMC formulations 
(ANOVA, p<0.05). There was found to be no significant difference among any of the 
groups which were immunised with either CaP-PCMC formulations even in 
combination with the different adjuvants.  
The groups that were given the CaP-PCMCs without CpG or soluble adjuvant had 
one animal show a response over 0.2. The other four animals showed low anti-PRP 
responses. In the groups immunised with the CaP-PCMC suspensions with the 
adjuvants, only one animal given the QuilA in combination with the CaP-PCMC 
formulated with CpG, this animal produced an OD of 0.21. The highest OD from the 
other groups given the adjuvants with the CaP-PCMCs was given Aluminium 
Phosphate with a non-CpG formulation, and had an OD of 0.61. These results 
indicate that the CaP-PCMC formulation is still not immunogenic enough to induce 
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an anti-PRP response, and this cannot be improved by use of any of the selected 
adjuvants.   
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Figure 6.6 Anti-PRP responses induced before and after 3 doses of CaP-PCMC suspension with and without formulation with CpG and in 
combination with soluble adjuvants . 
Animals were immunised with 3 doses of various CaP-PCMC formulations containing a 1µg of PRP/rat. Animals in the control group were given CaP-PCMCs formulated 
without CpG at a dose of 1µg/rat and the positive control group were immunised with Hib-TT conjugate (Menitorix) at a dose of 0.4µg/rat. Sera were tested after three 
immunisations at a dilution of 1/25. The anti-PRP response is presented as OD of individual animal sera and geometric mean response of the group (red horizontal bars; 
n=5). ANOVA was used and it was shown that there was a significant increase in the group immunised with the Hib-Conjugate and all other groups.
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6.4.7. Investigation of the T cell proliferation response in 
animals immunised with soluble adjuvants.  
Three groups immunised with Formulation 1 (formulated with CpG) in combination 
with Addavax (MF59), Aluminium Phosphate and QuilA were analysed for the 
proliferation of splenocytes in response to stimulation by TT. Splenocytes form the 
group immunised with the formulation without any adjuvant as well as the group 
immunised with the Hib-TT conjugate were included as controls. The stimulation 
indexes are shown in Figure 6.7.  
It was found that there were no significant differences among any of the groups 
tested (ANOVA). The groups given the adjuvants Addavax, Aluminium Phosphate 
and QuilA all showed  proliferative responses with indexes over 1, indicating the 
induction of a cellular response.  In both the Addavax and the Aluminium 
Phosphate groups, there was one animal that showed a high index over 5, with 
10.09 from the group immunised with Addavax and 9.35 from the group immunised 
with Aluminium Phosphate. The rest of a group had stimulation indexes below 2, 
which although less proliferative, indicates that all the animals induced a TT-specific 
pool of T cells in the spleen. The group given the QuilA showed a higher geometric 
mean index of 3.1, compared to 2 and 1.6 in the other groups. There were two 
animals within this group that had a stimulation index over 5. The highest index was 
16.17 and was from this group. Although the QuilA was not able to improve the 
anti-PRP IgG response induced by the CaP-PCMCs, it may be able to slightly increase 
the cellular response to the TT with its adjuvant properties.  
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Both of the groups immunised with the CaP-PCMCs formulated without CpG and 
the Hib-TT conjugate vaccine showed similarly lower indexes. The indexes from 
these groups were 1.6 and 1.44 respectively. The lower values maybe due to the 
lack of adjuvant present in the formulation.  
 
Figure 6.7. Stimulation index of splenocytes harvested after three immunisations 
of CaP-PCMC suspension with combinations of adjuvants. 
Animals were immunised subcutaneously three times with  CaP-PCMC suspensions containing 1µg of 
PRP and CpG per rat with various adjuvants. Animals in control groups were given equivalent PRP 
doses of CaP-PCMCs without CpG and 0.4µg PRP of Hib-TT conjugate vaccine, menitorix. After the 
third immunisation, splenocytes were harvested and incubated for 4 days with and without Tetanus 
toxoid and then for 5 hours with Tritium-thymidine and uptake measured.  
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6.4.8. Investigation of soluble adjuvants on the 
immunogenicity of the CaP-PCMC suspension with and 
without CpG 
The anti-TT response was measured in all the groups. In combination with soluble 
adjuvants and CaP-PCMC formulations with and without CpG. The resulting titres 
calculated from ELISA results are shown in Figure 6.8.  
In the immunogenicity studies in Chapter 4, the Hib-TT conjugate group had lower 
anti-TT titres than the CaP-PCMC formulations containing CpG. In this case, the Hib-
TT conjugate showed a higher anti-TT IgG titre than the negative control group with 
the CaP-PCMC formulation formulated without CpG. This is due to the high levels of 
TT included in the Hib-TT conjugate group, as the CaP-PCMC group was only 
administered 0.1µg/dose compared to 4µg/dose of conjugated TT. All of the test 
groups showed high levels of anti-TT response, although statistically, they fall 
within the confidence intervals, and therefore a conclusion on the most 
immunogenic combination is hard to decide.  
Between each CpG and ‘no CpG’ formulations given the same adjuvants. There is no 
clear pattern as to whether the inclusion of CpG makes a significant difference in 
the anti-TT response. One difference that can be noted is between the two groups 
administered Aluminium Phosphate; the group which was given the Aluminium 
phosphate without CpG showed a slightly higher geometric mean titre of 250530 
compared to the group that was given  Aluminium Phosphate with CpG which had a 
geometric mean titre of 147552, which may indicate that this adjuvant does not 
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work synergistically with the CpG. This was seen before in the anti-PRP responses 
shown in Figure 6.5. 
 
 
Figure 6.8. Anti-TT IgG response after 3 doses of CaP-PCMCs formulated with and 
without CpG administered with and without soluble adjuvant.  
Animals were immunised with three doses of various CaP-PCMC formulations (with and without 
CpG) containing 1µg of PRP per rat. Animals in the negative control group were given CaP-PCMCs 
formulated without CpG. A positive control group was immunised with three (0.4µg PRP equivalent) 
doses of Hib-TT conjugate (Menitorix). Sera were tested after the third immunisation at a dilution of 
1/1000. The anti-TT response is presented as relative titre and error bars show 95% confidence 
intervals (n=5). Two-Way ANOVA was used and it was shown that there was no significant difference 
between groups. 
 
6.4.9. Investigation of change of buffer and use of Aluminium 
Hydroxide on immunogenicity of CaP-PCMCs 
It had been suggested that the injection of the formulation into the intraperitoneal 
cavity could cause a drop in the pH of the tissue, which may negatively affect the 
Addavax AlPO4 MPLA QuilA 
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immunogenicity of the CaP-PCMC by altering the release of soluble PRP. The use of 
the phosphate buffer which did not contain any saline may act to prevent a drop in 
pH at the site of injection. Two groups were also immunised with the CaP-PCMC 
suspensions with Aluminium Hydroxide, as this may act to improve the ‘depot’ 
effect of the suspension within the intra-peritoneal cavity. The anti-PRP responses 
after the three immunisations are shown in Figure 6.9.  
All four of the groups given the CaP-PCMCs in this study shown low anti-PRP 
responses, and all the responses even between the group immunised with the Hib-
TT conjugate and the groups immunised with the CaP-PCMC formulations did not 
significantly differ (ANOVA). The lack of anti-PRP responses indicate that there was 
no effect of either the phosphate only buffer, or the inclusion of Aluminium 
Hydroxide on increasing the induction of an anti-PRP response by the CaP-PCMCs.   
The group immunised with the Hib-TT conjugate showed a high variation in anti-
PRP IgG responses. Three of the five animals in this positive control groups showed 
a PRP response of less than a 0.14 OD. This heterogeneity might have been due to 
genetic or environmental variations in the animals within the group. 
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Figure 6.9. Anti-PRP responses induced after 3 immunisations of CaP-PCMC 
suspensions in phosphate or phosphate saline buffer with and without Aluminium 
Hydroxide. 
Animals were immunised intra-peritoneally with 3 doses of CaP-PCMC suspensions (in either 
Phosphate Saline Buffer or Phosphate only buffer) containing 1µg of PRP/dose. Animals in the 
control group were immunised with a Hib-TT conjugate containing the equivalent of 0.4µg 
PRP/dose. Sera were tested after 3 immunisations at a dilution of 1/25. The anti-PRP response is 
presented as OD of individual animal sera and geometric mean response of the group (red horizontal 
bars; n=5). ANOVA was used and it was shown that there was a significant increase in the group 
immunised with the Hib-Conjugate and all other groups. 
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6.4.10. Investigation into pH at site of injection 
The immunogenicity results indicated that the phosphate buffer without saline 
does not increase the immunogenicity. The mechanism that this was thought to 
operate was that the reduction in pH was prevented with the use of this buffer.  
To determine whether the pH in the intra-peritoneal cavity drops after an injection 
of PBS, the pH was measured in the cavity at 5 min and 30 min after injection. The 
pH measurements are shown in Figure 6.10. The pH at the starting point was 
measured at around 7 in both the subcutaneous and the intraperitoneal spaces. 
Five min after the injection with the PBS, the pH was found to be 7.35 in both the 
subcutaneous and the intraperitoneal space, this is similar to the original pH seen at 
the starting point. After 30 min the pH at the subcutaneous site had increased to 
7.8 whilst the pH at the intra-peritoneal space remained at 7.35.  
These results indicate that there was no decrease seen in the pH measured at the 
sites of injection at either 5 min or 30 min. Although there is a small increase in the 
pH measurement at the subcutaneous site, the difference (0.45) was small given 
that the variation between the same site on different animals is 0.18. 
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Figure 6.10. pH measured at Intraperitoneal and Subcutaneous sites post 
injection.  
Animals were immunised intra-peritoneally or subcutaneously with 500µL of PBS. The pH of the 
intra-peritoneal cavity was measured with a probe after either 5 min or 30 min. A control rat was 
measured at both sites with no injection.  
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6.4.11. Investigation into the ability of the CaP-PCMC 
formulation to boost an existing anti-PRP response  
From the various immunogenicity studies using the CaP-PCMC formulations, it is 
clear that the combinations of dose, adjuvants and formulation used were not able 
to improve the immunogenicity of the crystals enough to induce a memory anti-PRP 
response. However, it is possible that when an already established pool of PRP 
specific memory pool cells exists, the PRP-CaP-PCMCs may be able to boost the 
response.  
To investigate the ability of the PRP-CaP-PCMCs to boost an existing anti-PRP 
response, animals which were immunised twice with the (0.4µg of PRP equivalent 
dose of) Hib-TT conjugate were then boosted with a CaP-PCMC suspension (using 
Formulation 1). There were also control groups boosted with soluble PRP, soluble 
PRP, TT and CpG, and soluble PRP (at a 1µg PRP dose per animal). There was also a 
positive control group given the Hib-TT for a third dose (0.4µg of PRP equivalent 
dose). 
The anti-PRP responses were measured from day 51 to day 104 and it was expected 
that a decline in the response would be seen after the second dose over time as the 
pool of anti-PRP antibody secreting plasma cells decline in number. In the positive 
control group it can clearly be seen that all 5 animals had an increase in their anti-
PRP response after the third immunisation with Hib-TT conjugate on day 126. 
Therefore, as expected, it is clear that the Hib-TT is able to boost the anti-PRP 
response.  
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In the groups immunised with the CaP-PCMC suspension as well as the soluble 
antigens, and the soluble PCMCs, the anti-PRP response also increased after the 
booster dose on day 126. The boosting effect is clear in each of the five animals in 
all apart from one animal in the group boosted with the soluble PCMCs with the TT, 
PRP and Cpg, which had the lowest anti-PRP response in the group, and also 
decreased at day 104 from an OD of 0.15 to 0.09, and appears to be a poor 
responder. 
The group immunised with soluble PRP indicate that the all animals have responded 
to the soluble PRP with a boost in the anti-PRP response. The minimum increase in 
this group was from 2.3 to 3, a difference of 0.6. These results indicate that the 
increase in the anti-PRP response in the other groups is due to the presence of the 
PRP, whether soluble or as part of the CaP-PCMC formulation. It also indicates that 
the PRP even when formulated as part of a CaP-PCMC is able to be recognised by 
the PRP-specific B cells, which confirms the specificity of the anti-PRP response 
shown in the inhibition ELISAs (Chapter 4).  
These results indicate that although the PRP from the CaP-PCMC formulation is able 
to reach the B cells it is meant to target, the formulation is not able to induce a T 
cell response. The group immunised with the soluble PRP showed a similar boost in 
the anti-PRP response to the group immunised with the CaP-PCMC suspension, 
which may indicate that the PRP may not be retained as part of the CaP-PCMC 
structure when it is in vivo. It is not known how long the PRP stays adsorbed to the 
crystal without doing in vivo imaging of labelled antigens. The uptake by the crystal 
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by certain cells of the immune system such as neutrophils or dendritic cells might 
lead to destruction of the crystal structure. 
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Figure 6.11 Anti-PRP responses after two doses of Hib-TT conjugate and boosted with CaP-PCMC suspension. 
Animals were immunised subcutaneously with two (0.4µg of PRP) doses of Hib-TT conjugate (Menitorix) on days 0 and 21 and boosted with a CaP-PCMC suspension on day 
126. Animals in the control group were immunised with; (i) soluble PRP only, (ii) soluble PRP, TT and CpG and (iii) soluble PCMCs containing PRP, TT and CpG all at a PRP 
dose of 1µg (and a TT dose of 0.1µg) and a positive control of Hib-TT conjugate (Menitorix) given at 0.4µg/dose. The anti-PRP response is presented as OD of individual 
animal sera.  
Soluble 
PCMCs & 
PRP, TT, CpG 
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6.5. Conclusions 
The preparation of the CaP-PCMC formulations with a low release of PRP in PBS was 
important, as previous immunogenicity studies in Chapter 4 showed low anti-PRP 
responses after immunisation of the CaP-PCMCs in a PBS suspension. The two 
formulations selected by XstalBio were used in these immunogenicity studies to 
reduce the levels of soluble PRP after injection. However, the results in this chapter 
indicate that even with these formulations, low numbers of animals were 
generating an anti-PRP response. The low immunogenicity may be due to larger 
proportions of the soluble PRP being released from the crystal than is measured by 
the Orcinol assay.  
A peritoneal route of injection was also used to increase the immunogenicity of the 
formulation. The route has previously been used for injection of particulate 
vaccines with some success for the T cell antigen, TT (191). Although none of the 
animals from the CaP-PCMC immunised group mounted an anti-PRP IgG response, 
the stimulation indexes of the splenocytes from this group are on average higher 
than those of the control groups that were tested, including the Hib-TT conjugate. 
This result is interesting as it may indicate that the particulate formulation may 
enhance the cellular response generated against the TT when administered 
intraperitoneally, something that might enhance the anti-PRP response should one 
be induced in the first place.  
The immunogenicity of the CaP-PCMC formulation combined with adjuvants 
Addavax, QuilA and Aluminium Phosphate were also investigated and found that 
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these adjuvants did not increase the anti-PRP response. A combination of a 
phosphate only buffer and aluminium hydroxide with the CaP-PCMC suspension 
was also tested in the model and neither was found to increase the 
immunogenicity, although it was later found that the pH of the site of injection may 
not change after injection. The effect of the injection of phosphate only buffer 
compared to phosphate saline on the local environment may require further 
investigation by injection of larger volumes of the solution. The effect of the 
phosphate buffer on the release of the soluble PRP also needs to be determined.  
The final investigation to determine if an existing PRP response induced by two 
doses of the Hib-TT conjugate could be boosted by a third dose containing the CaP-
PCMC suspension. The anti-PRP responses measured in these groups did show a 
boosting effect in the group immunised with the CaP-PCMCs, however, the same 
increase was shown to occur in the negative control groups which were 
administered soluble PRP with and without soluble PCMCs. These results may 
indicate that the boosting effect from the CaP-PCMC dose is not dependent on the 
retention of PRP on the crystal structure. The similarity of the responses between 
the CaP-PCMCs and the soluble PRP boosting responses may even indicate that the 
PRP boost may be solely from the free PRP released from the CaP-PCMCs, even if 
this is a small quantity. 
As it has been determined, that the PRP in the formulations is retained as part of 
the crystals in a suspension, the trafficking of the CaP-PCMCs route in vivo might be 
responsible for the low immunogenicity. The next step is to investigate the uptake 
and transportation of the crystals by cells of the immune system. 
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Chapter 7. Uptake of CaP-PCMC formulations by cells of 
the immune system 
7.1. Introduction 
Upon immunisation, inflammatory signals are produced at the site of injection after 
tissue damaged caused by the insertion of the needle. The signals increase the 
migration of antigen presenting cells to the area, and therefore also the interaction 
with, and transportation of the antigen through the lymphoid system. The 
interaction between the antigen and the antigen-specific lymphocytes is limited to 
secondary lymphoid tissues such as the lymph nodes or the spleen (192). Therefore, 
antigen needs to reach the lymphoid organs to be able to interact with the cells of 
the immune system. 
It can be assumed that for the particulate CaP-PCMCs to get to the secondary 
lymphoid tissues, there needs to be trafficking from the site of injection. Immature 
Dendritic cells and macrophages catch particulate (as well as soluble) antigenic 
material and carry it to lymph nodes via lymphatic vessels (182).  Due to the size of 
the CaP-PCMCs, the particles are likely to be internalised by endocytosis or 
phagocytosis into the antigen presenting cells in the tissue (193), or be bound to 
the surface of the cell. Studies have shown that T cell responses are dependent on 
the dendritic cell migration through the lymphatic vessels, indicating that the 
transport is crucial for a successful immune response (194). 
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Naïve B cells circulate through the blood to the secondary lymphoid organs. It is 
here they encounter antigens and T cell clones specific for the same antigen. Within 
the lymphoid organs, naïve B cells and T cells are distributed in distinct zones; 
lymphoid follicles for B cells and the paracortex in the lymph nodes and the peri-
arteriolar lymphoid sheaths in the spleen for T cells (195). A study by Liu et al (196) 
showed B blast cells were to be found in three sites; around interdigitating cells in 
the T cell-rich zones in the lymphoid organ;  in the follicular dendritic cell network 
and in association with macrophages in the red pulp.  
Memory B cells, which are not in cell cycle, accumulated in the marginal zones in 
response to T cell dependent and T cell independent antigens. It is these locations 
that are key for the B cell to act as an APC and present the T cell antigen for both 
induction of the T cell response, as well as induce full activation of the B cell, 
thereby enabling the development of memory B cells, Ig class switching and long-
lived plasma cells (97). 
Recent studies have investigated the B cell activation process in vivo by 
demonstrating that within minutes of injection, small soluble antigen diffuses 
directly through the SCS, leading to activation of follicular B cells according to their 
proximity to the SCS (197).  
Studies of the delivery of particulate antigens, immune complexes and viruses, to 
follicular B cells were investigated with multiphoton microscopy (198-200).  These 
larger antigens are found to localise at the SCS where macrophages can present the 
antigen and mediate the retention of specific B cells. This allows the B cells, having 
acquired antigen, migrated towards the boundary between B cell and T cell zones 
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to recruit cognate CD4+ T cell help for full activation, crucial for the T cell 
dependent memory response, as induced by the conjugate vaccine.  
A schematic representation of the dynamics of antigen trafficking within the lymph 
node is shown in Figure 7.1. Lymphatic fluid containing soluble antigens or 
particulate antigens carried by immune cells and chemokines (red and green 
respectively) flow through the afferent lymph vessel into the lymph node. Soluble 
antigens may be able to diffuse from the pores in the SCS to access the antigen-
specific B cells. Particulate antigens, such as CaP-PCMCs (diamonds) are taken up by 
SCS macrophages and can be directly presented to the Ag-specific B cell in the 
follicle. Particulate antigens can also be transported by nonspecific B cells to 
Follicular dendritic cells in a complement-dependent manner.  
 
 
Figure 7.1. Antigen presentation to follicular B cells in the Lymph Node 
Image taken from Batista and Harwood 2009 (192). 
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It has been shown that dendritic cells (DCs) are capable of capturing soluble 
antigens, whole microbes, apoptotic bodies and latex micro-particles (201-203), and 
therefore may be capable of taking up the CaP-PCMCs. It has been observed by 
Suzuki et al (204) that various antigens accumulating on the surface of follicular 
dendritic cells (FDCs) were detectable on the cell surface up to one week. Thiele et 
al (205) used micro-particles as an antigen delivery system to target macrophages 
and dendritic cells and found that positively charged particles became attached to 
the cell surface. They also found that the differently charged particles were 
phagocytosed by macrophages and dendritic cells at different rates, with negatively 
charged bovine serum albumin (BSA) coated particles taken up by macrophages at a 
slower rate than dendritic cells.  
It has been previously demonstrated that macrophages take up CaP-PCMCs 
formulated with BSA-FITC sample antigen following 1 h of incubation (206). 
Confocal imaging clearly showed the intracellular location of the CaP-PCMC and 
flow cytometry data indicates that a large number of the macrophage population 
took up the BSA-FITC when formulated as part of the CaP-PCMC compared to the 
cells incubated with soluble antigens which did not show any uptake.  
B cells have also been shown to capture antigen through their B-cell receptor (BCR). 
The cross-linking of the BCR triggers a cascade of signalling events which results in 
the activation of the B cell and initiate the development of germinal centres (GCs), 
required for the production of a high affinity antibody response. For this to occur, 
activated B cells must process and present the Ag on MHC class II molecules to 
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primed CD4 T cells. This process is known as T-cell-B-cell cooperation (207). The 
BCR is essential to modify the endocytic capacity of B cells. Resting mature B cells 
perform minimal endocytosis, but are efficient at specific Ag uptake, which 
optimises the presentation of the antigen at low concentrations (208). Binding of 
the BCR activates Src kinases which then act to phosphorylate clathrin and induces 
the association of the BCR to the lipid rafts which can then target the MHC class II 
containing intracellular compartments (209) where the antigen can be processed, 
bound to and presented by the MHC class II.  
Results from the immunogenicity studies in Chapters 4 and 5 show that the CaP-
PCMC formulation is not sufficiently immunogenic to induce an anti-PRP response 
comparable to that of the Hib-TT conjugate vaccine. Although it is shown that the 
PRP is retained on the crystal structure on the CaP-PCMC in vitro, it is possible that 
the crystals fail to reach the lymphoid organs due to poor uptake by innate immune 
cells or the recognition and uptake by B cells.  
7.2. Aims and Objectives 
The aim of this chapter is to investigate the ability of DCs and neutrophils to bind 
and take up CaP-PCMCs, which is necessary for trafficking of the CaP-PCMCs to B 
cells. This was carried out by incubation of dendritic cells and neutrophil-like cells 
with CaP-PCMCs containing fluorescent antigens and uptake of the crystals was 
measured by flow cytometry. Interactions between PRP-specific B cells and the 
PRP-CaP-PCMCs were investigated by isolation of splenocytes from Hib-TT 
conjugate and PRP-TT-CpG-CaP-PCMC immunised animals and incubation of the 
cells with fluorescently labelled PRP-CaP-PCMCs. The B cell uptake study will 
226 
 
determine if the crystals are able to be recognised through the PRP specific B cell 
receptor and if any cellular interaction follows. In addition we investigated the 
ability of B cells to interact with the antigens on the crystals. 
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7.3. Materials and Methods 
 
7.3.1. Materials 
Phosphate Buffered Saline (PBSA, 10 mM PO43−, 137 mM NaCl, and 2.7 mM KCl, 
5% Bovine Serum Albumin, w/v) 
Bovine Serum Albumin (BSA, Sigma, UK) 
75cm2 flasks (Costar, Cambridge, MA USA) 
Supplemented Culture Medium (RPMI-1640 (Sigma), 10% FCS, 1% L-glutamine, 1% 
Penicillin) 
All-Trans-Retinoic Acid (ATRA, Sigma) 
1α,25-Dihydroxyvitamin D3, (Vitamin D3 ,Sigma) 
Granulocyte Colony Stimulating Factor (G-CSF, Chemicon) 
Fetal Calf Serum (FCS, Invitrogen Life Sciences) 
Trypan Blue Stain (Sigma) 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF; NIBSC; 91/658) 
Interleukin-4 (IL-4, NIBSC, 91/656) 
FACS tube (BD Falcon) 
PBA buffer (PBS with 0.1% BSA, 0.1% Sodium Azide) 
Hanks’ Balanced Salt Solution (HBSS; Sigma) 
OptiPrep™ Density Gradient Medium (Sigma) 
FITC conjugated Anti-MHC class II monoclonal IgG1 antibody (AMS-32.1, 
Pharmingen)  
PE conjugated Anti-mouse anti-CD11c monoclonal IgG1 antibody (HL3, Pharmingen) 
PE conjugated Anti-rat anti-MHC class II monoclonal IgG2 antibody (eBioscience) 
FITC conjugated  BSA (eBioscience) 
Alexa-fluor 647 conjugated OVA (eBioscience) 
7-Aminoactinomycin D (7-ADD, eBioscience, UK) 
FITC labelled PRP (prepared by Innova, UK) 
Texas Red labelled TT (prepared by Innova, UK) 
6-well tissue culture plates (Greiner, UK) 
24 well tissue culture plates (Greiner, UK) 
96 well black plastic plates (Greiner, UK) 
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7.3.2. Preparation of CaP-PCMCs with fluorochrome-labelled 
antigens and determination of total and soluble antigen 
content  
Five different CaP-PCMCs were prepared as described in section Chapter 2, with 
9.4% CaP, a 5:2 CaCl2:NaH2PO4 ratio and a 1 step process. Formulations were 
prepared with only PRP-FITC, a combination of PRP-FITC and TT-Texas red, BSA-FITC 
and OVA-Alexa Fluor 647, PRP (unlabelled) and OVA-Alexa Fluor 647 and OVA alone 
(Table 7.1). 
Table 7.1. Antigen Loading on formulations prepared 
Formulation Antigen  Loading (%, w/w) 
1 PRP-FITC 0.5 
2 
PRP-FITC 0.5 
TT-Texas Red 0.05 
3 
BSA-FITC 0.5 
OVA- Alexa Fluor 647 0.5 
4 
PRP  (unlabelled) 0.5 
OVA- Alexa Fluor 647 0.5 
5 OVA- Alexa Fluor 647 0.5 
 
To determine of the level of total and soluble antigens in the CaP-PCMC 
formulation, the crystal solution and supernatant (after centrifugation of the CaP-
PCMC suspension) are collected as in chapter 3. However, the only difference was 
that the CaP-PCMC concentration was 4mg/mL (a theoretical antigen concentration 
of 20µg/mL), instead of 10mg/mL.  
In addition, as the antigens used were covalently conjugated to fluorochromes, 
measurement of the fluorochrome signal was used to detect the level of total and 
free antigen on the various CaP-PCMC formulations.  
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To quantify the fluorochrome-conjugated antigens, 200µL of supernatant and 
dissolved CaP-PCMCs were added to wells in the first column of a black 96-well 
plate. Multiple 1:1 dilutions were performed across the plate in PBS. The 
fluorescence level was read at 512nm (excitation at 488nm) for FITC, at 615 
(excitation at 596) for Texas-red and at 665 (excitation at 650) for Alexa-fluor 647 
fluorescence. Levels of total and soluble antigen on the CaP-PCMC crystals were 
calculated from a standard curve generated from serial dilutions of the soluble 
labelled antigen. The level of soluble antigen was expressed as percentage of the 
total antigen content of the CaP-PCMCs. 
7.3.3. Differentiation of HL-60 cells into neutrophil-like cells 
HL-60 cells were differentiated into neutrophil-like cells using a method previously 
described (210) .This method was optimised for the cell culture at NIBSC and the 
results can be seen in section A.1. HL-60 cells were seeded at 1 x 105 cells/mL in 
75cm2 flasks in supplemented culture medium and incubated at 37°C and 5% CO2. 
The culture medium was changed every 48-72 hr and cells were passaged upon 
reaching confluence.  
When the cell number reached 108 cells per flask, cells were collected and 
centrifuged to remove culture medium. Cells were differentiated by culturing them 
in 80mL of RPMI supplemented with 2.5µ M ATRA, 9.6fM Vitamin D3 and 30ng/ml 
G-CSF in a flask for 3 days at a seeding density of 105 cells per flask.  
The cells were then harvested and assessed for level of differentiation by measuring 
the level of expression of CD11b, using a CD11b specific monoclonal antibody, 
immuno-fluorescent staining method and flow cytometry analysis. 
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7.3.4. Isolation, differentiation and enrichment of murine 
bone marrow-derived dendritic cells 
Dendritic cells were generated from mouse bone marrow precursors using a 
method previously described by Inaba et al (211). .This method was optimised for 
the cell culture at NIBSC and the results can be seen in section A.2. Mouse tibias 
and femurs were collected from female 6-8 week old Balb/c mice and dipped into 
70% ethanol to reduce contamination. The bones were then washed in RPMI and 
placed in RPMI containing 100U/mL Penicillin, 100µg/mL Streptomycin, 2mM L-
glutamine and 10% heat inactivated FCS. 
To collect the bone marrow cells, a 25-guage needle was used to flush cold RPMI  
through the bone shafts into a container. The collected cells were washed twice by 
centrifugation at 1200rpm for 10 min. Cell viability was determined using trypan 
blue stain and cell number was adjusted to 1x106 cells/mL in RPMI supplemented 
with 20ng/mL of GM-CSF, and 20ng/ml of IL-4. Cells were cultured in 24-well tissue 
culture plates in a final volume of 2mL/well at 37°C and 5% CO2. The culture 
medium was changed every 2-3 days by exchanging 50% of the old medium (while 
cells are settled at bottom of well) with the same volume of freshly made GM-CSF 
and IL-4 supplemented culture medium. Cultures were maintained for a total 
period of 4-11 days. 
To enrich for dendritic cells at the end of the culture period, cells were harvested by 
gentle pipetting and centrifugation for 10 min at 1000 rpm. The cells were then 
washed three times in HBSS by centrifugation for 5 min at 1000 rpm. Pellets were 
resuspended in 3 mL of HBSS and cell viability was determined. Dendritic-like cells 
231 
 
were then enriched using an OptiPrep™ Density Gradient Medium (60% (w/v) 
solution of iodixanol in water, ρ=1.32g/mL) as follows: 3mL of cell suspension 
containing dendritic cells were gently mixed with 1mL of Optiprep stock (giving a 
15%(w/v) iodixanol solution; ρ=1.085g/mL). 5mL of an 11.5% (w/v) iodixanol 
solution (ρ=1.065g/mL), was carefully overlaid on top of the cell suspension and this 
was carefully overlaid with 3mL of HBSS. Following centrifugation for 20 min at 
1000 rpm, the rotor was allowed to decelerate without the break and dendritic cells 
were visible as a band at the interphase between the 11.5% iodixanol and HBSS. 
Cells at the interphase were harvested and washed twice in culture medium to 
remove iodixanol.  
To determine the number of dendritic cells in the cell population, the level of 
expression of MHC class II molecules and of CD11c were measured using specific 
monoclonal antibody, immuno-fluorescent staining method and flow cytometric 
analysis. 
7.3.5. Preparation of B cells 
Six to eight week old female Sprague-Dawley rats were immunised on days 0, 21 
and 42 with either the conjugate Hib-TT vaccine or a CaP-PCMC formulation 
prepared with 0.5% PRP, 0.05% TT and 0.5% CpG at a PRP dose of 1µg PRP per 
animal. Animals were sacrificed 10 days after the 3rd immunisation and the spleens 
were harvested.  
Single cell suspensions were prepared from individual spleens and lymph nodes as 
described previously in chapter 4. To remove macrophages, cells  were then 
incubated in RPMI (supplemented with 1% Penicillin/Streptomycin, 1% L-glutamine 
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and 10% FCS) in 6 well plates at a concentration of 2 x 106 cells per mL in 4mL 
volumes for 1 hour at 37°C and 5% CO2. The supernatant was then harvested 
leaving the adherent macrophage population on the plate.  
To determine the number of B cells in the cell population, the level of expression of 
MHC class II was assessed using specific monoclonal antibody and immuno-
fluorescent staining method and flow cytometric analysis. The results of this 
process can be seen in section A.3. 
 
7.3.6. Uptake of the CaP-PCMCs by immune cells 
HL-60, DCs or B cells were adjusted to 2 x 106 cells/mL. The cell suspension was 
dispensed in 1mL volumes into wells of a 24-well plate. One mL of the different 
concentrations of freshly prepared CaP-PCMC suspension or control (soluble 
antigen) were then immediately added to the wells. The plate was incubated at 
37°C and 5% CO2 for various time periods. In one experiment, HL-60 cells were co-
cultured with CaP-PCMCs that had been pre-incubated in a RPMI suspension for the 
different time periods. The cells were then harvested and prepared for flow 
cytometric analysis 
7.3.7. Immuno-fluorescent staining and FACS analysis 
Cells were adjusted to approximately 2x106 cells/mL, 100µLs of the cell suspension 
is added to a  FACS tube. 2µl of the fluorescent monoclonal antibody or appropriate 
isotype control was added to each tube and cells incubated for 40-60mins on ice. 
The cells were then washed twice in PBA buffer and fixed in 0.5ml of 2% 
formaldehyde in PBS. 
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In the case of the study of uptake by B cells, the cell population was also stained 
with a monoclonal antibody specific for MHC Class II before being fixed in the 2% 
formaldehyde.  
When cells were co-cultured with CaP-PCMC, all samples were subject to an 
additional two washes in Tris/Citrate/EDTA buffer to dissolve the CaP-PCMCs 
remaining in the culture medium to allow analysis by flow cytometry, before being 
finally resuspended in 500µL of 2% formaldehyde in PBS.  
Flow cytometric acquisition was performed using a BD FACSCanto II flow cytometer 
machine, 106 events were collected and analysed for frequency of stained cells and 
the intensity of the staining using BD FACSDiva Software. 
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7.4. Results and Discussion 
 
7.4.1. Uptake of CaP-PCMCs with both BSA-FITC and OVA-
Alexa-fluor-647 
The differentiation of a HL60 line into neutrophil-like cells was optimised. The 
optimum number of days was determined to be 3 days (see Appendix), which was 
shorter than the -9 days seen in previous studies (212), a difference that may be 
due to slight differences in the age and condition of the cell line.  
Both TT and PRP were difficult to label with fluorescent tags, it was for this reason 
that other labelled antigens with improved stability were chosen to use as model 
antigens adsorbed to the CaP-PCMC. A study was designed with CaP-PCMCs 
containing two fluorescent antigens, OVA-Alexa-fluor 647 and BSA-FITC.  
The total and soluble antigen content in the CaP-PCMCs were measured, to 
demonstrate that there would be enough fluorescent signal from the CaP-PCMCs to 
be detected at the location of the crystals. Analysis of the total and soluble content 
of the BSA and OVA, as measured by fluorescence assays showed that 36.2% of the 
BSA-FITC is adsorbed to the crystals in this formulation, and of this, 1.6% was 
soluble. The OVA content was 23.3% and of this, 14.4% was found to be soluble. 
Although the antigen content was not as high as intended, the level was considered 
appropriate to detect antigen uptake within the cells by flow cytometry. 
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Table 7.2. Total and soluble antigen content in CaP-PCMCs containing 0.5% BSA-
FITC and OVA-Alexa Fluor 647 
 
BSA-FITC OVA-Alexa Fluor 647 
Total antigen (%) 36.2 23.3 
Soluble antigen (%) 1.6 14.0 
The total and soluble antigen content of two antigens on the CaP-PCMC formulations (with 0.5% 
BSA-FITC and OVA-Alexa Fluor 647 loading) was determined by measurement of fluorescent 
intensity.   
 
The differentiated HL-60 cells when incubated with the crystals for 10, 30, 60 and 
120 min at CaP-PCMC concentrations of 1 or 2mg/mL. Control cells were incubated 
within culture medium alone, or soluble BSA-FITC and OVA-Alexa Fluor 647. The 
flow cytometric analysis is shown in Figure 7.2. 
Analysis of the live cells only showed that the cells incubated with the soluble 
antigens had a low level of uptake of OVA-Alexa Fluor 647 or BSA-FITC with few 
cells taking up both soluble antigens (6.8%) after two hr. Cells incubated with CaP-
PCMCs showed that following a 10 min incubation, the percentage of cells positive 
for both antigens are 82.4% and 92.2% at the 1mg/mL and the 2mg/mL 
concentrations of CaP-PCMCs. In cells incubated with 1mg/mL of CaP-PCMCs, the 
effect of time seems to decrease the percentage of cells with both antigens from 
82.4% to 67% at 2 h. This effect could be due to apoptosis in cells after uptake of 
the crystals. At the 2mg/mL concentration, the cells positive for uptake of both 
antigens remain over 90% for 1 h.  The time independent response seen at the 
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higher CaP-PCMC concentration could be due to early uptake and retention of CaP-
PCMCs for the duration of the experiment. The high number of double positive cells 
are a good indicator that both the antigens are taken up by the cell and are likely to 
be retained onto the crystal at least up the point of uptake by the cell.  
The fast uptake of the crystals within 10 min of incubation seen in this experiment 
may not be representative of the in vivo environment. Although neutrophils arrive 
at the site of inflammation within minutes (213), the concentration used for 
immunisation in the immunogenicity studies are much lower and the concentration 
will be much more diluted when encountering the immune cells. 
To more accurately simulate the in vivo environment where the crystals may 
remain in a suspension, for example within the interstitial space, for a longer period 
of time before cellular interaction, the CaP-PCMCs were incubated in the media at 
37°C for various time periods. The CaP-PCMC suspension was then added to the 
differentiated HL-60  cells and incubated for another 10 min. If the incubation time 
of the CaP-PCMC in the cell media resulted in any disintegration of the CaP-PCMCs 
or loss of antigens from the crystal, this would be seen in lower levels of uptake 
with increased incubation times. 
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Figure 7.2. Uptake of BSA and OVA CaP-PCMCs in differentiated HL-60 cells. 
Differentiated HL-60 cells were incubated with CaP-PCMCs contained 0.5% loaded BSA-FITC and 
OVA-Alexa-Fluor-647, control cells were incubated in culture or medium or with 10µg/mL of soluble 
BSA-FITC and OVA-Alexa-Fluor-647 (equivalent to theoretical on 2mg/mL).  
 
Results resented in Figure 7.3 show that cells positive for CaP-PCMC uptake at each 
time point. However, the plots show high levels of double positive cells, starting at 
76.1% after 10 min and peaking at 2 h at 99.9%. As shown before, the cells 
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incubated with the combination of the soluble control antigens and the blank-
PCMCs showed a very small increase of uptake of both antigens with time, 
increasing from 1% of the total population after a 10 min pre-incubation, to a 2% at 
30 min, a 7.7% at 50 min, and 13% of the population at 110 min.  
These results indicate that the pre-incubation of the CaP-PCMCs in culture media at 
37°C for up to 50 min did not reduce the uptake of particles compared to those 
seen in Figure 7.2. This may indicate that the crystal incubation can cause the cells 
to die after longer than 10 min incubation, or the incubation in the media could be 
decreasing the crystal size, thereby enabling easier cellular uptake. It also indicates 
that the crystals remain intact in media, as the majority of the cells have taken up 
both antigens at similar intensities. 
 
 
239 
 
 
Figure 7.3. Uptake of OVA and BSA by neutrophil-like cells when cells are 
incubated with CaP-PCMC suspension pre-incubated in media.  
BSA-FITC and OVA-Alexa-Fluor-647 loaded CaP-PCMCs were incubated in cell media at 37°C for 0, 
10, 30, 50 and 110 min before addition to neutrophils for 10 min, control cells alone or cells 
incubated with a solution of 10µg/mL of BSA-FITC and OVA-Alexa-Fluor-647.  
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7.4.2. Interaction of DC cells with CaP-PCMCs 
The optimisation of isolation and enrichment of DC cells from a primary cell culture 
was carried out, the details of the experiments can be seen in the appendix. The 
method used was based on that described in a study by Inaba et. al. (211), and 
similar findings of differentiation time were confirmed.  
To investigate interaction between the CaP-PCMC and the DCs, the cells were 
incubated with the OVA-Alexa-Fluor 647 and the BSA-FITC formulation in a similar 
experiment to that used with the differentiated HL-60 cells. The uptake of either 
antigen into the DCs is shown in Figure 7.4. Control cells were incubated with 
soluble antigens or with soluble antigens and blank CaP-PCMCs. 
It can be seen that uptake of either antigen was less than 1% of the total population 
in cells incubated with the soluble antigen. At 10 min, the cells incubated with 
soluble Ag only had 36% of the population positive for OVA, and had 43% of the 
cells positive for OVA when incubated with both soluble antigens and the blank 
PCMCs. Over time, this only increases to 56.3% at 30 min, and 68.4% at 1 h in the 
soluble antigen group, and 62.1% at 30 min and 71.6% with 1 h incubation of the 
soluble Ags with the blank CaP-PCMCs. In the same groups, the soluble BSA- FITC 
was also taken up by the cells, although at a slightly lower level and more delayed 
kinetics, 27.8% and 36.5% of BSA positive cells at one hour incubation with soluble 
antigens or soluble antigens and blank PCMCs respectively. These high rates of 
uptake of antigen in the soluble form may show that DCs are capable of taking 
soluble antigen. 
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When all cells are cultured with CaP-PCMCs (at 2mg/mL) containing BSA-FITC and 
OVA-Alexa Fluor 647 a much higher proportion of the cells have taken up the 
antigens (72.7% after 10 min). These values increase over a time period, reaching 
89.2% double positive cells at 1 h. This timescale is  longer than that of the 
neutrophils, which is not surprising as dendritic cells may either take up or bind to 
the antigens slower than neutrophils which take up antigen by phagocytosis (203) It 
is also clear from the results that there is a high correlation between uptake of BSA 
and OVA in the CaP-PCMC incubated cells compared to the cells with soluble 
antigen. This result indicates that the uptake must be from crystals which contain 
both antigens. 
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Figure 7.4. Uptake of two antigens on CaP-PCMCs into Bone Marrow Derived 
Dendritic Cells 
Dendritic cells were incubated with 2mg/mL BSA-FITC and OVA-Alexa-Fluor-647 (read through APC 
channel) labelled CaP-PCMCs in cell media for 10, 30 and 60 min. Control cells were incubated alone 
or with 10µg/mL of soluble BSA-FITC and OVA-Alexa-Fluor-647 with and without blank CaP-PCMCs 
which are not loaded with any antigen  
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7.4.3. Uptake of CaP-PCMCs by B cells 
For successful induction of an anti-PRP response following immunisation with the 
crystals, it is important that, given successful trafficking of the CaP-PCMCs to the 
lymphoid organs, the crystals containing both antigens would still be recognised, 
taken up and processed by the PRP specific B cell. To investigate if crystals could be 
recognised by PRP-specific B cells, the uptake of PRP-CaP-PCMCs was measured in 
splenocytes isolated from rats immunised with either the Hib-TT conjugate or the 
PRP-TT-CaP-PCMC to increase the frequency of PRP-specific B cells. As it was not 
possible to label PRP successfully with a fluorochrome, CaP-PCMCs which were 
prepared with unlabelled PRP and OVA-Alexa-Fluor-647. The uptake of these CaP-
PCMCs by B cells could be measurable by detection of OVA-Alexa Fluor 647. Non-
specific uptake by non-PRP specific B cells will be measured with the use of CaP-
PCMCs prepared with just OVA-Alexa Fluor 647 (without PRP).  
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7.4.4. Interaction of CaP-PCMCs with B cells 
A similar CaP-PCMC formulation was prepared, but with only fluorescently labelled 
OVA, as well as non-labelled PRP. The retention of both antigens was found to be 
satisfactory, as can be seen in the Appendix. To perform the uptake study, 
(macrophage depleted) splenocyte cultures were incubated with 1mg/mL of the 
CaP-PCMC suspension for 1 h. Cells were then analysed by flow cytometry after 
staining for MHC class II expression.  
The cells incubated with the soluble OVA-Alexa Fluor 647, showed high levels of 
OVA uptake in both the MHC class II positive and negative populations (26.8% and 
30.5% respectively in the Hib-TT conjugate immunised group). This was similar to 
results obtained from cells of animals immunised with CaP-PCMC immunised group 
(35.7% and 28.8% in MHC II positive and negative cells respectively). The uptake 
into the MHC class II positive group may have been due to pinocytosis of the 
soluble antigen, as has been shown to occur in CD4+ T cells (214). 
It was seen that in both the groups immunised with the OVA-CaP-PCMCs and the 
soluble OVA-Alexa-Fluor-647, there were two populations, one with higher MHC 
CLASS II levels and one lower. However, within each of these populations there 
appears to be continuous spread of levels of OVA-Alexa-Fluor-647, which may 
indicate cells from both populations taking up varying quantities of soluble antigen 
or OVA-CaP-PCMC non-specifically.  
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Interestingly, the splenocytes from both groups, when incubated with the PRP-
OVA-CaP-PCMCs showed lower levels of OVA uptake, with only 19.2 and 18.2% of 
the cells from the Hib-TT conjugate and the CaP-PCMC immunised group 
(respectively) showing fluorescence from the OVA-Alexa-Fluor 647, which may be 
due to the size of the crystals. In both the groups, a large proportion of MHC class II 
positive cells (65%) have taken in CaP-PCMCs. About two thirds the number of the 
cells which had taken up particles were MHC class II negative, which might indicate 
at that least some proportion of the B cells taking up the crystals through BCR-
dependent binding and endocytosis. The lower level of fluorescence intensity for 
OVA positive cells may also indicate that fewer crystals were taken up by the cells, 
but it is not known whether this uptake is mediated by BCR induced endocytosis or 
not. 
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Figure 7.5. Uptake of CaP-PCMCs and soluble antigen by splenocytes from rats 
immunised with a Hib-TT conjugate and a CaP-PCMC suspension  
Splenocytes from rats immunised with 3 doses of CaP-PCMC suspension or Hib-TT conjugate were 
harvested negatively selected for macrophages and incubated with 1mg/mL of CaP-PCMCs 
formulated with both PRP and Ova-Alexa-Fluor-647 CaP-PCMCs. Control cells were incubated with 
CaP-PCMCs formulated with just Ova-Alexa-Fluor-647 or soluble Ova-Alexa-Fluor-647. 
Representative plots from one animal out of group of 5 shown. 
MHC Class II 
OV
A 
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7.5. Conclusions 
The results from this chapter suggest that cells of the innate immune system, such 
as  neutrophils and DCs are able to bind and take in the CaP-PCMCs, which may 
help to transport the antigen to the lymphoid organs which happens with intact 
crystal structure. Neutrophils were not able to take in the soluble antigen, but did 
take up the crystals, whilst dendritic cells  
Dendritic cells also appear to take up CaP-PCMCs with two adsorbed antigens. 
However it is not clear if the same will happen in vivo.  To better investigate the 
trafficking route of the CaP-PCMC in vivo, a live-imaging system could be utilised 
with infra-red labelled antigens. The measurement and tracking of two antigens in 
vivo would also be used to assess the stability of the crystal and the delivery of both 
antigens as a virtual conjugate.  
The B cell uptake results may indicate that B cells are able to bind the soluble and 
CaP-PCMC antigens, but there is non-specific uptake of the CaP-PCMCs. This uptake 
may act to reduce the pool of CaP-PCMCs available if the uptake is high enough by 
the non-specific B cells. The uptake could also be occurring through remaining 
macrophages or dendritic cells, although the numbers positive for OVA and MHC 
CLASS II appear too high for this to be possible. Previous studies have focussed on 
using imaging techniques to track an antigen of interest through the lymphoid 
organ. It may be possible to use a fluorescently labelled antigen adsorbed to the 
crystal formulation to track if the crystal can be trafficked through the lymph vessel 
to the B cell zone.  
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Chapter 8. General Discussion and Further Work 
 
The development of a thermostable and more cost-effective virtual protein-
polysaccharide conjugate will provide a cheap vaccine for the immunisation of 
infants in areas where the current vaccine is not utilised due to the high current 
cost of production, purification and the requirement of the cold-chain (104, 215). 
Polysaccharides require stable conjugation to a protein antigen in order to induce a 
protective antibody response, however this process is costly and therefore has 
proved prohibitive for use in poorer areas in the past (27).  CaP-PCMCs have  been 
used to stabilise several antigens and have been investigated as a potential for 
vaccine delivery (206), as they have been shown to be thermostable over long 
periods of time (149). The aim of this project was to use this technology to prepare 
crystals that act to virtually conjugate the polysaccharide and the protein.  
A vital part of the crystal formulation is the insoluble Calcium Phosphate (CaP) layer 
that theoretically coats the crystal and prevents the crystal core from dissolving. To 
act as a virtual conjugate, both PRP and TT antigens need to remain adsorbed on 
the surface of the CaP-PCMC as the crystals are trafficked to follicular B cells. The 
quality of the CaP layer was only measurable by the quantification of the soluble 
PRP/TT release upon suspension of the crystals in Phosphate Buffered Saline (PBS).    
The crystals were prepared using two main methods to alter the formation if the 
CaP-layer. The single/one-step method involved the rapid precipitation of the 
glutamine, the antigens and the CpG, in the Isopropyl Alcohol which contains the 
Calcium Chloride (CaCl2). The two-step method involves adding the CaCl2 in a 
249 
 
second step, giving a delayed formation of a CaP-layer and therefore potentially 
changing the structure of the crystal. Other factor such as temperature and CaCl2 
concentration were also thought to be able to alter the rate at which the CaP layer 
on the PCMC formed and therefore the stability of the crystals in an aqueous 
suspension.  
The aim of the initial experiments described in Chapter 3 was to characterise the 
shape of the CaP-PCMCs  through the use of Scanning Electron Microscopy (SEM). 
The CaP-PCMCs were formulated using various preparation parameters to 
determine how these parameters might influence the morphology, and thereby the 
immunogenicity. An optimal vaccine delivery system should mimic a pathogen in  
size and shape (216), and it has been shown that for the best antibody responses, a 
particle in the micron range of size would be desirable (178, 217). Following the 
SEM imaging of the CaP-PCMCs, the water content during the preparation process 
was found to alter the morphology and size of the crystals. Cap-PCMCs with water 
contents of 5, 7 and 10% in the preparation mix were therefore selected to be 
tested for immunogenicity.  
Investigation into antigen retention on the CaP-PCMCs was therefore carried out in 
Chapter 4. Chemical assays including Orcinol and BCA protein assay showed that 
both the PRP and the TT were efficiently adsorbed to the crystal during the 
preparation process. However, the quantity of either antigen on the CaP-PCMCs 
was not effectively measured using ELISA. These results sparked concern about the 
antigenic quality of the PRP on the crystals. By using ELISA on various formulations, 
we found that the presence of calcium from the calcium phosphate in the 
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formulation was changing the PRP in a way that was not allowing its detection by 
ELISA. However the mechanisms by which this may have occurred is unknown and 
require further investigation.  
The immunogenicity of the first formulations were carried out by subcutaneous 
immunisation in the rat model with the CaP-PCMC suspensions in Chapter 5. The 
various crystal properties (resulting from different preparation parameters) were 
tested and the crystals were shown to be poorly immunogenic in terms of inducing 
anti-PRP antibodies. The three responding animals were found to be from groups 
immunised with the CaP-PCMCs prepared with a 7% or 10% water content. These 
water contents are higher than in the formulation prepared with 5% water content 
and was used in the pilot study. However, the levels of anti-PRP IgG responses in 
our study were lower than those in the pilot study. The use of the adjuvants MPLA, 
Pam2Csk4, Poly(I:C) and QuilA were also investigated with the aim of increasing the 
immune response to the crystals. However, the increased stimulation of the 
immune system by the adjuvants was not sufficient to induce a robust anti-PRP IgG 
antibody response. In contrast to the low anti-PRP responses, high anti-TT 
responses were induced in all groups of rats, and indicate that the TT on the crystal 
formulation remained immunogenic. 
The low immunogenicity of the CaP-PCMC formulation could be due to changes in 
the in the PRP during formulation, release of adsorbed PRP from the formulation or 
ineffective trafficking of the entire crystals to follicular B cells.  Some changes in the 
antigenicity of the PRP was indeed shown to occur when it was exposed to calcium 
chloride during the preparation process, through the use of ELISA on various 
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soluble PCMC formulations. However, the anti-PRP antibody response induced in 
some of the animals immunised by Cap-PCMC was higly specific for both the 
unformulated (native) PRP and when the PRP was part of a CaP-PCMC (Chapter 4), 
indicating that the changes seen in the antigenicity of the PRP during formulation 
have not completely changed its ability to induce PRP-specific antibody response.  
Investigation into the release of soluble PRP from the CaP-PCMC upon the latter’s 
suspension in an aqueous medium (for injection into animals) was not carried out 
initially, as previous results from XstalBio indicated a PRP release of less than 5% 
from the CaP-PCMC formulations when the Cap-PCMC was suspended in water 
(data not shown). Following the low immunogenicity results in Chapter 4, the 
release of PRP from CaP-PCMC formulation was tested, this time following the 
suspension of the CaP-PCMC in PBS, rather than water, as PBS was used in our 
immunogenicity studies. In contrast to earlier results by XstalBio, we found a high 
release of PRP, 73% as discussed in Chapter 4.  
The high PRP release being a problem, screening of various calcium phosphate 
(CaP) layer preparation parameters by XstalBio resulted in the selection of two 
formulations with low PRP release, one prepared with monobasic sodium 
phosphate and another with dibasic sodium phosphate. Both of these formulations 
had a higher excess of CaCl2 (5 times instead of 2 times reacting with the sodium 
phosphate), which might have acted to increase the speed at which the calcium 
phosphate layer is formed on the PCMC, or the efficiency with which the sodium 
phosphate reacts to form the calcium phosphate layer, and therefore increase the 
quality of the CaP layer and thereby reduce the release of soluble PRP.  The two 
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formulations were tested for immunogenicity, in Chapter 6, and it was found that, 
once again, the PCMC formulation was poorly immunogenic. 
Having demonstrated that the low immunogenicity of the formulation was not due 
to changes in PRP during formulation preparation, or high release of adsorbed PRP, 
it was hypothesised that the trafficking of the formulation to PRP-specific follicular 
B cells may be inadequate. The formulation was therefore injected intraperitoneally 
(instead of subcutaneously), as this route has been found to improve the mobility of 
particulates (218). In addition, aluminium hydroxide was added to the CaP-PCMC 
suspension to decrease the quantity of soluble antigen entering into the lymph, as 
has previously been demonstrated (219). Once again, low anti-PRP responses were 
obtained for the IP route of immunisation with or without Aluminium Hydroxide. 
There were two high responding animals from the group (of five animals) 
administered three doses of the CaP-PCMCs prepared using monobasic sodium 
phosphate and administered intraperitoneally at 1µg PRP per dose. Therefore these 
conditions were further investigated. The improved immunogenicity of the CaP-
PCMC prepared with the monobasic sodium phosphate could have been due to the 
lower PRP release from this formulation compared to the formulation prepared 
with the dibasic sodium phosphate. The efficacy of the antibody response was also 
investigated using a bactericidal assay against Hib bacteria (Chapter 6). Sera from 
the responding animals did kill the Hib colonies in this assay, demonstrating that 
when animals respond to the immunisation with Cap-PCMC, the induced response 
is PRP specific and efficacious  
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To improve the immunogenicity of these formulations, more adjuvants were tested, 
including Addavax , aluminium phosphate, QuilA and MPLA with the aim of 
increasing the trafficking of the CaP-PCMCs to the anti-PRP follicular B cells. 
However, these adjuvants did not improve the anti-PRP response.  
It was possible that the cellular response induced by TT may not be effective at co-
stimulating the PRP-specific B cells, however the proliferation responses of the 
splenocytes from the CaP-PCMC immunised animals in response to TT stimulation 
indicate that this is not the case. It was also thought that a potential reduction in 
the pH at the site of injection following the administration of PBS might be causing 
a degradation of the CaP-PCMC structure with a concomittent release of CaP-PCMC 
adsorbed PRP. Therefore the use of phosphate buffer without saline was 
investigated to decrease any such effect. However, immunogenicity results from 
immunisation with the two buffers did not show any increase in immunogenicity in 
the absence of saline. In vivo, pH at the site of injection was then measured and 
was not found to decrease following injection of CaP-PCMCs in PBS or phosphate 
buffer. This may explain the lack of difference in the immune responses when 
phosphate buffer or PBS were used to administer the CaP-PCMCs.  
Having demonstrated that the CaP-PCMCs are not immunogenic enough to prime 
the anti-PRP response, it was thought that CaP-PCMCs might be able to boost an 
existing anti-PRP response. This was investigated in Chapter 5 by priming rats with 
Hib-TT conjugate followed a booster dose of the Hib-TT conjugate or  CaP-PCMCs. 
The CaP-PCMCs were found to be as effective as soluble PRP at boosting the anti-
PRP IgG response, indicating that PRP-specific B cells were able to recognise and 
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respond to the PRP formulated in Cap-PCMC. However, the results also indicate 
that the formulation of PRP into a virtual conjugate does not confer any advantage 
in this situation.  
Interactions between the cells of the immune system and the CaP-PCMCs were 
investigated using flow cytometry in Chapter 7. CaP-PCMCs were prepared with two 
fluorescent antigens to model the two antigens on the PRP-TT-CaP-PCMCs. Both 
neutrophil-like cells and dendritic cells were found to take up the two antigens 
effectively. It is possible that uptake into, rather than presence of the crystals on 
the surface of the cells may result in degradation of the crystal and  the delivery of 
single antigens. The study of the kinetics of the uptake and processing of the 
crystals by dendritic cells and neutrophils can be further investigated using confocal 
microscopy of the crystals in cell culture. Live cell imaging would be able to 
demonstrate the kinetics of this process in real time. Interestingly, B cell uptake of 
PRP-CaP-PCMCs was shown to be just as effective as the uptake of CaP-PCMCs 
formulated without PRP. This result indicates that conditions ex vivo may not be 
optimal for specific uptake studies. This uptake study can also be optimised by use 
of a cell separation technique to enrich the cell population for B cells using specific 
markers such as B220 as well as MHC class II.  
To further investigate the trafficking of CaP-PCMCs in vivo, imaging systems such as 
Li-COR system can be used with fluorescently labelled antigens to track the 
movement of the two antigens in the animal model. The information gained will 
indicate whether the delivery of both antigens to the follicular B cells is occurring, 
or if the particles are not acting as a virtual conjugate. Similar techniques have been 
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used for lymph node mapping (220-222) and by developing a CaP-PCMC containing 
an antigen labelled with a dye that fluoresces in the far red region, the location of 
the antigen within the lymphoid system can be pinpointed. 
In summary, the results presented in this thesis have demonstrated that CaP-
PCMCs are poorly immunogenic in terms of inducing anti-PRP antibody response. 
This is likely to be due to a failure of the formulation to deliver both antigens to PRP 
specific follicular B cells. The CaP-PCMC formulation is not able to provide a virtual 
conjugation between the TT and the PRP. However it is not known at which stage in 
vivo the crystal fails to act as a virtual conjugate. This will require further 
investigation to determine if the formulation can be improved in a way that allows 
the induction of a T cell dependent anti-PRP antibody response.   
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Appendix 
A.1 Differentiation of HL-60 cells into neutrophils 
Neutrophils are the first cells to arrive at the site of injection and may act to take up 
the CaP-PCMCs and traffic them to the lymph nodes. To investigate if there is any 
interaction between the CaP-PCMC formulation and the neutrophils, differentiated 
HL-60 cells were co-cultured with the CaP-PCMCs prepared with the fluorescently 
labelled antigens. The method for this is detailed in section 7.3.3. 
Previous studies have found that three days of culture in supplemented media 
containing retinoic acid produces the highest proportion of cells displaying 
neutrophil morphology (212). In this project, HL-60 cells were incubated with the 
differentiation media for three days and analysed for morphological changes and 
CD11b expression. Changes in the light scattering properties in the differentiated 
HL-60 cells can be observed, indicating increase in size of the cells (FSC, Figure A.1).  
 
 
Figure A.1 Changes in the forward and side scattering properties of HL-60 cells 
following differentiation.  
HL-60 cells were incubated in supplemented media for 3 days. Control cells were incubated with 
normal culture media.  
Undifferentiated Differentiated 
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The larger cell population was analysed for CD11b expression, and results showed 
that while undifferentiated cells do not express CD11b (Figure A.2). Almost all the 
differentiated HL-60 cell population (97.4%) which had a three day incubation in the 
differentiation media was found to express CD11b. 
 
Figure A.2. Expression of CD11b on HL-60 cells before and after differentiation.  
HL-60 cells were incubated in differentiation media for 3 days. Histograms show levels of CD11b 
expression in cell population. Cells were stained for CD11b using a monoclonal antibody and 
matching isotype control. 
 
Isotype control Anti-CD11b 
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A.2 Interaction of BSA-FITC CaP-PCMCs with neutrophil-like cells 
To optimise the uptake of CaP-PCMCs, HL-60 cells were incubated with varying 
concentrations of labelled and unlabelled CaP-PCMCs. The method for these 
experiments is detailed in section 7.3.3. The differentiated HL-60 cells were 
incubated with the either 2.5 or 5mg/mL of CaP-PCMCs containing BSA-FITC for 30 
min, the resultant changes in the light scattering properties of the cells are shown 
in Figure A.3. While cells incubated in the culture medium show a low level of small 
and granular cells (13%), this cell population increased after the incubation with 
CaP-PCMCs (36 and 52%), which suggests that cells which take up the crystals may 
undergo apoptosis. 
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Figure A.3. Size and granularity of neutrophil-like cells incubated with CaP-PCMCs 
Neutrophil-like cells were incubated with 2.5mg/mL or 5mg/mL of CaP-PCMCs in media for 30 min. 
Dot plots showing size (FSC) and granularity (SSC). Gated populations are shown in the bottom row 
with percentage of total cell population.  
 
To investigate if changes in the cells occur upon incubation with CaP-PCMCs is due 
to cell death, cells with and without CaP-PCMCs were stained with a fluorescent 
dye 7-Aminoactinomycin D (7-AAD), which is a dead cell stain (excited at 488nm 
and emission measured at 647nm) analysed by flow cytometry. The histograms 
showing relative fluorescence from the stain can be seen in A.4. It is clear that the 
small and granular cells (green) are highly positive (75%) for the stain when 
compared to the larger and less granular cells (1.8%, red), indicating that the 
smaller and granular population contained mainly dead cells.  
No CaP-PCMCs 
CaP-PCMC 
concentration 
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Figure A.4. Effect of CaP-PCMC on the  viability of differented HL-60 cells.  
Neutrophil-like cells were incubated with CaP-PCMC suspension at 2.5mg/mL for 30 min. The cells 
were then stained with 7AAD dead cell stain. Mean Fluorescence Intensity (MFI) and percentage of 
cell population positive for the stain (dead) are shown for large and less granular cells (red) and 
small and more granular cells (green).  
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A.3 Differentiation of dendritic cells from murine bone marrow 
Bone marrow cells from mice were used to differentiate into dendritic cells by 
incubation in IL-4 and GM-CSF supplemented media. It has been shown that 4-8 day 
incubation in the media is optimum for dendritic cell differentiation (203). The 
method for this section is detailed in section 7.3.4. 
In our study, after culture of the bone marrow derived cells for the selected period 
of time, the cells are harvested and undergo an enrichment step. To confirm the 
enrichment process results in viable culture, the enriched and non-enriched 
populations were counted for viability, and the results are shown in Figure A.6. The 
viability is consistently higher at all three time-points in the enriched population, 
starting at 90% at day 4, reaching 97.5% at day 7 and finally dropping to 83.3%. 
These results indicate that the enrichment process is suitable for eliminating dead 
cells from the population before analysis by flow cytometry. Therefore, cells 
differentiated for seven days were used for the uptake study. 
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Figure A.6 Percentage viability of enriched and non-enriched cells on days 4, 7 and 
9 
The cells were enriched and viable cells counted and compared to cells from a non-enriched culture.  
 
To confirm that the cells harvested on day 7 are differentiated, they were analysed 
for expression of CD11c and MHC class II expression and the results are shown 
Figure A.7. The results show that 27% of the differentiated cells express MHC class 
II and of these, 46% also express CD11c.  
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Figure A.7. Expression of CD11c and MHC CLASS II on differentiated DC.   
Murine bone marrow cells were incubated in media supplemented to induce differentiation into 
dendritic cells. The level of differentiation on day 7 were established by analysis of CD11c and MHC 
CLASS II staining. Control cells were stained with isotype control antibodies. 
 
A.3 Preparation of CaP-PCMCs for B cell uptake 
Two formulations were prepared, one with 0.5% PRP and OVA-Alexa Fluor 647 
loading (Formulation 1), and one formulation with only 0.5% OVA-Alexa Fluor 647 
(Formulation 2) to control for non-PRP specific uptake of the CaP-PCMCs. The 
method for B cell preparation is detailed in section 7.3.5.  The levels of loading as 
well as free antigen were measured on the formulation using Orcinol assay for PRP 
and fluorescence assay for OVA and is shown in Table A.1.
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Table A.1. Levels of total free antigen in two PRP-CaP-PCMC formulations 
 
 
Formulation 1 Formulation 2 
 
PRP OVA-Alexa-Fluor 647 PRP OVA-Alexa-Fluor 647 
Total antigen (%) 64.4 14.4 n/a 16.4 
Soluble antigen (%) 34.4 9.3 n/a 7.4 
Levels of PRP and OVA-Fluor-647 were measured in the CaP-PCMCs solution in Tris/Citrate/EDTA 
buffer and the supernatant of a centrifuged CaP-PCMC suspension by Orcinol assay and Fluorescent 
readings. Free antigen in the suspension was calculated from the measured total loading of antigen 
and quantities calculated against a various concentrations of the antigens in solution. 
 
The level of PRP detected in Formulation 1 was 64.4% of the theoretical, and 34.4% 
of this was found to be soluble, which indicates that 65.6% of the total measured 
PRP remains on the CaP-PCMC  in suspension. The OVA-Alexa-Fluor loading was 
found to be only 14.4% in the CaP-PCMC formulation containing PRP and 16.4% in 
the formulation prepared without PRP. The release of soluble OVA-Alexa-Fluor-647 
was low at 9.3% and 7.4% respectively. 
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To gain an insight into the nature of the interaction of the CaP-PCMCs with various 
immune cells, CaP-PCMC were first prepared using PRP and TT covalently 
conjugated to FITC and Texas Red, respectively.  The level of total and soluble PRP 
and TT in the CaP-PCMC formulation was determined by measurement of 
fluorescent signal and the results are presented in Table A.2. The total PRP content 
on the crystal was found to be extremely low, (3.7% of the total PRP-FITC used to 
prepare the CaP-PCMCs). Furthermore, the release of soluble PRP-FITC from the 
crystal formulation was high (71.9% of total PRP), leaving on the crystals only 1% of 
the total PRP used. The total TT content of the crystals was also found to be low 
(14.5%), which is much lower than expected. However, the level of soluble TT was 
23.3% of total TT, which would suggest that, although only 11.1% of the total TT 
used is associated with the crystals a high proportion of any signal is derived from 
the TT on the crystals rather than from soluble TT. 
Table A.2. Total and soluble antigen content of the PRP-TT-CaP-PCMC.  
 
PRP-FITC TT-Texas Red 
Total measured antigen (%) 3.7 14.5 
Soluble Antigen Release (%) 71.9 23.3 
The total and soluble PRP and TT content of the CaP-PCMC were determined by 
measuring the fluorescent signal intensity for each antigen and compared to the 
standard curve generated from the different dilutions of soluble fluorochrome 
labelled- antigen dilutions. 
 
However, as the antigen content of the CaP-PCMC is relatively very low, at least for 
the PRP when compared to results obtained in the Orcinol assay for previous 
formulations, it was decided to compare the fluorescent assay with Orcinol to 
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determine if the low PRP values obtained are real or are caused by loss of the 
Fluorescein from the PRP during the CaP-PCMC preparation. 
The total and soluble PRP content of two CaP-PCMC formulations with a theoretical 
0.5% PRP loading (the first batch had a TT loading of 0.5% and the second batch was 
prepared without TT) were determined by Orcinol assay, and by measuring the 
fluorescence signal for comparison. The results are presented in Table A.3. The total 
PRP content as measured by the Orcinol assay was found to be close to 100% of the 
theoretical value in both batches. Soluble PRP from the CaP-PCMC for both 
formulations was 46.9 and 38.2% of the total. The total PRP content in both 
formulations was determined by the fluorescence assay and was found to be similar 
to the first formulation shown in Table A.2, with only 6.2 and a 5.9% of the 
expected level. The level of soluble PRP was also found to be high, with 51.8 and 
60.3% of the measured PRP content was released into solution. It is clear there is a 
large discrepancy in the results for total PRP when determined by the Orcinol assay. 
The fluorescence assays suggest that the low level of PRP detected in the 
fluorescence assay indicate that the conjugation between the PRP and FITC is either 
not stable or is affected by the CaP-PCMC preparation process.  
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Table A.3. Total and soluble PRP content of two CaP-PCMC formulations prepared 
using PRP-FITC 
 
Orcinol  Fluorescence  
 
Total (% 
expected) 
Soluble 
(%) 
Total (% 
expected) 
Soluble 
(%) 
Formulation 1 109.1 46.9 6.2 51.8 
Formulation 
2* 117.2 38.2 5.9 60.3 
The total and soluble antigen content of two CaP-PCMC formulations (with 0.5% 
PRP loading) was determined by measurement of fluorescent intensity. 
*Formulation 2 contains only PRP-FITC and not TT.  
 
Although the precise conjugation method used by Innova to covantly attach the 
FITC to the PRP is unknown, conjugation of the PRP to a carrier protein, as is the 
case for Hib conjugate vaccine is done by using cyanogen bromide to activate the 
polysaccharide, to introduce cyanate (OCN) groups that will react with spacer 
molecules, or directly with the carrier protein. Another method is the perodite 
oxidation of polysaccharide which generates aldehyde groups. The conjugation of a 
fluorophore to a protein however is a slightly simpler process, involving formation 
of a covalent amide bond with primary amines on the protein to be labelled (223).  
Due to the low level of the FITC conjugated PRP in the CAP-PCMC formulation, a 
CaP-PCMC preparation containing BSA-FITC was used as a model for the uptake 
studies as an alternative to the PRP-FITC. The total and soluble level of BSA-FITC in 
the CaP-PCMC formulation were measured to ensure that there were low levels of 
soluble antigen on the formulation before using them in cellular uptake studies.  
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Although the total BSA content of the crystals was relatively low (35.2). The low 
level of soluble BSA-FITC (1.6%), suggests that any fluorescence signal detected by 
the flow cytometry is likely to be from uptake of the CaP-PCMCs rather than from 
uptake of soluble BSA-FITC. 
269 
 
 
REFERENCES 
 
1. Organization WH. Initiative for Vaccine Research. State of the art of new vaccines 
Research & Development2003. 
2. Organisation WH. World Health Report 2005. 2005. 
3. Jones C. 4.31 - Bacterial Carbohydrate-Based Vaccines. In: Editor-in-Chief:  Johannis 
PK, editor. Comprehensive Glycoscience. Oxford: Elsevier; 2007. p. 569-605. 
4. Merino S, Tomás JM. Bacterial Capsules and Evasion of Immune Responses. 
eLS2015. p. 1-10. 
5. Tohyama Y, Yamamura H. Complement-mediated phagocytosis--the role of Syk. 
IUBMB Life. 2006;58(5-6):304-8. 
6. Hallström T, Riesbeck K. Haemophilus influenzae and the complement system. 
Trends Microbiol. 2010;18(6):258-65. 
7. Scott JA. The preventable burden of pneumococcal disease in the developing 
world. Vaccine. 2007;25(13):2398-405. 
8. Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health 
burden and control. World Health Stat Q. 1997;50(3-4):170-7. 
9. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden 
of disease caused by Streptococcus pneumoniae in children younger than 5 years: global 
estimates. Lancet. 2009;374(9693):893-902. 
10. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden 
of disease caused by Haemophilus influenzae type b in children younger than 5 years: 
global estimates. Lancet. 2009;374(9693):903-11. 
11. Madhi SA, Levine OS, Hajjeh R, Mansoor OD, Cherian T. Vaccines to prevent 
pneumonia and improve child survival. Bull World Health Organ. 2008;86(5):365-72. 
12. Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin 
Microbiol Infect. 2009;15 Suppl 3:7-11. 
13. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and 
proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that 
cause acute otitis media in an unvaccinated population. J Infect Dis. 2009;199(6):776-85. 
14. Kaplan SL, Mason EO, Wald E, Tan TQ, Schutze GE, Bradley JS, et al. Six year 
multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis 
J. 2002;21(2):141-7. 
15. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for 
drug selection. Clin Infect Dis. 2002;34(12):1613-20. 
16. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive 
methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 
2007;298(15):1763-71. 
17. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing 
epidemiology of invasive pneumococcal disease among older adults in the era of pediatric 
pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-51. 
18. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact 
of vaccines. Expert Rev Vaccines. 2010;9(3):285-98. 
270 
 
19. Pittman M. VARIATION AND TYPE SPECIFICITY IN THE BACTERIAL SPECIES 
HEMOPHILUS INFLUENZAE. J Exp Med. 1931;53(4):471-92. 
20. Anderson EC, Begg NT, Crawshaw SC, Hargreaves RM, Howard AJ, Slack MP. 
Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the 
pre-vaccination era (1990-2). Epidemiol Infect. 1995;115(1):89-100. 
21. Anderson P. The protective level of serum antibodies to the capsular 
polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1984;149(6):1034-5. 
22. Turk DC. Acute laryngeal obstruction due to haemophilus. Lancet. 
1967;2(7521):895. 
23. Crisel RM, Baker RS, Dorman DE. Capsular polymer of Haemophilus influenzae, type 
b. I. Structural characterization of the capsular polymer of strain Eagan. J Biol Chem. 
1975;250(13):4926-30. 
24. Moxon ER, Vaughn KA. The type b capsular polysaccharide as a virulence 
determinant of Haemophilus influenzae: studies using clinical isolates and laboratory 
transformants. J Infect Dis. 1981;143(4):517-24. 
25. LEIDY G, HAHN E, ZAMENHOF S, ALEXANDER HE. Biochemical aspects of virulence 
of Hemophilus influenzae. Ann N Y Acad Sci. 1960;88:1195-202. 
26. MacPHERSON CF, HEIDELBERGER M. The specific polysaccharides of types A, B, C, D 
and F Hemophilus influenzae. J Immunol. 1946;52:207-21. 
27. Funkhouser A, Steinhoff MC, Ward J. Haemophilus influenzae disease and 
immunization in developing countries. Rev Infect Dis. 1991;13 Suppl 6:S542-54. 
28. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, et al. Elimination of 
Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of 
routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 
2005;366(9480):144-50. 
29. Bijlmer HA, van Alphen L, Greenwood BM, Geelen-van den Broek L, Valkenburg HA, 
Dankert J. Antibiotic susceptibility of invasive and non-invasive isolates of Haemophilus 
influenzae from the Gambia, west Africa. J Antimicrob Chemother. 1994;34(2):275-80. 
30. Hugosson S, Silfverdal SA, Garpenholt O, Esbjörner E, Lindquist B, Vikerfors T, et al. 
Invasive Haemophilus influenzae disease: epidemiology and clinical spectrum before large-
scale H. influenzae type b vaccination. Scand J Infect Dis. 1995;27(1):63-7. 
31. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of 
the 21st century: global analysis of the disease burden 25 years after the use of the 
polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 
2000;13(2):302-17. 
32. Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type 
b. Emerg Infect Dis. 1996;2(3):176-82. 
33. Howard AJ, Dunkin KT, Millar GW. Nasopharyngeal carriage and antibiotic 
resistance of Haemophilus influenzae in healthy children. Epidemiol Infect. 
1988;100(2):193-203. 
34. Michaels RH, Poziviak CS, Stonebraker FE, Norden CW. Factors affecting pharyngeal 
Haemophilus influenzae type b colonization rates in children. J Clin Microbiol. 
1976;4(5):413-7. 
35. Michaels RH, Norden CW. Pharyngeal colonization with Haemophilus influenzae 
type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. 
influenzae type b. J Infect Dis. 1977;136(2):222-8. 
36. Bruyn GA, Zegers BJ, van Furth R. Mechanisms of host defense against infection 
with Streptococcus pneumoniae. Clin Infect Dis. 1992;14(1):251-62. 
37. Joiner KA. Complement evasion by bacteria and parasites. Annu Rev Microbiol. 
1988;42:201-30. 
271 
 
38. Macleod CM, Hodges RG, Heidelberger M, Bernhard WG. PREVENTION OF 
PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR 
POLYSACCHARIDES. J Exp Med. 1945;82(6):445-65. 
39. Coutinho A, Möller G. Mitogenic properties of the thymus-independent antigen 
pneumococcal polysaccharide S3. Eur J Immunol. 1973;3(10):608-13. 
40. Anderson P, Peter G, Johnston RB, Wetterlow LH, Smith DH. Immunization of 
humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b. J 
Clin Invest. 1972;51(1):39-44. 
41. Peltola H, Käyhty H, Sivonen A, Mäkelä H. Haemophilus influenzae type b capsular 
polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 
months to 5 years of age in Finland. Pediatrics. 1977;60(5):730-7. 
42. Zandvoort A, Timens W. The dual function of the splenic marginal zone: essential 
for initiation of anti-TI-2 responses but also vital in the general first-line defense against 
blood-borne antigens. Clin Exp Immunol. 2002;130(1):4-11. 
43. Timens W, Boes A, Poppema S. Human marginal zone B cells are not an activated B 
cell subset: strong expression of CD21 as a putative mediator for rapid B cell activation. Eur 
J Immunol. 1989;19(11):2163-6. 
44. Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. Immaturity of the human 
splenic marginal zone in infancy. Possible contribution to the deficient infant immune 
response. J Immunol. 1989;143(10):3200-6. 
45. Amlot PL, Grennan D, Humphrey JH. Splenic dependence of the antibody response 
to thymus-independent (TI-2) antigens. Eur J Immunol. 1985;15(5):508-12. 
46. Siber GR, Ambrosino DM, McIver J, Ervin TJ, Schiffman G, Sallan S, et al. Preparation 
of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, 
and Neisseria meningitidis. Infect Immun. 1984;45(1):248-54. 
47. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of 
meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 
2004;364(9431):365-7. 
48. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria 
with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213-20. 
49. Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype 
b conjugate vaccine in the United Kingdom. Clin Ther. 2012;34(2):385-99. 
50. . !!! INVALID CITATION !!! 
51. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline of 
childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 
1993;269(2):221-6. 
52. Mawas F, Newman G, Burns S, Corbel MJ. Suppression and modulation of cellular 
and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine 
in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat 
model. J Infect Dis. 2005;191(1):58-64. 
53. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of 
meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282(8):417-
20. 
54. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. 
Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. 
1997;337(14):970-6. 
55. NHS. Childhood vaccine guide  [Available from: 
http://www.nhs.uk/Planners/vaccinations/Pages/childvaccines.aspx. 
56. Organisation WH. Progress introducing Haemophilus influenzae type b vaccine in 
low-income countries, 2004–2008. Weekly Epidemiological Record: World Health 
Organisation; 2008. p. 61-8. 
272 
 
57. Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of 
the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American 
Indian population. Int J Epidemiol. 2000;29(4):753-6. 
58. Murphy TV, White KE, Pastor P, Gabriel L, Medley F, Granoff DM, et al. Declining 
incidence of Haemophilus influenzae type b disease since introduction of vaccination. 
JAMA. 1993;269(2):246-8. 
59. Murphy TV, Pastor P, Medley F, Osterholm MT, Granoff DM. Decreased 
Haemophilus colonization in children vaccinated with Haemophilus influenzae type b 
conjugate vaccine. J Pediatr. 1993;122(4):517-23. 
60. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a 
Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. 
influenzae type b among Gambian children. J Infect Dis. 1998;177(6):1758-61. 
61. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy 
data. Pediatr Infect Dis J. 1998;17(9 Suppl):S117-22. 
62. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine 
use and effectiveness. Lancet Infect Dis. 2008;8(7):435-43. 
63. Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a Haemophilus 
influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae 
Vaccine Study Group. N Engl J Med. 1990;323(20):1393-401. 
64. Mäkelä PH, Käyhty H. Evolution of conjugate vaccines. Expert Rev Vaccines. 
2002;1(3):399-410. 
65. Eskola J, Peltola H, Takala AK, Käyhty H, Hakulinen M, Karanko V, et al. Efficacy of 
Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in 
infancy. N Engl J Med. 1987;317(12):717-22. 
66. Peltola H, Eskola J, Käyhty H, Takala AK, Mäkelä PH. Clinical comparison of the 
Haemophilus influenzae type B polysaccharide-diphtheria toxoid and the oligosaccharide-
CRM197 protein vaccines in infancy. Arch Pediatr Adolesc Med. 1994;148(6):620-5. 
67. Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in 
infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a 
United States population of 61,080 children. The Northern California Kaiser Permanente 
Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991;10(2):97-104. 
68. Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, et al. The 
efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type 
b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J 
Med. 1991;324(25):1767-72. 
69. Booy R, Moxon ER, MacFarlane JA, Mayon-White RT, Slack MP. Efficacy of 
Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet. 
1992;340(8823):847. 
70. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after 
Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 
2003;361(9368):1521-3. 
71. Ladhani S, Heath PT, Ramsay ME, Slack MP. Changes in antibiotic resistance rates of 
invasive Haemophilus influenzae isolates in England and Wales over the last 20 years. J 
Antimicrob Chemother. 2008;62(4):776-9. 
72. Poolman J, Kaufhold A, De Grave D, Goldblatt D. Clinical relevance of lower Hib 
response in DTPa-based combination vaccines. Vaccine. 2001;19(17-19):2280-5. 
73. Dagan R, Fraser D, Greif Z, Keller N, Kaufstein M, Shazberg G, et al. A nationwide 
prospective surveillance study in Israel to document pediatric invasive infections, with an 
emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and 
Meningitis Group. Pediatr Infect Dis J. 1998;17(9 Suppl):S198-203. 
273 
 
74. Clemens J, Brenner R, Rao M. Interactions between PRP-T vaccine against 
Haemophilus influenzae type b and conventional infant vaccines. Lessons for future studies 
of simultaneous immunization and combined vaccines. Ann N Y Acad Sci. 1995;754:255-66. 
75. Herzenberg LA, Tokuhisa T. Carrier-priming leads to hapten-specific suppression. 
Nature. 1980;285(5767):664-7. 
76. Herzenberg LA. Epitope-specific regulation of memory B-cell expression. Ann N Y 
Acad Sci. 1982;399:368-74. 
77. Schutze MP, Deriaud E, Przewlocki G, LeClerc C. Carrier-induced epitopic 
suppression is initiated through clonal dominance. J Immunol. 1989;142(8):2635-40. 
78. Leclerc C, Schutze MP, Deriaud E, Przewlocki G. The in vivo elimination of CD4+ T 
cells prevents the induction but not the expression of carrier-induced epitopic suppression. 
J Immunol. 1990;145(5):1343-9. 
79. Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R. Epitopic overload at the site of 
injection may result in suppression of the immune response to combined capsular 
polysaccharide conjugate vaccines. Vaccine. 1999;17(2):126-33. 
80. Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, et al. Serogroup C 
meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal 
antibodies and kinetics of the immune response to a booster vaccine more than 3 years 
after immunization. Clin Infect Dis. 2006;43(11):1387-94. 
81. Kitchin NR, Southern J, Morris R, Hemme F, Thomas S, Watson MW, et al. 
Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus 
influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine 
at 2, 3 and 4 months of age. Arch Dis Child. 2007;92(1):11-6. 
82. Pape KA, Catron DM, Itano AA, Jenkins MK. The humoral immune response is 
initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. 
Immunity. 2007;26(4):491-502. 
83. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte 
extravasation: chemokine transport and presentation by the endothelium. Blood. 
2002;100(12):3853-60. 
84. Bredius RG, Fijen CA, De Haas M, Kuijper EJ, Weening RS, Van de Winkel JG, et al. 
Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in 
phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. 
1994;83(4):624-30. 
85. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, Tanguy M, et al. 
Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal 
vaccination and shuttle live bacilli to the draining lymph nodes. Blood. 2005;106(5):1843-
50. 
86. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, et al. The 
formation of immunogenic major histocompatibility complex class II-peptide ligands in 
lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med. 
2000;191(6):927-36. 
87. Turley SJ, Inaba K, Garrett WS, Ebersold M, Unternaehrer J, Steinman RM, et al. 
Transport of peptide-MHC class II complexes in developing dendritic cells. Science. 
2000;288(5465):522-7. 
88. Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly 
with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-
dependent response. J Immunol. 1998;161(3):1313-9. 
89. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat 
Rev Immunol. 2008;8(12):958-69. 
274 
 
90. Ambrosino DM, Bolon D, Collard H, Van Etten R, Kanchana MV, Finberg RW. Effect 
of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate 
vaccine on macrophages. J Immunol. 1992;149(12):3978-83. 
91. eBioscience. Antigen Processing and Presentation by MHCs 2012 [Available from: 
http://www.ebioscience.com/resources/pathways/antigen-processing-and-presentation-
by-mhc.htm. 
92. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K. Extent of T cell 
receptor ligation can determine the functional differentiation of naive CD4+ T cells. J Exp 
Med. 1995;182(5):1591-6. 
93. Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell 
autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol. 
2006;177(7):4481-7. 
94. Cassell DJ, Schwartz RH. A quantitative analysis of antigen-presenting cell function: 
activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing 
costimulation. J Exp Med. 1994;180(5):1829-40. 
95. Ronchese F, Hausmann B. B lymphocytes in vivo fail to prime naive T cells but can 
stimulate antigen-experienced T lymphocytes. J Exp Med. 1993;177(3):679-90. 
96. Mamula MJ, Janeway CA. Do B cells drive the diversification of immune responses? 
Immunol Today. 1993;14(4):151-2; discussion 3-4. 
97. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149-
59. 
98. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol. 1993;11:331-60. 
99. Mills DM, Cambier JC. B lymphocyte activation during cognate interactions with 
CD4+ T lymphocytes: molecular dynamics and immunologic consequences. Semin Immunol. 
2003;15(6):325-9. 
100. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature. 
2005;438(7066):364-8. 
101. WHO. vaccine introduction status into routine infant immunization worldwide, 
2003. 2003. 
102. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of 
vaccines. J Pharm Sci. 2003;92(2):218-31. 
103. Cheyne J. Vaccine delivery management. Rev Infect Dis. 1989;11 Suppl 3:S617-22. 
104. Chen D, Kristensen D. Opportunities and challenges of developing thermostable 
vaccines. Expert Rev Vaccines. 2009;8(5):547-57. 
105. Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine 
adjuvants and delivery systems. Dev Biol Stand. 1998;92:63-78. 
106. Omenetto FG, Kaplan DL. New opportunities for an ancient material. Science. 
2010;329(5991):528-31. 
107. Zhang J, Pritchard E, Hu X, Valentin T, Panilaitis B, Omenetto FG, et al. Stabilization 
of vaccines and antibiotics in silk and eliminating the cold chain. Proc Natl Acad Sci U S A. 
2012;109(30):11981-6. 
108. Vepari C, Kaplan DL. Silk as a Biomaterial. Prog Polym Sci. 2007;32(8-9):991-1007. 
109. Lawrence BD, Cronin-Golomb M, Georgakoudi I, Kaplan DL, Omenetto FG. Bioactive 
silk protein biomaterial systems for optical devices. Biomacromolecules. 2008;9(4):1214-
20. 
110. Colinet G, Rossignol J, Peetermans J. A study of the stability of a bivalent measles--
mumps vaccine. J Biol Stand. 1982;10(4):341-6. 
111. Treuel L, Jiang X, Nienhaus GU. New views on cellular uptake and trafficking of 
manufactured nanoparticles. J R Soc Interface. 2013;10(82):20120939. 
112. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. 
Vaccine. 2014;32(3):327-37. 
275 
 
113. Mamo T, Poland GA. Nanovaccinology: the next generation of vaccines meets 21st 
century materials science and engineering. Vaccine. 2012;30(47):6609-11. 
114. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A 
therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and 
immunogenicity. Eur J Immunol. 2005;35(7):2031-40. 
115. Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in 
vaccine development. Expert Rev Vaccines. 2010;9(10):1149-76. 
116. Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: insights and future 
perspectives. Int J Pharm. 2013;440(1):27-38. 
117. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine 
platform: diversity of targets and production systems and advances in clinical development. 
Vaccine. 2012;31(1):58-83. 
118. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms 
for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 
2011;3(2):174-96. 
119. Ferreira SA, Gama FM, Vilanova M. Polymeric nanogels as vaccine delivery systems. 
Nanomedicine. 2013;9(2):159-73. 
120. Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, et al. T cell immunomonitoring 
and tumor responses in patients immunized with a complex of cholesterol-bearing 
hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 2007;7:9. 
121. Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, et al. In vitro 
stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-
bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-
binding CD4 T-cell epitope. Clin Cancer Res. 2006;12(6):1921-7. 
122. Li P, Luo Z, Liu P, Gao N, Zhang Y, Pan H, et al. Bioreducible alginate-
poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-
elicited humoral and cellular immune responses. J Control Release. 2013;168(3):271-9. 
123. Honda-Okubo Y, Saade F, Petrovsky N. Advax™, a polysaccharide adjuvant derived 
from delta inulin, provides improved influenza vaccine protection through broad-based 
enhancement of adaptive immune responses. Vaccine. 2012;30(36):5373-81. 
124. Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine 
containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust 
humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 
2013;31(15):1999-2007. 
125. Doavi T, Mousavi SL, Kamali M, Amani J, Fasihi Ramandi M. Chitosan-Based 
Intranasal Vaccine against Escherichia coli O157:H7. Iran Biomed J. 2016;20(2):97-108. 
126. Saeed MI, Omar AR, Hussein MZ, Elkhidir IM, Sekawi Z. Development of enhanced 
antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 
vaccine encapsulated carrier. Hum Vaccin Immunother. 2015;11(10):2414-24. 
127. Liu Q, Chen X, Jia J, Zhang W, Yang T, Wang L, et al. pH-Responsive Poly(D,L-lactic-
co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune 
Response. ACS Nano. 2015;9(5):4925-38. 
128. Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC. Chitosan microparticles 
and nanoparticles as biocompatible delivery vehicles for peptide and protein-based 
immunocontraceptive vaccines. Mol Pharm. 2012;9(1):81-90. 
129. Günbeyaz M, Faraji A, Ozkul A, Puralı N, Senel S. Chitosan based delivery systems 
for mucosal immunization against bovine herpesvirus 1 (BHV-1). Eur J Pharm Sci. 
2010;41(3-4):531-45. 
130. Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, et al. 
Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG 
ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm. 2008;69(2):405-16. 
276 
 
131. Zhao K, Chen G, Shi XM, Gao TT, Li W, Zhao Y, et al. Preparation and efficacy of a 
live newcastle disease virus vaccine encapsulated in chitosan nanoparticles. PLoS One. 
2012;7(12):e53314. 
132. Feng G, Jiang Q, Xia M, Lu Y, Qiu W, Zhao D, et al. Enhanced immune response and 
protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 
and FL against Mycobacterium tuberculosis infection. PLoS One. 2013;8(4):e61135. 
133. Zhao F, Zhang X, Liu S, Zeng T, Yu J, Gu W, et al. Assessment of the immune 
responses to Treponema pallidum Gpd DNA vaccine adjuvanted with IL-2 and chitosan 
nanoparticles before and after Treponema pallidum challenge in rabbits. Sci China Life Sci. 
2013;56(2):174-80. 
134. Nanda RK, Edao BM, Hajam IA, Sekar SC, Ganesh K, Bhanuprakash V, et al. An 
effective mannosylated chitosan nanoparticle DNA vaccine for FMD virus. Virol Sin. 
2012;27(6):373-6. 
135. Götze O, Müller-Eberhard HJ. The C3-activator system: an alternate pathway of 
complement activation. J Exp Med. 1971;134(3 Pt 2):90s-108s. 
136. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, et al. Nanogel 
antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater. 
2010;9(7):572-8. 
137. Debache K, Kropf C, Schütz CA, Harwood LJ, Käuper P, Monney T, et al. Vaccination 
of mice with chitosan nanogel-associated recombinant NcPDI against challenge infection 
with Neospora caninum tachyzoites. Parasite Immunol. 2011;33(2):81-94. 
138. Kalkanidis M, Pietersz GA, Xiang SD, Mottram PL, Crimeen-Irwin B, Ardipradja K, et 
al. Methods for nano-particle based vaccine formulation and evaluation of their 
immunogenicity. Methods. 2006;40(1):20-9. 
139. Ow H, Larson DR, Srivastava M, Baird BA, Webb WW, Wiesner U. Bright and stable 
core-shell fluorescent silica nanoparticles. Nano Lett. 2005;5(1):113-7. 
140. Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, et al. 
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human 
melanoma. J Clin Invest. 2011;121(7):2768-80. 
141. Niut Y, Popatt A, Yu M, Karmakar S, Gu W, Yu C. Recent advances in the rational 
design of silica-based nanoparticles for gene therapy. Ther Deliv. 2012;3(10):1217-37. 
142. Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C. Hyaluronic acid modified 
mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer 
cells. Nanoscale. 2013;5(1):178-83. 
143. Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, Uludağ H. Formulation 
and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm. 
2009;6(1):121-33. 
144. Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S, et al. Polyethyleneimine 
coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe 
delivery of siRNA and DNA constructs. ACS Nano. 2009;3(10):3273-86. 
145. He XX, Wang K, Tan W, Liu B, Lin X, He C, et al. Bioconjugated nanoparticles for 
DNA protection from cleavage. J Am Chem Soc. 2003;125(24):7168-9. 
146. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature. 
1974;252(5480):252. 
147. Deng S, Bai L, Reboulet R, Matthew R, Engler DA, Teyton L, et al. A peptide-free, 
liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, 
generates robust antibody responses in vivo. Chem Sci. 2014;5(4):1437-41. 
148. Ltd. X. 2016 [Available from: http://www.xstalbio.com/technology. 
149. Murdan S, Somavarapu S, Ross AC, Alpar HO, Parker MC. Immobilisation of vaccines 
onto micro-crystals for enhanced thermal stability. Int J Pharm. 2005;296(1-2):117-21. 
277 
 
150. Khosravani A, Parker MC, Parton R, Coote J. Formulation of the adenylate cyclase 
toxin of Bordetella pertussis as protein-coated microcrystals. Vaccine. 2007;25(22):4361-7. 
151. Mäkelä PH, Peltola H, Käyhty H, Jousimies H, Pettay O, Ruoslahti E, et al. 
Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae 
type b: a field trial in Finland. J Infect Dis. 1977;136 Suppl:S43-50. 
152. Gupta RK, Anderson R, Cecchini D, Rost B, Xu J, Gendreau K, et al. Evaluation of a 
guinea pig model to assess interference in the immunogenicity of different components of 
a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine 
and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals. 
1999;27(2):167-76. 
153. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major 
histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by 
macrophages. Proc Natl Acad Sci U S A. 1993;90(11):4942-6. 
154. Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL. 
Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol. 
1996;156(8):2809-18. 
155. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured 
human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor 
plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 
1994;179(4):1109-18. 
156. Steinman RM, Swanson J. The endocytic activity of dendritic cells. J Exp Med. 
1995;182(2):283-8. 
157. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad 
Sci U S A. 2006;103(13):4930-4. 
158. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer 
particles. Pharm Res. 2009;26(1):244-9. 
159. Westwood A, Healey GD, Williamson ED, Eyles JE. Activation of dendritic cells by 
microparticles containing Bacillus anthracis protective antigen. Vaccine. 2005;23(29):3857-
63. 
160. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect 
particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315-
22. 
161. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric 
particles in vaccine delivery. Curr Opin Microbiol. 2010;13(1):106-12. 
162. Goldblatt D. Immunisation and the maturation of infant immune responses. Dev 
Biol Stand. 1998;95:125-32. 
163. Jódar L, Griffiths E, Feavers I. Scientific challenges for the quality control and 
production of group C meningococcal conjugate vaccines. Vaccine. 2004;22(8):1047-53. 
164. Costantino P, Norelli F, Giannozzi A, D'Ascenzi S, Bartoloni A, Kaur S, et al. Size 
fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. 
Vaccine. 1999;17(9-10):1251-63. 
165. Frasch CE. Preparation of bacterial polysaccharide-protein conjugates: analytical 
and manufacturing challenges. Vaccine. 2009;27(46):6468-70. 
166. Warren HS, Vogel FR, Chedid LA. Current status of immunological adjuvants. Annu 
Rev Immunol. 1986;4:369-88. 
167. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem 
Biophys Res Commun. 2009;388(4):621-5. 
168. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A 
as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 2008;65(20):3231-40. 
278 
 
169. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine 
adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 
2007;316(5831):1628-32. 
170. Duggan JM, You D, Cleaver JO, Larson DT, Garza RJ, Guzmán Pruneda FA, et al. 
Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung 
infection in mice. J Immunol. 2011;186(10):5916-26. 
171. Buwitt-Beckmann U, Heine H, Wiesmüller KH, Jung G, Brock R, Akira S, et al. Toll-
like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol. 
2005;35(1):282-9. 
172. Cheng C, Jain P, Bettahi I, Pal S, Tifrea D, de la Maza LM. A TLR2 agonist is a more 
effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to 
other TLR and NOD receptors. Vaccine. 2011;29(38):6641-9. 
173. Fortier ME, Kent S, Ashdown H, Poole S, Boksa P, Luheshi GN. The viral mimic, 
polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent 
mechanism. Am J Physiol Regul Integr Comp Physiol. 2004;287(4):R759-66. 
174. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, et al. Synthetic 
double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza 
virus infection. J Virol. 2005;79(5):2910-9. 
175. Naarding MA, Falkowska E, Xiao H, Dragic T. Hepatitis C virus soluble E2 in 
combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine. 
2011;29(16):2910-7. 
176. Baldrick P, Richardson D, Elliott G, Wheeler AW. Safety evaluation of 
monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol. 
2002;35(3):398-413. 
177. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum 
and alum's adjuvant effect are mediated by NLRP3. J Immunol. 2008;181(1):17-21. 
178. Katare YK, Muthukumaran T, Panda AK. Influence of particle size, antigen load, 
dose and additional adjuvant on the immune response from antigen loaded PLA 
microparticles. Int J Pharm. 2005;301(1-2):149-60. 
179. Johansen P, Gander B, Merkle HP, Sesardic D. Ambiguities in the preclinical quality 
assessment of microparticulate vaccines. Trends Biotechnol. 2000;18(5):203-11. 
180. Peyre M, Sesardic D, Merkle HP, Gander B, Johansen P. An experimental divalent 
vaccine based on biodegradable microspheres induces protective immunity against tetanus 
and diphtheria. J Pharm Sci. 2003;92(5):957-66. 
181. Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, Panda AK. Improved 
immune response from biodegradable polymer particles entrapping tetanus toxoid by use 
of different immunization protocol and adjuvants. Int J Pharm. 2002;245(1-2):109-21. 
182. De Temmerman ML, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC. 
Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov 
Today. 2011;16(13-14):569-82. 
183. Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM. Modulation of the 
human immune response by the non-toxic and non-pyrogenic adjuvant aluminium 
hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol. 
1985;61(1):143-51. 
184. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. 
Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the 
absence of IL-4- or IL-13-mediated signaling. J Immunol. 1999;163(12):6448-54. 
185. FLUAD®(MF59®-Adjuvanted Influenza Vaccine)Fact Sheet: Novartis; 2014 [Available 
from: https://www.novartis.com/sites/www.novartis.com/files/Fluad_Fact_Sheet.pdf. 
186. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with 
the MF59-adjuvanted vaccine. Vaccine. 2001;19(17-19):2673-80. 
279 
 
187. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human 
vaccines. Curr Opin Immunol. 2010;22(3):411-6. 
188. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. 
MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm 
Biotechnol. 1995;6:277-96. 
189. Bolgiano B, Mawas F, Burkin K, Crane DT, Saydam M, Rigsby P, et al. A retrospective 
study on the quality of Haemophilus influenzae type b vaccines used in the UK between 
1996 and 2004. Hum Vaccin. 2007;3(5):176-82. 
190. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines--US perspective. 
Vaccine. 2002;20 Suppl 3:S18-23. 
191. Alonso MJ, Gupta RK, Min C, Siber GR, Langer R. Biodegradable microspheres as 
controlled-release tetanus toxoid delivery systems. Vaccine. 1994;12(4):299-306. 
192. Batista FD, Harwood NE. The who, how and where of antigen presentation to B 
cells. Nat Rev Immunol. 2009;9(1):15-27. 
193. Peyre M, Fleck R, Hockley D, Gander B, Sesardic D. In vivo uptake of an 
experimental microencapsulated diphtheria vaccine following sub-cutaneous 
immunisation. Vaccine. 2004;22(19):2430-7. 
194. Angeli V, Hammad H, Staels B, Capron M, Lambrecht BN, Trottein F. Peroxisome 
proliferator-activated receptor gamma inhibits the migration of dendritic cells: 
consequences for the immune response. J Immunol. 2003;170(10):5295-301. 
195. Crivellato E, Vacca A, Ribatti D. Setting the stage: an anatomist's view of the 
immune system. Trends Immunol. 2004;25(4):210-7. 
196. Liu YJ, Zhang J, Lane PJ, Chan EY, MacLennan IC. Sites of specific B cell activation in 
primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur 
J Immunol. 1991;21(12):2951-62. 
197. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S. Lymph-borne 
chemokines and other low molecular weight molecules reach high endothelial venules via 
specialized conduits while a functional barrier limits access to the lymphocyte 
microenvironments in lymph node cortex. J Exp Med. 2000;192(10):1425-40. 
198. Carrasco YR, Batista FD. B cells acquire particulate antigen in a macrophage-rich 
area at the boundary between the follicle and the subcapsular sinus of the lymph node. 
Immunity. 2007;27(1):160-71. 
199. Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, et al. 
Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present 
them to antiviral B cells. Nature. 2007;450(7166):110-4. 
200. Phan TG, Grigorova I, Okada T, Cyster JG. Subcapsular encounter and complement-
dependent transport of immune complexes by lymph node B cells. Nat Immunol. 
2007;8(9):992-1000. 
201. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic 
cells and induce class I-restricted CTLs. Nature. 1998;392(6671):86-9. 
202. Reis e Sousa C, Austyn JM. Phagocytosis of antigens by Langerhans cells. Adv Exp 
Med Biol. 1993;329:199-204. 
203. Inaba K, Inaba M, Deguchi M, Hagi K, Yasumizu R, Ikehara S, et al. Granulocytes, 
macrophages, and dendritic cells arise from a common major histocompatibility complex 
class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci U S A. 
1993;90(7):3038-42. 
204. Suzuki K, Grigorova I, Phan TG, Kelly LM, Cyster JG. Visualizing B cell capture of 
cognate antigen from follicular dendritic cells. J Exp Med. 2009;206(7):1485-93. 
205. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter 
E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does 
280 
 
phagocytosis activity of dendritic cells measure up with macrophages? J Control Release. 
2001;76(1-2):59-71. 
206. Jones S, Asokanathan C, Kmiec D, Irvine J, Fleck R, Xing D, et al. Protein coated 
microcrystals formulated with model antigens and modified with calcium phosphate exhibit 
enhanced phagocytosis and immunogenicity. Vaccine. 2014;32(33):4234-42. 
207. Mitchison NA. The discovery of T cell-B cell cooperation. Front Immunol. 
2014;5:377. 
208. Aluvihare VR, Khamlichi AA, Williams GT, Adorini L, Neuberger MS. Acceleration of 
intracellular targeting of antigen by the B-cell antigen receptor: importance depends on the 
nature of the antigen-antibody interaction. EMBO J. 1997;16(12):3553-62. 
209. Cheng PC, Steele CR, Gu L, Song W, Pierce SK. MHC class II antigen processing in B 
cells: accelerated intracellular targeting of antigens. J Immunol. 1999;162(12):7171-80. 
210. Jian P, Li ZW, Fang TY, Jian W, Zhuan Z, Mei LX, et al. Retinoic acid induces HL-60 
cell differentiation via the upregulation of miR-663. J Hematol Oncol. 2011;4:20. 
211. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large 
numbers of dendritic cells from mouse bone marrow cultures supplemented with 
granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693-702. 
212. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards 
neutrophils subsequently die via apoptosis. Clin Exp Immunol. 1990;79(3):448-53. 
213. Kamenyeva O, Boularan C, Kabat J, Cheung GY, Cicala C, Yeh AJ, et al. Neutrophil 
recruitment to lymph nodes limits local humoral response to Staphylococcus aureus. PLoS 
Pathog. 2015;11(4):e1004827. 
214. Burgdorf S, Kautz A, Böhnert V, Knolle PA, Kurts C. Distinct pathways of antigen 
uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 
2007;316(5824):612-6. 
215. Parmar D, Baruwa EM, Zuber P, Kone S. Impact of wastage on single and multi-dose 
vaccine vials: Implications for introducing pneumococcal vaccines in developing countries. 
Hum Vaccin. 2010;6(3). 
216. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics 
and molecular patterns. Nat Rev Immunol. 2010;10(11):787-96. 
217. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, et al. 
Pathogen recognition and development of particulate vaccines: does size matter? 
Methods. 2006;40(1):1-9. 
218. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, et al. Virus-like particle 
(VLP) lymphatic trafficking and immune response generation after immunization by 
different routes. J Immunother. 2009;32(2):118-28. 
219. de Veer M, Kemp J, Chatelier J, Elhay MJ, Meeusen EN. The kinetics of soluble and 
particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based 
adjuvant. Vaccine. 2010;28(40):6597-602. 
220. Frangioni JV, Kim SW, Ohnishi S, Kim S, Bawendi MG. Sentinel lymph node mapping 
with type-II quantum dots. Methods Mol Biol. 2007;374:147-59. 
221. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, Nakayama A, et al. Near-infrared 
fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol. 
2004;22(1):93-7. 
222. Tanaka E, Choi HS, Fujii H, Bawendi MG, Frangioni JV. Image-guided oncologic 
surgery using invisible light: completed pre-clinical development for sentinel lymph node 
mapping. Ann Surg Oncol. 2006;13(12):1671-81. 
223. Fernandez Santana V, Peña Icart L, Beurret M, Costa L, Verez Bencomo V. 
Glycoconjugate vaccines against Haemophilus influenzae type b. Methods Enzymol. 
2006;415:153-63. 
 
281 
 
 
